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Abstract
Lentiviruses such as Maedi-Visna Virus (MVV) in sheep and Human
Immunodeficiency Virus (HIV) often cause a variety of neurological symptoms in
later stages of infection. In sheep, MVV infection results in paralysis and ataxia,
with post-mortem investigations revealing astrocytosis, demyelination and axonal
damage. At present it is unclear how such neurodegeneration is mediated as MVV,
like HIV, does not directly infect neurons. There is much debate as to the
mechanisms involved in lentivirus related brain damage, centred around three main
possibilities. Firstly, there may be a direct detrimental action of a viral fragment on
neuronal cell types. Secondly, MVV infected cells may be releasing diffusible
mediators such as cytokines which could cause neural damage or act on astrocytes
and microglia causing them to produce factors to induce neurodegeneration. Thirdly,
the prospect of an immune response occuring within the brain, involving infected
macrophages or microglia, is highly probable.
In order to investigate the possible mechanisms at work in lentivirus induced
neurodegeneration, several sets of experiments were carried out. Firstly, a putative
model ofMVV encephalopathy was established in severe combined immunodeficient
(,scid) mice. Scid mice lack T and B cells and are thus unable to mount any immune
response. Blood derived macrophages were obtained from healthy sheep and
infected with MVV in vitro. These were intracerebrally injected into scid mice, as
were uninfected macrophages, in order to assess the occurrence of any neural cell
damage. Cell preparations of peripheral blood mononuclear cells (PBMCs),
uninfected, supplemented with virus, or obtained from productively MVV infected
sheep, were also administered to scid mice in the same manner, to evaluate the role
of immune cells in causing any neurodegeneration. The results show that the
administration of MVV infected macrophages produces greater gliosis and
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astrocytosis in the brains of these mice as compared to those injected with control
uninfected macrophages or vehicle. However, the injections of PBMCs did not cause
any detectable differences in astrocytes and microglia between the groups. No
neuronal loss or demyelination was evident with any of the injections. These results
suggest that neural cell disruption in MVV encephalopathy may be due to the
presence of MVV infected macrophages in the Central Nervous System (CNS) of
infected sheep, acting indirectly through the release of diffusible mediators.
To investigate further the underlying causes of these changes, the possible
detrimental contribution of cytokines in this model was evaluated through the use of
the reverse transcriptase-polymerase chain reaction (RT-PCR) of MVV infected and
uninfected blood derived macrophages in vitro. The results show an increase in the
levels of the pro-inflammatory cytokine interleukin-1 beta (TL-113) mRNA in MVV
infected macrophages. Interpretation of this model therefore suggests that MVV
exerts an indirect disruptive effect on neural cells via the release of pro-inflammatory
cytokines from infected macrophages, causing microgliosis and astrocytosis which in
turn lead to major disturbances of brain function.
The possibility of a neurotoxic action of a viral product was also investigated.
Peptides derived from the basic region of the transactivating protein Tat from both
MVV and HIV have previously been shown to be lethal to neurons in vivo and in
vitro, through a mechanism believed to involve Nitric Oxide (NO)-mediated
glutamate neurotoxicity and cytokines. The actions of the MVV tat peptide when
injected intracerebrally in rats are diminished one week post-operatively by the N-
methyl-D-aspartate (NMDA) receptor antagonist (+)-5-methyl-10,ll-dihydro-5H-
dibenzo[a,d]cyclohepten-5,10-imine maleate (MK801) and the Nitric Oxide Synthase
(NOS) inhibitor NG-nitro-L-arginine methyl ester (L-NAME). Here, its short term
effects were examined and its neurotoxic mechanisms probed through the use of in
vivo stereotaxic injections and pharmacologic manipulations. The results show that
the MVV and HIV tat peptides were very rapidly neurotoxic, causing neuronal cell
death within 0.5 hours, and displayed a distinctive and unusual lesion profile.
Changes in astrocytes and microglia were also observed. The acute effects of the
MVV tat peptide were blocked by MK801, an NMDA receptor antagonist. However,
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the administration of L-NAME, a NOS inhibitor, alpha melanocyte stimulating
hormone (aMSH), a TNFa inhibitor, or 2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo-
(F)-quinoxaline (NBQX), a non-NMDA glutamate receptor antagonist, did not
reduce the volume of the lesion. This suggests that the MVV tat peptide acts at the
NMDA receptor to cause cell death either directly or via an excitotoxic mechanism.
The findings of the current experiments show that macrophages infected with
MVV cause activation of astrocytes and microglia in the brains of scid mice. These
changes may be detrimental to the normal function of the CNS. Furthermore, they
may be caused by the increased release of pro-inflammatory cytokines, especially IL-
1(3 from infected macrophages. The acute in vivo neurotoxic capability of a peptide
derived from the lentiviral protein Tat was also demonstrated and may contribute




1.1. INTRODUCTION TO LENTIVIRUSES.
1.1.1. Description and history of MVV.
Maedi Visna Virus (MVV) and Human Immunodeficiency Virus (HIV) belong
to the Lentivirinae subfamily of the Retroviridae family of viruses which also includes
Caprine Arthritis Encephalitis Virus (CAEV), Feline Immunodeficiency Virus (FIV),
Bovine Immunodeficiency Virus (BIV) Simian Immunodeficiency Virus (SIV), and
Equine Infectious Anaemia Virus (EIAV). MVV is prototypic of the lentivirus family
and causes a very slow disease in sheep, characterised by a long interval between the
time of infection and the onset of clinical signs. Maedi, literally meaning dyspnoea, was
first described by Sigurdsson in 1954 (Sigurdsson 1954b), as was visna, meaning
wasting (Sigurdsson 1954a), after a particularly severe outbreak in Iceland, caused by
the importation of infected European sheep. MVV occurs throughout the world and
usually affects animals between 3 and 5 years old when they are at their most
agriculturally productive (Dawson 1980). The disease progresses slowly, with an
incubation period of 1 to 3 years, and can affect the Central Nervous System (CNS),
lungs, joints and mammary glands.
In sheep with Maedi, the respiratory rate will increase severely after exercise,
and will eventually stay high even at rest. Hollowed flanks and a dry cough are also
evident. If no secondary bacterial infections occur, then death ensues from anoxia.
Visna affected animals usually suffer the onset of symptoms slightly earlier, usually
around 2 years old. A similar loss of body condition occurs, with emaciation despite
normal appetite, and the animal shows an unsteady gait. Trembling facial muscles is
another characteristic, and paresis in the hind limbs eventually leads to paraplegia.
Other symptoms can include ataxia, mastitis, particularly in lactating animals, synovitis
and arthritis. Eventually, chronic pneumonitis or paralysis induced by a progressive
demyelinating encephalitis causes death.
In 1967, a single virus, MVV, was shown to be the causative agent of both sets
of symptoms (Gudnadottir et al. 1966). This virus was later shown to be a retrovirus
(Lin et al. 1971). The disease was shown to be transmitted horizontally through
respiratory exudates, particularly where housing conditions were cramped, and from
ewe to lamb via colostrum and milk (Narayan et al. 1985), and could result in the whole
2
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of the flock becoming infected from the addition of just one diseased animal (Palsson
1976).
Several countries have instrumented plans to eradicate MVV with varying
degrees of success. In Holland, the removal of infected ewes and lambs from flocks
failed to stop the spread of the disease (Houwers et al. 1984). The slaughter of all
infected animals from affected farms, as has been practised in Iceland, has however
resulted in the elimination of MVV (Palsson 1976). In the United Kingdom, pedigree
flocks are subject to an accreditation scheme, controlling the number of flocks affected
by MVV to under 5%. However, some countries still have no control programs and
infectivity of flocks by ruminant lentiviruses can often reach 100% (Crawford et al.
1981).
1.1.2. Genomic description of Lentiviruses.
Lentiviruses possess a positive sense single stranded (ss)RNA genome (Brahic et
al. 1977), an RNA dependant DNA polymerase (reverse transcriptase) (Lin et al. 1970)
and replicate via a DNA intermediate (Haase et al. 1973). Molecular cloning has
enabled the analysis of nucleotide sequences of MVV and their comparison with other
lentivirus genes, both structural and regulatory. Lentiviruses differ from other
retroviruses by possessing a more complex genome structure. Six strains of MVV have
been sequenced to date. Four of the strains have been derived from the 1514 Icelandic
strain (Sonigo et al. 1985; Braun et al. 1987; Staskus et al. 1991), one from Britain (EV-
1) (Sargan et al. 1991) and the other from South Africa, termed Ovine Maedi Visna
Virus (SA-OMVV) (Querat et al. 1990). All are broadly similar but retain minor
differences. Two species of HIV, HTV-1 and HIV-2 have been identified, but unless
otherwise specified all data presented here will refer to HIV-1 since this type has been
the most extensively studied. Also present in the lentiviral genome are a TATA box and
a long terminal repeat (LTR) at both ends of the genome, containing initiation sites for
positive strand DNA synthesis (Carey et al. 1993).
1.1.2.1. Structural genes.
The functions of the structural genes gag, pol and env ofMVV, CAEV and HIV
are broadly similar. In common with other lentiviruses, MVV is characterised by a large
structural env gene which codes for two envelope glycoproteins (Narayan et al., 1993).
3
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Gpl35, (gpl20 in HIV), is the highly glycosylated surface glycoprotein which contains
the receptor-binding site of the virus. This is non-covalently attached to the highly
hydrophobic transmembrane glycoprotein gp46, (gp41 in HIV), which contains the
fusion domain of the virus envelope (Crane et al. 1991). The gag gene encodes the
major structural proteins: p30 (or p25) - the core protein, pl6 - the matrix protein, and
pl4 - the nucleoprotein (Vigne et al. 1982). Pol encodes the reverse transcriptase, an
endonuclease and a protease (Narayan et al., 1993, Figs. 1 and 2). All the structural
proteins are cleaved from precursors during the replication and maturation of the virus.
1.1.2.2. Regulatory genes.
Lentiviral regulatory proteins are encoded by the small open reading frames
(ORFs) vif, rev and tat (Fig. 2) MVV Tat, the tat gene product, is a transactivating
protein, of 10 (Davis et al. 1989) or 11 kDa (Gourdou et al. 1989). MVV Tat is
encoded from one exon, whereas HIV Tat requires transcription from two exons (Arya
et al. 1985). It has been reported that Tat is necessary for efficient viral replication and
enhanced viral transcription. However, the function of Tat seems to vary between
lentiviruses. SIV (Arya et al. 1987), BIV (Pallansch et al. 1992), EAIV (Derse et al.
1991) and HIV (Arya et al. 1985) Tat strongly transactivate the viral LTR, by binding to
a TAR (trans-activating responsive) binding sequence. In these viruses it acts as a
switch which initiates the expression of all viral genes, allowing more frequent initiation
and more efficient elongation during transcription (Gourdou et al. 1989). In contrast,
CAEV (Harmache et al. 1995), FIV (Sparger et al. 1992) and MVV (Carruth et al.
1994) Tat proteins are only weak transactivators. Furthermore, these viruses do not
contain TAR elements. Instead, Tat may bind to AP-1, AP-4 or CBF sequences in the
LTR (Gabuzda et al. 1989; Sutton et al. 1997). These findings suggest that, at least for
MVV, FIV and CAEV, the regulatory gene product Tat may have functions other than in
the effective replication of the virus. Lentiviral Tat proteins contain three essential
domains: the acidic amino terminal, necessary for effective transactivation, a cysteine
rich domain, necessary for Tat dimerisation, and the carboxy terminal region, necessary
for nuclear localisation (Steffy et al. 1991, Fig. 3).
Rev is encoded by exons at both ends of the env gene to form a 19 kDa
polypeptide (Mazarin et al. 1990). Deletion of Rev results in a replication incompetent
virus (Toohey et al. 1994). It is believed to aid the expression of incompletely spliced
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env mRNA coding for the envelope glycoprotein (Tiley et al. 1990). There exists little
sequence homology between HIV and MVV Rev.
Little is known of the 29kDa protein encoded by vif, however, its deletion results
in reduced CAEV and HIV production and infectivity. In CAEV, Vif appears to act at
the stage of virus formation and release, whereas HIV Vif plays a role in reverse
transcription by the virus (Ma et al. 1994; Goncalves et al. 1996).
In addition, the SA-OMVV posesses an extra novel ORF W, not found in the
other strains of MVV (Querat et al. 1990). HIV also has four more regulatory ORFs:
vpr, vpu, tev and nef, which are not present in MVV. The nef gene product seems to
play an important role in HIV infectivity, by its degradation of CD4 molecules, and




Fig. 1.1: Diagram of a mature MVV virion
Mature virions measure approximately 80-120 nm in diameter with the nucleoid























Fig. 1.2: The MVV genome and encoded proteins.
Synthesis and processing of MVV strutural proteins are cleaved from precursor
polyproteins during maturation and replication of the virus. Relative nucleotide
positions are indicated by the scale bar. From Carey and Dalziel (1991).
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Fig. 1. 3: Transactivating protein Tat ofMVV
The acidic amino terminal contains the domain essential for effective transactivation of M
cysteine rich domain is necessary for Tat dimerisation and contains the neurotoxic fragment of th
The carboxy terminal is also needed for nuclear localisation of the protein.
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1.1.3. Cellular tropism ofMVV and HIV.
MVV primarily infects cells of the monocyte/macrophage lineage in vivo
(Gendelman et al. 1985) but can also infect other cell types in vitro including sheep
choroid plexus cells, lung epithelia, astrocytes, oligodendrocytes, microglia and
fibroblasts (Narayan et al. 1982). Studies performed on infection of fibroblasts in vitro
show that the virus first binds to a specific cellular receptor. This receptor is as yet
uncharacterised but MHC class II antigens have been reported to bind MVV, and
soluble class II molecules can inhibit infection of choroid plexus cells (Dalziel et al.
1991). The presence of MHC class II molecules alone is not sufficient, however, as T
and B lymphocytes possess such molecules but do not become infected. Antibodies to
an unidentified 50 kDa protein from sheep choroid plexus cells can also block infection
in culture, and this protein may represent another constituent of the MVV receptor
(Crane et al. 1991).
The life cycle of MVV is also linked to the stage of maturation of the cell
(Gendelman et al. 1986). Monocytes are believed to be latently infected, possibly
providing a reservoir of infection and allowing viral persistence in the host.
Macrophages in infected tissues, however, are laden with virus particles. Indeed it has
been demonstrated that virus replication depends on cellular factors present in the
mature macrophage (Gabuzda et al. 1989). MVV infection of lymphocytes has been
reported (Georgsson et al. 1979), and specifically of T-helper cells (Jolly et al. 1989).
HIV, by contrast, mainly infects T-helper cells, via association with the CD4 receptor, as
well as cells of the monocyte/macrophage lineage. In HIV positive patients,
approximately 10% of T cells are infected with the virus. However, levels of virus in
the blood are low, approximating 1 in 105 or 106 cells for both viruses.
1.1.4. The MVV life cycle
Following binding of MVV to its cellular receptor, the virus is internalised
through pH-independant fusion of the transmembrane glycoprotein with the plasma
membrane of the cell. The virus is subsequently uncoated and the ribonucleoprotein
complex is liberated into the cytosol (Narayan et al., 1993). Reverse transcription of
viral ssRNA ensues with the formation of double-stranded (ds)DNA, probably through
9
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the binding of tRNAlysi,2 to the primer binding site of the LTR (Sonigo et al. 1985).
Entry of proviral DNA into the nucleus and incorporation of viral DNA into host cell
DNA follow. Thus, MVV integrates itself into the host cell genome. Once this has
been accomplished levels of proviral DNA continue to rise, resulting in synthesis of
genomic and spliced mRNA. Viral proteins are then produced and MVV assembly
occurs by budding from the plasma membrane.
Less is known about the in vivo infection of monocytes/macrophages, where
replication of the virus seems to be blocked to some extent. Binding of MVV to
macrophages in vivo occurs via an uncharacterised receptor but also via Fc receptors
when the virus is already bound to an antibody (Jolly et al. 1989). The whole Fc-IgG-
virion complex is then internalised into the macrophage. It is not known whether
proviral DNA integrates into macrophage DNA. A further difference exists in the in
vivo packaging of virus, which occurs through budding of the endoplasmic reticulum
into intracytoplasmic vacuoles in the macrophage (Narayan et al. 1982).
1.2. PATHOLOGY OF MVV AND HIV INFECTION.
1.2.1. Lungs.
One of the most extensive descriptions of the pathology of lungs in naturally
occuring Maedi comes from Sigurdsson's first account of the disease (Sigurdsson
1954b). The carcass of the diseased sheep is thin with some occasional serous fluid
present in the abdomen. When the thorax is opened the lungs collapse less than usual
and are four to five times heavier than in a normal individual. Both the tracheobronchial
and the mediastinal lymph nodes are greatly enlarged. The lung tissue is dry and
diffusely thickened and differs in colour from healthy lungs, ranging from greyish
yellow to greyish blue. At the microscopic level, the alveoli are infiltrated with
numerous macrophages and the alveolar septa are thickened. The smooth muscle at the
alveolar ducts appears thickened. Cellular exudates are composed mainly of alveolar
macrophages with relatively few lymphocytes. The pathological changes are confined
to the lymph nodes and the lungs, with the bronchial tree being free of lesions.
HIV positive patients often present respiratory complications. Often, these are
due to opportunistic bacterial, fungal and viral infections as well as increased incidences
of pulmonary malignancies and lymphoma. The discussion of these diseases is beyond
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the scope of this work, but some pulmonary complications occur due to HIV infection
alone, particularly in children. The major manifestations of these disorders are
lymphocytic interstitial pneumonitis (LIP) and non-specific interstitial pneumonitis
(NIP). In individuals affected by LIP, the main symptoms are the insidious onset of
dyspnoea, a non-productive cough and fever (Andiman et al. 1985; White et al. 1989).
In HIV positive children with LIP, the onset of disease usually occurs in the second or
third year of life and is observed as pulmonary lymphoid hyperplasia with hyperplasia of
bronchus-associated tissue and lymphoid infiltration of the lung parenchyma (Schneider
1996). Histologically, LIP is characterised by infiltration of small lymphocytes and
plasma cells along lymphatic vessels and into the alveolar septae (Halprin et al. 1972).
NIP is less well characterised and symptoms are usually mild, involving a non¬
productive cough (Ognibene et al. 1988). The pathology of infected lungs showing NIP
reveals nodular lymphoid aggregates around the bronchioles with interstitial fibrosis,
loose alveolar septal fibrosis and diffuse alveolar damage (Travis et al. 1992).
Infiltrates of mononuclear cells and lymphocytes are distributed along the pleura and the
interlobular septae as well as along the bronchioles and blood vessels (Travis et al.
1992). The prognosis for these disorders is good, as both respond to treatment with
steroids, but inevitably other more serious pulmonary disorders occur in these patients
which are often fatal.
1.2.2. Joints.
Lentiviruses are associated with disorders of joints, resulting in synovitis and
arthritis. Symptoms of joint disease are most frequently seen in goats infected with
CAEV, but are also present in sheep infected with MVV and HIV positive patients
(Crawford et al. 1981; Oliver et al. 1981a; Dalton et al. 1990). In HIV positive
individuals with musculoskeletal symptoms, the largest joints, such as the knee and
elbow, are the most frequently affected. The most common manifestation of H1V-
induced joint problems is articular arthralgia causing intermittent or persistent pain in
the affected joints (Buskila et al. 1990). AIDS-associated arthritis, an unclassified
inflammatory articular disease, is also described in HIV positive individuals, and
appears to be a reactive phenomenon caused by the action of immune complexes on the
synovium, as opposed to a direct action of the virus (Berman et al. 1988).
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The main joint affected in CAEV and MVV is the carpus, followed by the tarsal
joints. Tissue surrounding the articulations becomes visibly swollen causing lameness
in the infected animal. On post-mortem examination, the affected joints are edematous.
Hyperplasia of the synovial membrane is evident with periarticular fibrosis and areas of
mineralisation and necrosis. These features are also present in sub-synovial tissues.
Erosion and necrosis of cartilage and bone present another trait of affected joints (Oliver
et al. 1981b; Cutlip et al. 1985). The most striking feature however, is the infiltration of
lymphoid cells and macrophages into synovial tissue. Of the lymphoid cells, CD8+ T-
cells are the preponderant cell type in the synovium at all stages of the disease
(Anderson et al. 1994). This is paralleled in HIV associated arthritis (Espinoza et al.
1990).
1.2.3. Central Nervous System
The CNS lesions observed in visna appear to be mainly inflammatory in nature
with invasion of inflammatory cells along the ventricular system. In naturally occurring
and experimental visna, there is a marked pleocytosis in the cerebrospinal fluid (CSF)
with the main invading inflammatory cell type being the macrophage followed by
reactive lymphocytes and eventually phagocytes (Sigurdsson 1954a; Georgsson et al.
1977; Georgsson et al. 1982; Georgsson et al. 1979) although some reports have
identified T-cells as the preponderant cell type (Torsteindottir et al. 1992).
Inflammatory lesions consisting of increased cellular infiltrates and glial cell
abnormalities appear in the frontal lobes, cerebellum, thalamus, mesencephalon, pons
and medulla but are rarer in the occipital lobes (Sigurdsson 1954a). Scattered foci of
activated microglial nodules and astrocytosis are the most prevalent features of MVV
neuropathology although some neuronal damage is also observed. Secondary
degeneration of nerve cells in the CNS has been described, observed as chromatolysis
and sclerosis (Sigurdsson 1954a).
Ultrastructural studies on the brains of experimentally infected sheep have been
carried out at various stages after infection. In the shorter term (Georgsson et al. 1977),
one month post-injection, no virions are found within the CNS, but cellular infiltrates
are found perivascularly, with a widening of the extracellular spaces. Astrocytes are
found to be swollen and axonal damage is observed without myelin breakdown. In those
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brains recovered years after experimental infection (Georgsson et al. 1982), intense
inflammation is observed around the ventricular system and the choroid plexus. The
ependymal lining appears destroyed and inflammation is further observed in the
neuroparenchyma, especially in the corpus callossum, the fasciculus subcallossus and
the hippocampi with some infiltration of the meninges. In areas showing particularly
intense inflammation, axonal degeneration and primary demyelination are evident
accompanied by liquefactive necrosis. In the spinal cord, neuronal degeneration in
naturally occuring visna is especially prevalent in the cervical segments (Sigurdsson
1954a). Later work on experimental visna indicates spinal cord lesions in grey matter
(Georgsson et al. 1977) and white matter (Georgsson et al. 1982), with axons stripped
of myelin sheaths and secondary demyelination evident as axonal atrophy without
myelin degradation. In areas of primary demyelination, astrocytes with densely packed
microfilaments are evident, as well as the presence of macrophages.
The neurological symptoms resulting from HIV infection culminate in Aids
Dementia Complex (ADC). Early ADC is characterised by slowing of motor and
cognitive functions, as well as tremor and gait unsteadiness. In later ADC,
forgetfulness, a worsening of the intellectual impairment, apathy, motor weakness and
hypokinesia become apparent, eventually resulting in overt dementia and loss of motor
control (Navia et al. 1986; Price et al. 1988). Cases of paediatric AIDS result in the
child suffering developmental delay and failing to reach milestones. Spasticity is also
common.
The neuropathology observed in HIV infected individuals has been divided into
HIV encephalitis and HIV leukoencephalopathy in the CNS, with vacuolar myelopathy
occuring in the spinal cord. HIV encephalitis is characterised by the spread of
inflammatory cell infiltrates, and the presence of multinucleated giant cells, consisting
of fused HIV infected and uninfected microglial cells (Sharer et al. 1986; Budka 1986;
Dickson 1986). HIV leukoencephalopathy is characterised by intense reactive
astrocytosis, where astrocytes become activated and overexpress glial fibrillary acidic
protein (GFAP), and diffuse white matter pallor, probably due to loss of myelin (Budka
1991). Multinucleated giant cells are present, as in HIV encephalitis, but there appears
to be less infiltration of inflammatory cells.
Spinal cord abnormalities are detectable in both adult and paediatric HIV
positive individuals. In adult patients this consists of vacuolar myelopathy with
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swelling within the myelin sheath of axons, and only a thin layer of myelin surrounding
the underlying vacuoles (Petito et al. 1985). In areas of intense vacuolation, axonal
degeneration is observed. As in HIV encephalopathy, spinal cord myelopathy is
accompanied by an infiltration of macrophages expressing HIV antigens, with some
macrophages demonstrating active ingestion of myelin (Eilbott et al. 1989). In
paediatric AIDS, corticospinal tract degeneration is evident, with loss of myelin or
axonal degeneration or both (Dickson et al. 1989). This may be a consequence of
pathological changes within the CNS, extending to the spinal cord by the mechanism of
Wallerian degeneration. Both HIV encephalitis and HIV leukoencephalopathy
preferentially affect subcortical regions of the brain, with pathology occuring mainly in
areas such as the basal ganglia, pons and cerebral white matter. Neuronal loss is also
evident in these areas, but can extend to the cerebral cortex and the cerebellum (Everall
et al. 1991). Neurons that are not completely lost display dilated and vacuolated
dendrites, with less spines and decreased length and branching (Masliah et al. 1992).
Paediatric HIV encephalitis is manifest preponderantly by astrocytic gliosis, with
mineralisation of the basal ganglia and brain atrophy (Belman et al. 1986).
1.3. LENTIVIRAL INVASION OF THE CNS.
1.3.1. Neurotropism of MVV and HIV.
Although it is well established that MVV infects monocytes/macrophages and
HIV infect monocyte/macrophages and T-helper cells, it is necessary, for the purposes
of understanding the neurodegeneration involved in HIV dementia, to elucidate the
neural cell types which become infected with HIV. Co-localisation studies performed
on post-mortem brains, simultaneously identifying viral antigens and specific cell type
markers have revealed that the main type of cells infected in both MVV and HIV are
glial cells as well as circulating macrophages (Wiley et al. 1986; Kure et al. 1990a;
Vaseux et al. 1987; Stoler et al. 1986; Stowring et al. 1985). In HIV, the main type of
glial cell expressing viral antigens is the microglial cell (Wiley et al. 1986; Kure et al.
1990a; Kure et al. 1990b; Vaseux et al. 1987; Stoler et al. 1986). Microglia have also
been shown to support HIV and MVV infection in vitro (Cheng-Mayer et al. 1987;
Chiodi et al. 1987; Dewhurst et al. 1987; Jordan et al. 1991; Tornatore et al. 1994;
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Watkins et al. 1990; Bagasra et al. 1996; Wigdahl et al. 1987; B. Ebrahimi, personal
communication).
Other types of glial cells, notably astrocytes and oligodendrocytes, have also
been shown to express MVV and HIV viral antigens in vivo (Epstein et al. 1985;
Gyorkey et al. 1987; Kohleisen et al. 1992; Pumarole-Sune et al. 1987; Saito et al.
1994; Tomatore et al. 1994; Stowring et al. 1985), although the evidence for this is not
as emphatic as for the infection of microglia. Reports of astrocyte infection are rare in
adult HIV encephalitis but do seem to be a more prominent feature in paediatric AIDS
cases, where astrocytes generally appear to be more involved in the pathologic process,
and may thus play a more pivotal role in the neuropathogenesis of HIV (Blumberg et al.
1994). In vitro, astrocyte infection by HIV is restricted, the virus only expressing early
regulatory gene products but no structural genes (Blumberg et al. 1994; Ma et al. 1994).
Further doubt regarding the productive infection of astrocytes also arises from the
finding that immunocytochemical markers for some HIV antigens, in particular the nef
gene product, are expressed at low levels in the uninfected nervous system (Saito et al.
1994).
Neurons do not seem to support MVV replication, although MVV antigens have
been detected in cells that cannot be morphologically identified as microglia, astrocytes
or oligodendrocytes and thus could be neurons (Stowring et al. 1985). Similarly, there
are a few reports of HIV infection of neurons in vivo (Bagasra et al. 1996; Stoler et al.
1986; Wiley et al. 1986), although there is little evidence that neurons support HIV
replication in vitro.
Although it is known that HIV infects lymphocytes via an association of the
envelope glycoprotein gpl20 with the CD4 receptor on T-helper cells, little is known as
to the mechanism by which HIV infects microglia. Some authors report the blocking of
HIV infection of brain derived microglia with CD4 antigens (Jordan et al. 1991)
suggesting that the same mechanism which mediates HIV entry into lymphocytes is at
play in microglia. This is supported by the finding that microglia can be stained in situ
for CD4 antigens and that CD4 specific RNA is detected in these cells (Funke et al.
1987). However, other authors report that glial cell infection is not CD4 dependant (Ma
et al. 1994; Harouse et al. 1989; Kunsch et al. 1989). Moreover, neurons have been
shown to express the CD4 molecule (Funke et al. 1987), but as has previously been
discussed, do not seem to be productively infected by HIV. It is possible that CD4 does
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play a role in the binding of the virus to microglial cells, but that there may also be
another mode of entry of HIV into glial cells. This may involve the presence of a
second receptor on microglial cells, which would allow infection of these by HIV.
Indeed, recently, the chemokine receptors CCR5 and CCR3 have been proposed as
microglial co-receptors for HIV (He et al. 1997).
1.3.2. Mechanisms ofHIV and MVV entry to the CNS.
Much has still to be elucidated regarding the entry of HIV and MVV into the
CNS. There is little evidence of cell-free entry of MVV into the brain although freely
circulating virus has been detected in the brains of HIV positive patients. Levels of free
virus, however, do not correlate with the extent of dementia whereas the number of
infected cells does. Indeed, there is little evidence that HIV or MVV infect brain
microvascular endothelial cells (BMVECs), which would provide a direct route of
infection to the CNS. Lymphocytotropic strains of HIV have been shown to infect
BMVECs in vitro (Moses et al. 1994). However, it is rarely found that BMVECs are
infected on post-mortem analysis and macrophage tropic strains of HIV, which have
more neuroinvasive potential, are not found to infect BMVECs (Nottet et al. 1996b). It
is more likely that lentiviruses gain access to the CNS via the Trojan Horse mechanism,
disguised under the cover of infected monocytes (Peluso et al. 1985).
HIV infected monocytes have been shown to produce elevated levels of the
cytokines TNFa and IL-1(3 (Tyor et al. 1992; Wesselingh et al. 1993). These have in
turn been shown to upregulate the cell adhesion molecules E-selectin and vascular cell
adhesion molecule-1 (V-CAM1) on BMVECs (Staunton et al. 1988; Osborn et al. 1989;
Bevilacqua et al. 1987). Molecules on the cell surface of monocytes, sialylated and
sulfated fucosylated lactosamine oligosaccharides and antigen-4 integrins (Bevilacqua et
al. 1993; Varki 1994; Elices et al. 1990), can bind to E-selectin and V-CAM1 to allow
the transendothelial migration of monocytes across the BBB (Carlos et al. 1991;
Hakkert et al. 1991). E-selectin and V-CAM1 also promote BMVEC adhesion to other
cells including polymorphonuclear cells, memory T-cells, lymphocytes, basophils and
eosinophils (Bevilacqua et al. 1987; Shimizu et al. 1991; Dobrina et al. 1991; Bochner
et al. 1991). Therefore it is possible that agents are released by infected monocytes that
act as specific chemoattractants for other monocytes to allow the preferential permeation
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of these cells across the BBB. Levels of Transforming Growth Factor beta (TGF(3), a
powerful monocyte attractant molecule, are elevated in cases of HIV encephalitis (Wahl
et al. 1987; Wahl et al. 1991), as are the levels of expression of the chemokines MlPla
and MIP1(3 which also act as chemoattractants for monocytes as well as subpopulations
of lymphocytes (Schmidtmayerova et al. 1996). Induction of MlPla and MIPlp
(macrophage inflammatory protein-1 a and (5) is also upregulated in HIV infected
monocytes. Furthermore, activated BVEMCs have been shown to produce increased
levels of MCP a macrophage chemotactic protein (Rollins et al. 1990). In addition to
these molecules, HIV infected monocytes produce leukotrienes (LT) which have been
shown to increase BBB permeability (Black et al. 1985).
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Infected monocyte Chemotactic agents
TGF, MCP.MIP
Fig. 1. 4: Proposed mechanism of HIV entry into brain.
BBB: Blood Brain Barrier, BMVECs: Brain Microvascular Endothelial Cells, TNF:
Tumour Necrosis Factor a, IL-1: Interleukin ip, LT: Leukotrienes, TGF:
Transforming Growth Factor p, V-CAM1: Vascular Cell Adhesion Molecule 1.
Infected monocytes release TNFa and IL-ip which upregulate the cell adhesion
molecules E-selectin and V-CAM1, whilst also releasing chemotactic agents to recruit
further infected cells. V-CAM1 and E-selectin then bind molecules on the surface of
infected monocytes and permit their migration across the BBB. Once entry to the CNS
has been achieved, resident microglia become infected with HIV and release TNFa and
IL-ip to sustain the expression of V-CAM1 and E-selection on BVEMCs, as well as
chemoattractants which diffuse across the BBB, and leukotrienes which increase the




1.4. NEUROPATHOGENESIS OF LENTIVIRAL INFECTIONS.
Several hypotheses have been put forward regarding the causes of the
neuropathology observed in MVV and HIV. Firstly, it is possible that viral proteins
may be exerting direct detrimental effects on cells in the CNS. Secondly, cells infected
with HIV or MVV may be releasing agents that cause neural damage, or act on resident
cells of the CNS causing these to produce neurodegeneration. Thirdly, although the
brain has long been regarded as immunologically privileged, there is now increasing
evidence that immunological responses do occur within the CNS in response to invading
pathogens, and that these may have deleterious consequences on surrounding brain
tissue.
1.4.1. Direct action of viral fragments.
Several MVV and HIV proteins have been volunteered as neurotoxic agents.
1.4.1.1. gP120
The HIV envelope glycoprotein gpl20 has been intensely investigated as a
possible neurodegenerative agent, probably due to the fact that it is located on the
surface of lentiviruses, and thus would be one of the first elements to come in contact
with host cells, and that it is shed extracellularly upon infection of cells. Gpl20 has
been shown to be directly neurotoxic to various neuronal cultures including cortical,
hippocampal, retinal ganglion and cerebellar granule cell cultures (Brenneman et al.
1988; Brenneman et al. 1994; Corasaniti et al. 1995; Dawson et al. 1994; Meucci et al.
1996; Mucke et al. 1995; Dawson et al. 1993; Ushijima et al. 1993; Sweetnam et al.
1993). The neurotoxic mechanism involved in gpl20 killing of neuronal cultures has
been ascribed to excessive extracellular calcium influx to neurons, via the L-type
voltage sensitive calcium channel (Lo et al. 1992; Lipton 1991). Gpl20 has also been
reported to act at the NMDA receptor of neurons, a receptor for glutamate, which, when
inappropriately activated, as in some disease states, can cause a superfluous amount of
glutamate release, causing adjacent neurons to die (Sweetnam et al. 1993). Indeed,
inhibition of the NMDA receptor by MK801 results in lower neurotoxic rates of gpl20
(Corasaniti et al. 1995; Lipton 1992a). However, gpl20 has only been reported as a
weak agonist of the NMDA receptor and is more likely only to act synergistically with
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other NMDA receptor activators (Lipton 1991). Another mechanism that may be at play
in the gpl20 induced killing of neurons is apoptosis, whereby the affected cell is
induced to self destruct with minimal damage to surrounding cells (Aggoun-Zouaoui et
al. 1996; Muller et al. 1992). However, some studies do not report any in vitro gpl20
induced neurotoxicity, whilst others have only found a harmful effect of gpl20 when
neurons are co-cultured with microglia, astrocytes or macrophages (Lipton 1992b),
indicating that the sole presence of gpl20 is not sufficient to elicit considerable
neurotoxicity. In these cases gpl20 causes the release of neurotoxins from macrophages
or microglia (Giulian et al. 1993). Gpl20 has also been found to damage astrocytes in
culture, causing changes in GFAP immunoreactivity and some astrocytic cell death
(Benos et al. 1994; Pulliam et al. 1993; Levi et al. 1993).
In vivo experiments consisting of stereotaxic injections have also demonstrated
the neurotoxic capability of gpl20 (Hill et al. 1993; Lipton et al. 1995), including
neuronal loss, decreases in glucose utilisation and impairment of memory function
(Kimes et al. 1991; Glowa et al. 1992). However, this capacity seems to vary greatly,
depending on the age of the experimental animal as well as the method and site of
administration of gpl20 (Bagetta et al. 1994). In cases where gpl20 is found to cause
toxicity to neurons, this seems to be mediated by an apoptotic mechanism. More
convincing evidence for the neurotoxic potential of gpl20 in vivo comes from the
development of transgenic mice overexpressing gpl20 where neuronal damage is
evident (Toggas et al. 1994). This is manifest by the drop-out of cortical neurons,
vacuolar degeneration of dendrites and a decrease in the number of presynaptic
terminals of neurons. Astrocytosis and microgliosis are also observed. None of these
changes occur in wild type mice or in transgenic control mice overexpressing (3-
galactosidase. These neurotoxic changes occur from 7 days post-natally in gpl20
transgenic mice. This correlates with the time of development of NMDA receptors in
mice (MacDonald et al. 1993), therefore reinforcing the putative role of these receptors
in mediating gpl20 induced neurodegeneration.
1.4.1.2. Tat
The transactivating protein Tat has also been found to be neurotoxic in vitro and
in vivo. Studies on HIV infected lymphocytes have shown that Tat can be released from
these cells in vitro (Ensoli et al. 1990). Furthermore, Tat can be taken up by uninfected
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cells when it is present in their culture medium (Frankel et al. 1988; Mann et al. 1991),
and may move from infected cells to uninfected cells via cell to cell contact resulting in
the transactivation of the adjacent uninfected cell (Helland et al. 1991; Marcuzzi et al.
1992a; Marcuzzi et al. 1992b). These findings suggest that, at least some of the time,
Tat is present extracellularly and may have an effect on different cell types.
Application of HIV Tat to hippocampal neurons in rodent brain slices results in
the depolarisation of neurons (Magnuson et al. 1995). Tat also depolarises rat glioma
and murine neuroblastoma cells (Sabatier et al. 1991). This is mediated by non-NMDA
glutamate receptors on neurons since it can be blocked by the excitatory amino acid
antagonist kynurenate. These findings, and the observation that Tat bears some
sequence homology with snake venom neurotoxins (Garry et al. 1992), imply that Tat
may be having a direct action on neuronal cell types which may result in neurotoxicity.
Indeed, the in vitro application of HIV and MVV Tat or tat peptide, derived from the
basic cysteine rich region of Tat, to rodent cortical cell cultures results in cell death as
measured by Lactate Dehydrogenase (LDH) assay (Strijbos et al. 1995b) and trypan blue
exclusion (Magnuson et al. 1995; Sabatier et al. 1991). In both cases, neurotoxicity is
attenuated by the administration of NMDA receptor antagonists, and involves calcium
influx. However, HIV Tat has also been found to cause neuronal death in culture by
apoptosis (New et al. 1997) and to alter the normal organisation of astrocytes in culture
although no astrocytic cell death ensues (Kolson et al. 1993)
In vivo, HIV and MVV Tat and tat peptides are also neurotoxic when injected
stereotaxically into rat and mouse striatum (Gourdou et al. 1990; Hayman et al. 1993;
Sabatier et al. 1991). Infusion of the tat peptide results in neuronal loss, microglial
activation, macrophage invasion and astrocytosis. Similarly to the in vitro findings, this
neurotoxicity can be diminished by the co-administration of MK801, an NMDA
receptor antagonist, and by L-NAME, a NOS inhibitor, suggesting that the mechanism
causing neuronal cell death is NO-mediated glutamate neurotoxicity via NMDA
receptors. Also in vivo, the blocking of TNFa reduces the neurotoxic effects of





Few experiments have been performed on the neurotoxic capability of Rev. One
investigation, however, has revealed that, when injected into mice
intracerebroventricularly, the basic domains of HIV and SIV Rev do cause neurotoxicity
(Mabrouk et al. 1991). Like Tat, Rev contains numerous arginine residues and an
unusual basic domain, which may confer it a neurotoxic ability. HIV Rev is also
abundantly expressed in glial cells in the brains of HIV positive patients and correlates
with the level of dementia (Ranki et al. 1995).
1.4.1.4. Nef
As for gpl20, Tat and Rev, the HIV nef gene product has been shown to exhibit
sequence and structural homology to other known neurotoxins. In this case, Nef
resembles a scorpion neurotoxin which interacts with K+ channels (Werner et al. 1991).
However, no studies on any neurotoxic potential of Nef have been published, although
some investigators ascribe it a potential neurotoxic role since it is produced in
abundance in glial cells during restricted HIV infection of astrocytes (Werner et al.
1991; Ranki et al. 1995)
1.4.1.5. gp41
The transmembrane protein gp41 has similarly been suggested to have a
neurotoxic role since it resembles natural peptides with cytopathic abilities and has itself
been found to be neurotoxic in culture (Miller et al. 1991).
1.4.2 Indirect causes of neurodegeneration
Although the viral fragments listed above have neurotoxic properties, little cell
free virus is detected in HIV and MVV infection. This suggests that a direct action of
viral proteins may not be the single cause of lentiviral neurodegeneration, although this
possibility should not be discounted especially since gpl20 and Tat are released from
infected macrophages. It is more likely that any direct effects of viral proteins are
accompanied by indirect effects of infected cells. These effects may be due to the
combined release of viral proteins such as gpl20 and Tat, and soluble mediators such as
cytokines, from infected macrophages. These may be directly neurotoxic or may affect
microglia and astrocytes, causing them to release neurotoxic substances, thus perturbing
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the local microenvironment in the CNS, and interfering with the natural homeostasis
achieved by the normal interaction of neurons with microglia, astrocytes and
oligodendrocytes.
1.4.2.1. Quinolinic acid (QA).
Levels of QA have been shown to be elevated in patients with ADC and are
positively correlated with the level of dementia (Heyes et al. 1992). Furthermore, levels
of secreted QA by macrophages are elevated when these cells are activated and infected
with HIV (Nottet et al. 1996a). QA is an agonist at the NMDA receptor, and has been
found to be neurotoxic, albeit at relatively high doses, both in vitro and in vivo
(Schwarcz et al. 1983; Kim et al. 1987). Thus, although it is unlikely that the presence
alone of small amounts of QA is sufficient to result in neurotoxicity, it is possible that
QA acts in concert with other infected cell-secreted factors, for example Tat or gpl20,
to cause neurotoxicity via the NMDA receptor. Another detrimental action of QA may
result from its synthesis. The precursor for QA is L-tryptophan, an amino acid which
also participates in the synthesis of the neurotransmitter 5-hydroxy-tryptamine (5-HT).
Increased production of QA in HIV may result in a depletion of tryptophan, and thus 5-
HT, to further add to CNS dysfunction.
1.4.2.2. An NMDA-like neurotoxin.
Biochemical, physical and pharmacological evaluations of lentivirus induced
neurotoxicity in vitro point to an unknown substance released from HIV infected
macrophages that may be responsible for neuronal injury. These investigations point to
an element that is protease-resistant, therefore not a protein or cytokine, heat-stable,
therefore not a free radical, which is neither a glycolipid nor an amino-acid, but is
blocked by NMDA receptor antagonists, although is not a classical NMDA receptor
agonist as it lacks a COO- moiety. It is also cationic and less than 500 Da in mass
(Giulian et al. 1990; Giulian et al. 1993). It is possible that this substance modulates the
NMDA receptor in some way or increases extracellular levels of NMDA receptor
agonists to incur neurotoxicity. Recently this substance has been characterised as a
neurotoxic amine called NTox (Giulian et al. 1996). This is not an established
neurotoxin, but has been found to be neurotoxic when injected in vivo. Furthermore,




Cytokines are a large family of cellular mediators which are widely believed to
play an important role in the regulation of tissue homeostasis and integrity, either via
local influences or by the recruitment of other factors from the circulation. Typically,
they are expressed at very low levels in healthy situations, but their expression can
change markedly in disease states and in response to tissue stress. Their actions cover a
broad range of activities, some known to act as trophins, others as toxins and yet others
as both depending on the level of their expression, and they are secreted by a wide range
of different cell types. The size and structure of cytokines has provoked controversy as
to whether they are able to penetrate the BBB, but it is now firmly established that
cytokines are synthesised and expressed within the CNS, or cells isolated from the CNS.
There exists a veritable plethora of cytokines, but for the purposes of this thesis only a
few will be discussed, those that seem to play a role in response to central nervous tissue
damage and disease states, in particular IL-ip, IL-6, TNFa, and TGFp.
1.4.2.3.1. Cytokine receptors in the CNS.
Receptors for EL-la and P, IL-6 and TNFa have been characterised in brain, but
their precise cellular location is unclear. Two receptors for IL-la and p, types I and II,
exist in the CNS. Some reporters attribute the actions of IL-la and P in the brain
exclusively to the type I receptor (Sims et al. 1993). However, other investigators have
shown that the actions of EL-ip, when administered directly to the brain, can be
inhibited by antibodies to the IL-1 type II receptor (Luheshi et al. 1993). This treatment
does not have any effect on the actions of IL-la, suggesting that the two isoforms of IL-
1 may be acting at the two different receptors. Detection of the IL-1 type I receptor
locates it predominantly in the dentate gyrus of rodents (Takao et al. 1990). In the brain,
as well as peripheral tissues, a naturally occuring antagonist to the actions of IL-1 exists
(IL-lra), although its functions are unknown (Licinio et al. 1991).
In human cells, EL-6 binds to a 80 kDa glycoprotein which associates with a 130
kDa glycoprotein (gpl30) for signal transduction (Taga et al. 1989). IL-6 receptors are
expressed in rodent brain and are localised in the hippocampus, hypothalamus, the
internal capsule, the optic tract and the piriform cortex (Schobitz et al. 1992). These
receptors are also expressed in cultured neurons and glial cells (Sawada et al. 1993).
Interestingly, like some other cytokine receptors, the extracellular portion of the IL-6
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receptor can be released as a ligand binding protein. However, unlike other cytokine
receptors, the binding of the free receptor to its ligand fails to cause inactivation of the
ligand and instead increases the affinity of the interaction between the IL-6 receptor and
gpl30 (Hopkins et al. 1995).
TNFa binds two distinct receptors p55 and p75 (Smith et al. 1994), which are
linked to different signal transduction pathways (Tartaglia et al. 1991), and may
modulate different effects of TNFa. In the CNS, TNF receptors are widely distributed
(Smith et al. 1992). TNFa receptor subtypes also show homology with Fas/Apo-1 cell
surface receptors, which are implicated in programmed cell death of many types of cell
(Suda et al. 1993).
Three types of receptors have been identified for TGF(5 (Derynck 1994).
Evidence suggests that the type I and II receptors act as the principal signal transducer
elements and that the type III receptor plays a role in presenting TGF(3 to the other two
receptors (Miyazono et al. 1994).
1.4.2.3.2. TNFa in HIV andMW infection.
The role of the pro-inflammatory cytokines TNFa, EL-1(3 and IL-6 in the
neuropathogenesis of HIV has been the subject of much research. TNFa has been
reported to be elevated in the CSF of patients suffering from HIV dementia as compared
to HIV positive patients with no dementia (Grimaldi et al. 1991; Perrella et al. 1992),
although this correlation is not always present (Vitkovic et al. 1994). In situ detection
ofmRNA for TNFa has also found that the message for this cytokine is expressed in the
brains of HIV positive individuals, but not in uninfected individuals (Nuovo et al.
1996), and that expression of TNFa mRNA positively correlates with the level of
dementia in HIV posistive individuals (Wesselingh et al. 1993). Interestingly TNFa
mRNA is not always co-localised in cells expressing HIV antigens, suggesting that it
may be released from other cell types in response to HIV infection. In post mortem
brains, TNFa mRNA expression is observed in microglia and occasionally astrocytes
(Tyor et al. 1992). In vitro, activation of astrocytes results in the release of a substance
resembling TNFa (Robbins et al. 1987). HIV infected activated monocytic cells have
been shown to produce increased levels of TNFa in vitro (Merrill et al. 1989; Molina et
al. 1989). Astrocytes have also been found to produce higher levels of TNFa when
infected with HIV but only when these are co-cultured with macrophages (Fiala et al.
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1996). Similarly, TNFa is upregulated in glial cells and human cultured monocytes,
when exposed to HIV gpl20 (Koka et al. 1995; Clouse et al. 1991), and rises in T-cells
exposed to HIV Tat (Buonaguro et al. 1992). Cultured sheep microglia infected with
MVV also display increased levels of TNFa as revealed by RT-PCR (B. Ebrahimi,
personal communication). Supernatant from these infected cells also causes the death of
mouse trigeminal ganglion cells.
TNFa has been proposed as a mediator in causing demyelination in Multiple
Sclerosis (MS) and Human T-lymphotropic Virus 1 (HTLV1) associated myelopathy
(Brosnam et al. 1988; Moore et al. 1989) and has been implicated as a neurotoxin in
animal models of stroke (Liu et al. 1994). Indeed, TNFa has been found to be
neurotoxic to human neuronal cultures (Westmoreland et al. 1996) via the AMPA
glutamate receptor (Gelbard et al. 1993), or by the binding of TNFa to the p55 receptor
on neurons. Human neuronal cells can also be killed in vitro by TNFa via the
mechanism of apoptosis (Talley et al. 1995). Furthermore, rodent oligodendrocytes are
killed by TNFa in vitro (Robbins et al. 1987; Selmaj et al. 1988). TNFa also induces
the proliferation of astrocytes (Barna et al. 1990), and can change their profile of
cytokine release (Benveniste et al. 1994). In vitro, TNFa has also been reported to
protect neurons against excitotoxic, metabolic and oxidative stresses (Barger et al. 1995;
Cheng et al. 1994), possibly by the stabilisation of calcium homeostasis together with
suppression of the accumulation of free radicals and the induction of the neuroprotective
proteins calbindin and Mn-superoxide dismutase (Warner et al. 1991). However, the
sheer weight of evidence seems to point to a definite detrimental action of increased
levels of TNFa on neuronal cells.
The possibility of a neuroprotective role of TNFa has also been suggested in
vivo since knockout mice deficient in both TNFa receptors display greater cellular
responses to middle cerebral artery occlusion and seizure induced damage to
hippocampal neurons than their wild-type counterparts (Bruce et al. 1996). In these
same mice, microglial activation is also decreased. In another transgenic model of
disease, mice with a disruption in the gene encoding TNFa show a greater vulnerability
to autoimmune-mediated demyelination (Liu et al. 1998). This model suggests that
TNFa may be exerting an anti-inflammatory role. However, other reports seem to
confirm the pro-inflammatory role of TNFa. Transgenic mice overexpressing TNFa
26
Chapter 1: Introduction
develop more severe symptoms of the demyelinating disease experimental allergic
encephalomyelitis than their wild type counterparts (Taupin et al. 1997). The
overexpression of TNFcc alone does not seem to directly damage myelin or
oligodendrocytes, but appears to be mediated by excessive prolonged activation of
microglial cells.
1.4.2.3.3. 1L-1(3 and 1L-6 in HIV andMW infection.
The cytokines EL-1(3 and EL-6 are normally expressed in some CNS cells.
Immunocytochemically, EL-1(3 is found mainly in endothelial cells, microglia and
macrophages (Tyor et al. 1992) but it can also be detected in astrocytes and
oligodendrocytes (da Cunha et al. 1993b). IL-6 is detectable in macrophages,
astrocytes, endothelial cells and microglia (Van Snick 1990). As with TNFa, reports of
increased levels of EL-1(3 and IL-6 in the CSF of HIV positive demented patients are
inconsistent, some investigators reporting increased levels (Gallo et al. 1989; Perrella et
al. 1992), others not (Weller et al. 1991). In situ detection of EL-1 j3 in the brains of
AIDS patients has shown greater levels of EL-1 (3 immunoreactivity in these individuals
as compared to EEEV negative controls (Tyor et al. 1992). EL-6 expression does not seem
to alter, although some reporters have found that microglia stain positively for EL-6 in
AIDS brains but not in control brains (Vitkovic et al. 1994), as well as in the spinal cord
of patients with AIDS (Yoshioka et al. 1994). In vitro, levels of IL-1 (3 and IL-6 are
upregulated in human glial cells and monocytes when these are treated with EEIV gpl20
(Koka et al. 1995; Clouse et al. 1991). EEIV infected astrocytes co-cultured with
macrophages also produce higher levels of EL-6 (Fiala et al. 1996). EL-1(3 levels are also
increased in EEIV infected monocytes (Harouse et al. 1991; Molina et al. 1989), and in
sheep microglia infected with MVV (B. Ebrahimi, personal communication).
The pro-inflammatory cytokines IL-1 (3 and IL-6 do not seem to be neurotoxic
per se, since their direct application to brain cells in vitro and in vivo does not always
result in cell death. In vitro low concentrations of IL-1(3 can be neuroprotective whereas
higher concentrations are neurotoxic (Araujo et al. 1993; Lapchak et al. 1993). In vivo,
infusion of large quantities of EL-1(3 directly into the brain of rodents causes neuronal
loss and microglial activation (Bourdiol et al. 1991).
Moreover, EL-1(3 exerts a neurotoxic intensifying action when other excitotoxic
factors are present (Strijbos et al. 1995a). Levels of IL-1 (3 and IL-6 are increased
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following brain damage, and IL-1 (3 mRNA is rapidly upregulated following
experimental ischemia (Olsson et al. 1987; Minami et al. 1992). IL-1 (3 has also been
shown to release arachidonic acid, a precursor for pro-inflammatory eicosanoids
(Rothwell et al. 1993). These can mediate glutamate action at the NMDA receptor and
have been shown to positively enforce glutamate release presynaptically. Furthermore,
IL-1 (3 causes increases in intracellular calcium levels and causes the production of NO
from glial cells, both of which are factors involved in excitotoxic cell death (Rothwell et
al. 1993). IL-1 (3 can also activate astrocytes, possibly leading them to secrete
excitotoxins (Lee et al. 1993). The study of these cytokines in other neurological
diseases also points to their possible neurodegenerative role. Inhibitors of IL-1 (3 have
been shown to reduce neuronal injury in animal models of stroke and Parkinson's
disease where glutamate neurotoxicity is believed to be at play (Rothwell et al. 1993).
In Alzheimer's disease, 1L-1(3 and IL-6 are synthesised in the amyloid plaques
characteristic of the disease (Griffin et al. 1989; Strauss et al. 1992), and IL-lf3 can
induce the production of (3-APP, a protein involved in the deposition of these plaques in
the brain (Gray et al. 1993). As for IL-1 (3, IL-6 has been proposed as a
neurodegenerative cytokine, since it has been shown to increase levels of intracellular
calcium (Qiu et al. 1995). Furthermore, transgenic mice which overexpress IL-6
develop severe neurological problems resulting in ataxia, tremors and seizures,
suggesting that this cytokine is potentially lethal to cells in the CNS when its levels are
unchecked (Campbell et al. 1993).
1.4.2.3.4. TGF\3 in HIV andMW infection.
Three isoforms of TGF(3 exist but the most extensively studied form in the CNS
is TGF(3-1. The mRNA for TGF(3-1 is constitutively expressed in astrocytes, microglia
and oligodendrocytes but not neurons, under normal conditions (da Cunha et al. 1993a).
The detection of the protein, however, is rare in healthy brains (da Cunha et al. 1992).
Post-mortem examination of AIDS brains have revealed the presence of TGF(3-1
immunoreactivity (da Cunha et al. 1995). The extent and localisation of this
immunoreactivity correlate with levels of IL-1(3. These findings are supported by in
vitro evidence that IL-1 (3 stimulates the expression of TGF(3-1 by astrocytes,
oligodendrocytes and microglia (da Cunha et al. 1993b).
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To investigate the role of TGFP-1 in normal and pathologic conditions,
transgenic mice overexpressing TGFp-1 in astrocytes under the control of the GFAP
promoter have been studied (Wyss-Coray et al. 1995). Such mice develop increased
levels of extracellular matrix proteins (ECM), such as laminin, fibronectin and heparan
sulfate proteoglycan. These subtances are suspected to be involved in the deposition of
(3-amyloid, a substance which forms plaques in the brains of patients suffering
Alzheimer's disease (Fillit et al. 1995; Finch et al. 1993). Many of these mice do not
survive to adults but those that do most often become hydrocephalic. Furthermore,
when they are immune-challenged, these mice more readily develop symptoms of
experimental autoimmune encephalitis, with greater levels of mononuclear cell
infiltrates in the CNS and more overt clinical signs than their wild-type counterparts.
However, in in vitro cultures of astrocytes, TGFP-1 has been found to enhance
production of IL-6, Nerve Growth Factor (NGF), a trophic element for some neurons,
and suppress proliferation of astrocytes as well TNFa production from these cells,
suggesting that some functions of TGFp-1 may be protective to neurons (Lindholm et
al. 1992; Benveniste et al. 1994). TGFP-1 also downregulates the proliferation of
microglial cells and alters their pattern of cytokine release (Suzumura et al. 1993).
Furthermore, TGFP-1 can promote the survival of various types of neurons, such as
motor neurons, midbrain dopaminergic neurons and hippocampal neurons when these
are grown in culture (Ishihara et al. 1994; Krieglstein et al. 1995; Martinou et al. 1990).
The application of TGFP-1 to cortical cell cultures also conferred on neurons a degree
of resistance to toxicity (Krieglstein et al. 1995; Chao et al. 1994) and can protect
neurons against excitotoxic and ischaemic insults in vivo (McNeill et al. 1994; Prehn et
al. 1993). These findings suggest that steady states of TGFP-1 production may be
neuroprotective, but that upmodulation of this cytokine, as in HIV infected neuroglial
cells in response to increased levels of IL-ip, may be detrimental and further contribute
to CNS disruption already evoked by other cytokines.
Taken together these findings suggest that TNFa and other pro-inflammatory
cytokines may be involved in lentiviral induced neurodegeneration by two mechanisms:
firstly, by being directly released from infected macrophages and microglia to cause
neurotoxicity, secondly by being upregulated in microglia and astrocytes by diffused
viral proteins such as Tat and gpl20, which would cause an internal disruption to these
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cells as well as the concomittant discharge of proinflammatory cytokines and other
mediators to neighbouring cells.
In addition, LL-1(3 and TNFa causes the up-regulation of HIV gene expression in
neural cells, by enhancing the liberation of the NFk(3 protein from its inhibitor protein
Ik[3, allowing NFk(3 to bind to the enhancer region of the HIV LTR (Swingler et al.
1992). In MVV, up-regulation of gene expression is believed to occur through the Jun
and Fos proteins binding to AP-1 or CBF sites of the viral LTR (Gabuzda et al. 1989,
Sutton et al. 1997). Thus, a vicious circle of cytokine mediated neurotoxicity and viral
gene amplification may be established in lentiviral encephalopathies.
1.4.2.4. Arachidonic Acid (AA) and its metabolites
Macrophages are highly enriched in lipids and, as part of their role in the
immune system, naturally phagocytose cellular debris. Membrane phospholipids are
metabolised by the formation of arachidonic acid, which is subsequently degraded either
by the cyclooxygenase pathway to produce prostaglandins (PG) and thromboxanes (TX),
or through the lipoxygenase pathway to produce leukotrienes (lt). These have been
proposed as toxins in some neurological diseases as they can affect neuronal function
and interfere in the regulation of cytokines (Egg et al. 1980; Merrill et al. 1983). In
cases of HIV encephalitis, levels of the prostagalandins PGE2 and PGF2a have been
found to be elevated in the CSF (Griffin et al. 1994). In vitro, gpl20 has been shown to
produce increases of arachidonic acid metabolites in cultures of monocytes (Wahl et al.
1989), and amounts of these molecules are also raised in co-cultures of astrocytes with
HIV infected macrophages (Genis et al. 1992). Prostaglandins have recently been found
to stimulate glutamate release from astrocytes, via a calcium dependant mechanism
(Bezzi et al. 1998). Since excessive glutamate is toxic to neurons, prostaglandins may
be exerting an indirect neurotoxic effect. As yet, however, neither prostaglandins,
thromboxanes or leukotrienes have been shown to be directly neurotoxic. Nevertheless,
since they seem to disrupt the normal regulation of cytokine production, they may be
causing increased levels of the pro-inflammatory cytokines previously mentioned, thus
adding further weight to the neurotoxic threat of these mediators.
1.4.2.5. Nitric Oxide
As has previously been mentioned NO plays a role in certain types of cell death,
by the mechanism of NO mediated glutamate neurotoxicity. Much attention has
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therefore focused on whether NO may be having a detrimental effect in lentiviral
encephalopathies. NO has been shown to be released from HIV infected macrophages
(Bukrinsky et al. 1995) and may therefore also be released from other infected cell
types. NO has also been shown to be released from blood derived macrophages when
these are exposed to the HIV envelope glycoprotein gpl20 (Pietraforte et al. 1994).
Increased levels of NO have also been found to be elevated in peripheral blood
mononuclear cells and polymorphonuclear lymphocytes in HIV positive individuals,
especially those displaying signs of HIV encephalopathy (Torre et al. 1995). In vitro,
gpl20 induced neurotoxicity in the presence of glutamate and extracellular calcium in
rodent primary cortical cultures can be reduced by inhibitors of NO formation (Dawson
et al. 1993). Moreover, soluble NO has been shown to be toxic to rodent
oligodendrocytes. Thus, it seems that increased levels of NO in HIV infection may lead
to damage of healthy tissues, for example by the exhaustion of antioxidants, or by its
role in glutamate toxicity to brain cells. However, the ability of HIV infection to
increase levels of NO is not always paralleled in human studies. Levels of the inducible
form of NOS are not elevated in post-mortem sections of individuals with HIV
encephalitis (Bagasra et al. 1997), and levels of nitrite or nitrate, by products of the
synthesis of NO, in the CSF of HIV positive patients are not always consistent, as some
reporters find no significant differences in occurrence (Milstien et al. 1994), whilst
others do (Baldeweg et al. 1996). Furthermore the ability of human macrophages, as
opposed to rodent macrophages, to synthesise increased levels of NO has been
questioned. Human macrophages have less of the enzyme pyruvoyltetrahydropterin
synthase, which causes rate limitation in the activity of NOS (Fuchs et al. 1994).
Instead large amounts of neopterin are produced, evident in the CSF of HIV infected
patients (Fuchs et al. 1989). Neopterin has been shown to enhance programmed cell
death caused by TNFa (Fuchs et al. 1995).
1.4.2.6. Neuroleukin and vasoactive intestinal polypeptide (VIP)
Gpl20 shares sequence homology with the neurotrophic factors neuroleukin and
VIP. It may be that gpl20 competes with the receptors for these substances and thus
diminishes the production of neurotrophins necessary for the survival and well-being of




NO, OH and O2 can all be produced by astrocytes, macrophages and microglia,
and can cause neuronal damage by the disruption of cellular proteins, nucleic acids and
membrane peroxidation through their oxidative properties. Normally they are
counterbalanced by Nerve Growth Factor (NGF) or metabolised by Super Oxide
Dismutase (SOD), but the oxidant-anti-oxidant equilibrium may be disrupted by
lentivirus infection (Jackson et al. 1990).
1.4.2.8. PlateletActivating Factor (PAF)
Yet another molecule that has been implicated in HIV encephalitis due to its
augmented levels in HIV positive patients with dementia is PAF (Gelbard et al. 1994).
PAF is directly neurotoxic to cultures of human fetal neurons and rat retinal cultures, via
its actions on NMDA receptors (Gelbard et al. 1994). It has also been shown to be




Fig. 1.5: Neurotoxic mechanisms involved in lentiviral neurodegeneration.
HIV infected macrophages may either directly release neurotoxic agents such as viral
proteins or cytokines, or may exert effects, via these agents on surrounding brain cells,
such as microglia and astrocytes. These glial cells may then, in turn, exert a detrimental
action on neurons via the release of neurotoxic mediators.
33
Chapter 1: Introduction
1.4.3. Inflammation and immunological mechanisms in the CNS
For many years, the brain has been considered an immunologically privileged
site, due to the presence of the BBB preventing the migration of immune mediating cells
into the CNS. Recently, however, more and more evidence points to the likelihood of
cells within the CNS, in particular microglia, being able to mount an intrinsic response
to invading pathogens, with concomittant detrimental side effects on other cell types in
the brain. This mechanism has been put forward as one of the main contenders in the
demyelination observed in MS, where it is hypothesised that cells are mounting an
immune response to myelin, and thus destroying it (Hartung 1993). It is therefore
possible that the invasion of the CNS by macrophages infected with lentiviruses triggers
the outbreak of an inflammatory response from neuroglial cells, which may at the same
time stimulate the invading macrophages to produce increased levels of neurotoxins,
whilst also causing damage themselves by the release of neurotoxic factors due to their
activated state.
1.4.3.1. Microgliosis.
1.4.3.1.1. Description andfunctions ofmicroglia.
Microglia were first characterised by del Rio Hortega in 1932 and, despite much
controversy, are now generally accepted as the resident macrophages of the CNS. They
arise from monocytes during development and express some of the same markers as
macrophages (Perry et al. 1985). Monocytes migrating to the CNS can give rise to other
populations of macrophages in the CNS such as perivascular macrophages and the
macrophages of the choroid plexus and meninges, but by far the largest is the microglial
cell population. The main difference between these types of brain macrophages is the
presence of MHC class II antigens on perivascular macrophages and those in the choroid
plexus, which are down-regulated in microglia. Microglia can vary morphologically,
having a simple stellate form in areas lacking a BBB, a branched and ramified form in
grey matter, or a more linear pattern running along axon fibres in white matter (Perry et
al. 1994). Similarly, the distribution ofmicroglia can vary. They are at their most dense
in areas of grey matter, particularly in the substantia nigra and pallidum, but occur much
more rarely in white matter regions such as the brainstem and cerebellum (Lawson et al.
1990). However, the general pattern of distribution seems to remains homogeneous, as
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microglia are usually evenly spaced, and do not seem to touch each other (Perry et al.
1985). This suggests that they may be under the influence of astrocytes and neurons, as
well as each other, through the means of diffusible mediators.
As for astrocytes, microglia perform important supportive functions for neurons.
It is generally believed that microglia in a resting state act as monitors of the
extracellular environment. However, they are known to react rapidly to any pathological
changes, even when these are very subtle, such as disruptions in ion homeostasis
(Gehrmann et al. 1993). Microglia possess a variety of receptors for CNS signalling
molecules, for example noradrenaline, ATP and ACh, and can therefore react to any
changes in the signalling patterns involving these molecules (Walz et al. 1993;
Langosch et al. 1994; Priller et al. 1995; Whittemore et al. 1993). One of the ways in
which this may be accomplished is by the presence of an inward rectifying potassium
channel (Kettenman et al. 1990; Kettenman et al. 1993). As the resident macrophages
of the CNS, they also have the capability to scavenge cellular debris in an effort to
maintain tissue homeostasis (Streit et al. 1988a). However, as a result of this ability,
macrophages that are activated in response to tissue damage or soluble mediators may
have deleterious effects on surrounding bystander cells.
1.4.3.1.2. Microgliosis.
The activation and proliferation of microglia, microgliosis, occurs rapidly in
reaction to injury. This response occurs in injury models which preserve or destroy the
BBB. Injection of a neurotoxin, kainic acid, into the brain of rodents causes the
activation of microglia within three days of the lesion (Marty et al. 1991). Similarly,
axotomy of the facial nerve causes the proliferation and hypertrophy of microglia within
a few days, accompanied by synaptic stripping of neurons (Streit et al. 1988b; Graeber
et al. 1988). Microgliosis also causes the expression of several marker molecules in
microglia. These include MHC class 1 and II antigens, TNFa, IL-6 and TGF(3 (Streit et
al. 1989; Buttini et al. 1996; Kiefer et al. 1993). In vitro, activated microglia have also
been shown to release reactive oxygen intermediates (ROI), NO, proteases, arachidonic
acid derivatives, excitatory amino acids, quinolinic acid and the cytokines TNFa, IL-1(3,
IL-6 and TGF(3 (Banati et al. 1993; Colton et al. 1987). This points to a detrimental
action of microgliosis, since many of these substances have been shown to be
neurotoxic, although levels of TGF(3 may be neuroprotective. The induction of
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microgliosis can also be achieved by the administration of cytokines including IL-ip,
IL-6, TNFa and IFN-y (Wekerle et al. 1986; Fagan et al. 1990; Campbell et al. 1993).
The cytokine TGF(3, on the other hand, seems to exert an inhibitory effect on the
hypertrophy and hyperplasia of microglia (Suzumura et al. 1993).
1.4.3.2. Astrocytosis.
1.4.3.2.1. Types ofastrocyte.
Astrocytes represent one of the most heterogeneous cell populations of the CNS.
They vary morphologically and phenotypically. At first, two kinds of astrocyte were
defined on the basis of shape, the fibrous and the protoplasmic astrocyte (Privat et al.
1986). Differentiation of astrocytes in the rat optic nerve on the basis of phenotype has
also revealed two sets, type I and type II, although these do not necessarily correspond to
the two types revealed by morphological characterisation (Raff 1989).
Astrocytes, unlike neurons, are not structurally independant, but form syncytial-
like networks connected by gap junctions (Kettenman et al. 1983). These neuroglial
cells are found throughout the brain, but occur particularly surrounding vascular
structures, on the surface of the brain and around neuronal cell bodies and synapses.
Specialised intramembrane structures found in astrocytes, termed assemblies, differ in
their frequency between these locations. Thus high concentrations of these assemblies
are found in astrocytes investing the vasculature of the CNS and in astrocytes forming
the surface of the brain, but only low concentrations of these assemblies are found in
astrocytes located around synapses and even lower levels near cell bodies (Landis et al.
1974; Landis 1981; Landis et al. 1982). Furthermore the shape of astrocytes may
change in response to neurotransmitters, neuronal interactions and physiological stresses
(Hatten 1985; Cornell-Bell et al. 1990b; Hatton 1990).
Astrocytes also differ regionally, their shape differs in white matter and in grey
matter, as do their patterns of expression of various proteins and enzymes. Most
astrocytes express receptors for neurotransmitters (Murphy et al. 1987) but, for example,
in the cerebellum astrocytes additionally express somatostatin (SS) mRNA, whereas in
the cortex and striatum, astrocytes express mRNA for proenkephalin as well as the
enkephalin peptide, but do not produce cholecystokinin (Shinoda et al. 1989; Denis-
Donini et al. 1984). This suggests that astrocytes may be differing based on the
neuronal population of a particular area of the CNS. The glutamate receptor on the cell
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surface of astrocytes is also expressed heterogeneously in vitro, and the expression of
the enzyme glutamine synthetase in astrocytes varies between the developing and
mature rodent brain (Hallermeyer et al. 1984; Holzwarth et al. 1994; Wilkin et al.
1990). The capability of astrocytes to secrete the cytokines IL-1 (3 and TNFa also
differs, as these cytokines are expressed either alone or together in some but not all
astrocytes (da Cunha et al. 1993b).
1.4.3.2.2. Functions ofastrocytes.
Astrocytes were long regarded as bystanders to most functions of the CNS and
merely assigned a supportive role for neurons. Increasing research has found that this is
not the case and that while astrocytes do indeed provide neurons with structural support,
by playing a role in neuronal migration, neurite outgrowth, synaptogenesis and synaptic
plasticity, they also confer functionnal support by the maintenance of tissue
homeostasis, the regulation of water, ion and amino acid neurotransmitter metabolism,
energy and nutrition balance, maintenance of the BBB and modulation of immune and
inflammatory responses (Norenberg 1994). Furthermore, some of the functions of
astrocytes are positively beneficial to neurons, particularly with regard to the
metabolism of ammonia, glutamate, free radicals and metals, substances which are toxic
to neurons.
Astrocytes are the only cells in the CNS which express the enzyme glutamine
synthetase (Mearow et al. 1989). This enzyme catalyses the formation of glutamine
from glutamate, and consumes the resulting by-product of ammonia, detoxifying it in
the process (Mearow et al. 1989; Mennerick et al. 1994). Astrocytes also take up
glutamate released from synaptic junctions of neurons as well as the inhibitory
neurotransmitter y-amino-butyric acid (GABA). Glutamate analogues can depolarise
astrocytes via ligand-gated receptors, but these are not responsive to NMDA (Bowman
et al. 1983; Kettenman et al. 1993; Tang et al. 1986).
Potassium homeostasis within the CNS is another function of astrocytes.
Potassium is taken up by astrocytes in regions where its concentration is high and is
redistributed either to areas where potassium levels are low or, if potassium
concentrations are uniformly high throughout the brain, for example due to diffuse
neuronal activity, potassium is released into the circulation by the astrocytic end-feet
present on blood vessels (Gardner-Medwin 1983; Paulson et al. 1987). Potassium is
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also extruded from astrocytes when these uptake glutamate and sodium (Brew et al.
1987). A possible pathological consequence of this may therefore be the inhibition of
glutamate uptake into astrocytes in the presence of high extracellular potassium causing
the build-up of extracellular glutamate and possible excitotoxicity (Barbour et al. 1988).
The presence of carbonic anhydrase in astrocytes contributes to the metabolism
of CO2 within the CNS and maintenance of uniform pH. Normal neuronal metabolism
releases C02. This is taken up by astrocytes and degraded into bicarbonate, which is
exchanged with endothelial cells for sodium and chloride. The simple diffusion of C02
from neurons to the circulation would cause disturbances in pH, and possible cell
damage. The presence of astrocytes thus enables the elimination of C02 without pH
changes (Landis 1994).
Astrocytes, however, do not serve merely to control the extracellular
environment in the CNS. The binding of glutamate to receptors on astrocytes causes
increases in levels of free intracellular calcium. These oscillations can propagate to
neighbouring astrocytes and to neurons causing modulations of intracellular calcium
levels. Therefore, the activity of neurons influences the activity of astrocytes which in
turn induce changes in neuronal responses (Charles et al. 1991; Cornell-Bell et al.
1990a; Dani et al. 1992; Nedergaard 1994). Thus a bi-directionnal flow of information
between neurons and astrocytes occurs, similar to the signalling capabilities of neuronal
networks.
1.4.3.2.3. Astrocytosis.
Astrocytosis is defined as hypertrophy, increases in size, and hyperplasia,
increases in density, of astrocytes. Astrocytosis is most usually indicated by an increase
in immunocytochemical staining for GFAP, a subunit of an intermediate filament
present only in astrocytes. Some investigators have questioned this method as a tool for
measuring astrocytosis since the intensity of GFAP staining depends on its
polymerisation and therefore may not reflect the amount of protein present (Lipsky et al.
1987). Nevertheless, it is still the most commonly used detection method for the
presence of astrocytosis. Mechanical injury to the brain causes astrocytosis within one
to three days of the procedure (Landis 1994). Astrocytosis can also occur, however, in
response to axonal degeneration at a site distant from the astrocyte, for example in the
spinal cord after sciatic nerve transection (Murray et al. 1990). This suggests that
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astrocytosis can occur in response to changes in normal neuronal function. Furthermore,
GFAP expression occurs over a large area in response to local injury. This is probably
due to the communication between astrocytes and not just reactions to changes in the
extracellular environment since astrocytosis in this situation occurs more readily in the
grey matter than in the white matter, whereas the pattern would be more uniform if
diffusible elements were at play (Landis 1994). This also presents further evidence as to
the heterogeneity of astrocytes and their differing responses to injury, which must
therefore be taken into account when studying pathological changes in injured or
diseased brains.
The early changes in astrocytes are reflections of their homeostatic functions.
Within seconds to minutes of injury the normal metabolic activities of astrocytes can
become disrupted. The normal regulation of potassium levels becomes overstretched
and due to osmotic equilibrium, astrocytes swell. As a consequence of disrupted
potassium uptake, local blood flow may decrease leading to deficiencies in oxygen
availability. This in turn can cause the increase of bicarbonate metabolism in astrocytes,
leading to further swelling. Furthermore, astrocytes may switch to anaerobic glycolysis.
Normally, astrocytes metabolise glycogen to provide glucose for neurons when blood
flow decreases, but this may be lost during astrocytosis causing a lack of glucose.
Lactate also builds up in astrocytes causing further swelling as well as acidosis of the
extracellular matrix, which may be further detrimental to neuronal function (Kraig et al.
1990; Staub et al. 1990). The decrease in glutamate uptake may lead to excitotoxicity of
neurons, as well as overstimulation of astrocytes to cause calcium influx and ultimately
astrocytic death (Kimelberg et al. 1990). The swelling of astrocytes will cause an
increase in their volume and thus will further distort any mechanical injury, as well as
eventually causing an increase in intracranial pressure, which further serves to reduces
the perfusion of brain tissue.
Within hours of mechanical injury to the brain, increases in GFAP staining are
seen. Increases in astrocyte number and density are observed. Accompanying these
changes is the expression of MHC classes I and II on astrocytes, which do not normally
express these molecules. This is particularly true in viral infections (Olsson et al. 1987;
Suzumura et al. 1986). In vitro, astrocytes can be stimulated to express MF1C class II
molecules in response to interleukins, interferons, TNFa and TGFf3 (Hertz et al. 1990;
Johns et al. 1992).
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After several days following a lesion to the brain, astrocytosis can decrease
reflecting a return to steady state functions. However, if an injury is severe, hypertrophy
and hyperplasia of astrocytes persist, and there is some evidence that at this stage
astrocytes undergo mitosis (Miyake et al. 1992). There is also evidence that astrocytes
can migrate from other areas of the CNS to the site of the lesion. Ultimately, astrocytic
responses are deemed to exert a curative action following injury, re-establishing tissue
homeostasis and lending suport to neurons by secreting members of the NGF family.
However, astrocytic scars are a common result of injury to the brain, and these can often
be detrimental to the regeneration of axons. During development, astrocytes guide the
establishment of axons, but this function is lost once cellular connectivity is established.
Indeed, in vitro the presence of astrocytes past a certain stage of maturity can inhibit the
progress of axons. Furthermore in injured spinal cords, axons do not regrow past
astrocytes at the site of injury (Liuzzi et al. 1987). This suggests that astrocytes can
exert both regenerative and detrimental actions once an injury has been established, and
may participate in the degeneration of neurons in during injury.
In summary, there is compelling evidence that microglial and astrocytic
activation in response to injury can have detrimental inflammatory effects within the
CNS. Since astrocytosis and microgliosis are a common neuropathological finding in
MVV and HIV infection, the role of any detrimental effects of these cells must be
evaluated.
1.4.3.3. The role of the immune response
Much research has focused on immune mechanisms occuring in MVV and HIV
infection. Much of this work is beyond the scope of this thesis, but several points need
to be addressed in order to understand better lentiviral infection of the CNS. The
diseases caused by MVV and HIV differ in one vital respect. Whereas HIV causes the
depletion of CD4+ T cells, sheep infected with MVV seem to mount a good humoral and
cellular immune response throughout the progress of the disease. The importance of
this variation must be taken into account when considering parallels between the two
lentiviral diseases, as well as when designing any experiments or animal models to
investigate lentiviral neurodegeneration. The question remains however, as to how
much of the damage encountered in lentiviral encephalopathies can be attributed to the
effects of immune cells. Nathanson et al (1993), for example, have found that the
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blocking of the immune response by cyclosporin A and cycloheximide in sheep
experimentally infected with visna, reduced the extent of neuropathology observed as
compared to sheep infected with visna with no immunosuppression. However, there is
still much debate as to the relevance of this since the major cell type that infiltrates the
CNS is the macrophage and not lymphocytes. Other investigators have proposed that
HIV infection of macrophages only results in the release of neurotoxins when these are
immune-activated by endogenous regulatory factors (Nottet et al. 1995a).
In HIV, a switch from a Thl type immune response to a Th2 type immune
response may occur. These responses are characterised by different cytokine profiles. A
down-regulation of the cytokines IL-4 and IL-10, which ordinarily exert an inhibitory
action on the number and action of macrophages, is usually encountered. This may be
due to the killing of CD4+ T cells by the virus (Nottet et al. 1995a). Indeed, some
investigators have found that levels of pro-inflammatory cytokines such as TNFa rise
whilst levels of other cytokines such as IL-4 are decreased in the brains of patients with
HIV (Wesselingh et al. 1994), and that this unbalance may further contribute to any
neurodegeneration.
In any case, the role of immunological responses both within the brain,
incorporating astrocytosis and microgliosis, and outwith the CNS, including the
circulating lymphocytes and their cytokine profile, needs to be taken into consideration,
both when evaluating post-mortem damage to the CNS in lentiviral infection, and when
designing any experimental models of the diseases.
1.5. INTRODUCTION TO EXPERIMENTS
Recently, a model of HIV encephalopathy has been described in scid mice (Tyor
et al., 1992). These mice lack T and B cells and are thus unable to mount an immune
response. Their manipulation therefore allows the investigation into how much a
pathology relates to non-immune mechanisms. Gendelman and colleagues have shown
that the injection of HIV infected human macrophages into these mice causes
astrocytosis, the presence of multinucleated giant cells and the death of neurons via
apoptosis (Persidsky et al. 1996; Persidsky et al. 1997). These are all hallmarks of the
naturally occuring disease and the model therefore presents a valuable experimental tool
for the study and manipulation of HIV infection of the brain.
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In MVV, as previously mentioned, the immune response seems to play a more
significant role in the development of lesions within the CNS. To assess whether
neurodegeneration in MVV is entirely a factor of immunological responses, a similar
model of MVV encephalopathy in scid mice is investigated here. Firstly, the ability of
MVV infected and uninfected ovine macrophages to cause neurodegeneration was
investigated through the injection of these cells into the striatum of scid mice. The
contribution of immune cells was also investigated by the administration of these in the
same manner to scid mice. The presence of neurons, activated astrocytes and microglia
was then ascertained through the immunocytochemical detection of these in fixed scid
brain tissue, and any changes in the relative density of these cells between mice
receiving MVV infected or uninfected cells was assessed through the use of image
analysis.
The contribution of mediators released from virally infected cells was also
probed. Firstly, the reverse transcriptase - polymerase chain reaction (RT-PCR) was
carried out on MVV infected and uninfected macrophages to determine whether
infection of these cells caused their activation. Cytokine induction was used as a
measure of monocyte/macrophage activation. Therefore, the amounts of mRNA being
synthesised for the pro-inflammatory cytokines IL-1(3, IL-6, TNFa and TGF(3 was
assesed by RT-PCR in uninfected and macrophages infected with MVV in vitro.
Secondly, the possible neurotoxicity of the supernatant from these cells was also tested,
by the incubation of rat cortical cell cultures (RCC) with the supernatant from MVV
infected and uninfected macrophages.
Since the Tat protein has been shown to be relesed by HIV infected cells, the
effects of this lentiviral protein were also investigated by the application of both an
MVV and HIV tat peptide, derived from the basic region of each Tat protein, to rat
cortical cultures in vitro. Acute in vivo neurotoxicity assays were also carried out, by
the injection ofMVV and HIV tat peptides to rat striatum. The neurotoxic mechanisms
of the MVV tat peptide were further probed by the administration ofMK801, an NMDA
receptor antagonist, NBQX, a non-NMDA receptor antagonist, L-NAME, a NOS
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2.1. CELL CULTURES
2.1.1. PBMC and macrophage (M0) cell preparation.
All procedures were carried out under sterile conditions in a laminar flow hood.
For the macrophage cell preparation, blood was collected from healthy sheep, in 50 ml
tubes containing 500 units heparin (10 units per ml), and centrifuged at 200g for 20 min.
The buffy coat, the layer between plasma and red blood cells, was removed with a
pasteur pipette, and resuspended in 10 ml sterile Phosphate Buffered Saline (SPBS), and
underlaid with 10 ml Ficoll Hypaque (Lymphoprep, Nycomed, Birmingham, UK). The
solution was again centrifuged at 200g for a further 20 min, resulting in the
accumulation of PBMCs at the interface of the SPBS and the Lymphoprep. These were
harvested with a pasteur pipette and washed twice in SPBS, by centrifugation at 150g,
resuspension and centrifugation at lOOg. At this stage, PBMCs destined for injection
were ready for infection with MVV. Some PBMCs were also obtained from sheep
experimentally infected with MVV. Cells destined for macrophage cell preparations
were washed once further in the culture medium, with one centrifugation at lOOg. The
culture medium consisted of RPMI 1640 (Gibco/Life Technologies, Paisley, UK)
containing 0.4 mM L-glutamine (L-gln), to which was added 0.04 mM Hepes (BDH,
Lutterworth, UK), 20 units/ml of penicillin and streptomycin (P/S, BDH), 0.01 mM of
mercaptoethanol (M/E, BDH), 10% fetal calf serum (FCS, Gibco) and 10% lamb serum
(LS, Seralab, Crawley Down, UK). Flasks for macrophage cultures were coated with a
2% gelatin solution for 1 hour, dried and incubated with plasma from the buffy coat spin
for 30 minutes at 37°C. Cells were plated out at a density of 5xl06 cells/ml. Care was
taken to ensure that cells and serum taken from each blood sample were not mixed with
any other, in order to minimise the risk of a mixed lymphocyte reaction occuring in the
cell preparations. Once the cells were plated out, they were incubated for one hour or
overnight at 37°C, in 95% air, 5% CO2, to enable the macrophages to stick to the flask,
at which time the non-adherent cells were washed off with a solution of RPMI
containing 2% FCS. The resulting macrophage cell preparation was then maintained at
37°C in humidified atmosphere of 95% air, 5% CO2, for the appropriate amount of time
until infection and injection into the scid mice.
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2.1.2. Rat cortical cultures (RCC).
All procedures were carried out in sterile conditions in a laminar flow hood.
Embryonic day 17 rats were used. Brains were dissected out in Hank's Balanced Salt
Solution (HBSS, Gibco) on ice, and the cortices removed and chopped. These were
then incubated with a mixture of trypsin and DNase (5000 IU DNase, Sigma, Poole,
UK; 0.9% trypsin, Sigma, in 10 ml HBSS) for 12 min at 37°C. A trypsin inhibitor
(ovomucoid, Sigma, 0.9% in 10 ml HBSS) was then added and the solution centrifuged
at 200g for 5 min. The supernatant was removed, 10 ml DNase added (5000 IU in
HBSS), the mixture homogenised, and spun at 200g for a further 10 min. The resulting
pellet was then resuspended in 10 ml of culture medium and passed through a piece of
200 nm gauze to remove any remaining large pieces of tissue. The culture medium
consisted of Dulbecco's Modified Eagle's Medium (DMEM, Sigma) supplemented with
0.01% Bovine Serum Albumin (BSA, Sigma), 0.03 mg/ml putrescine (Sigma), 200
pg/ml apo-transferrin (Sigma), 10 p,g/ml insulin (Sigma), 6.7 ng/ml selenium (Sigma),
5.5 ng/ml tri-iodo thyronine (Sigma), 12.6 ng/ml progesterone (Sigma), 200 ng/ml
corticosterone (Sigma), 0.5 mM L-gln (Gibco). A sample of cells were then counted on
a haemocytometer, and the solution suspended in the appropriate volume of culture
medium to give 5x10s cells/ml. Cells were then plated out in 24 well plates (Corning,
Stone, UK). These had previously been incubated for 1 hour with a solution of poly-D-
lysine (0.01 mg/ml, Sigma), washed in HBSS once and dried. Cultures were maintained
at 37°C in a humidified environment of 95% air, 5% CO2. After 24 hours, the culture
medium was renewed, and changed every two days.
2.2. VIRAL INFECTION OF MACROPHAGES AND PBMCs.
2.2.1. 50% Tissue Culture Infectivity dose (TCID50)
All procedures involving manipulation of virus and infected cells were carried
out in a Class II Microbiological safety cabinet. Sheep chondrocytes were used to
determine the TCID50 of the virus supernatant used. Sheep chondrocytes were removed
from storage in liquid nitrogen, thawed quickly and kept on ice. The culture medium of
DMEM supplemented with 0.5 mM L-gln, 20 units/ml P/S and 10% FCS was slowly
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added to the suspension of cells to dilute out the cryoprotectant, up to a final volume of
10 ml, and centrifuged gently at lOOg for 5 min. The cells were then resuspended in
cold culture medium, transferred to tissue culture flasks and maintained at 37°C in a
humidified atmosphere of 95% air, 5% CO2. Once the chondrocytes had reached
confluence, they were washed in versene and removed from the tissue culture flask by
adding a solution of 0.05% trypsin and 0.02% versene, spun at lOOg, resuspended in
culture medium and seeded in 96 well plates (Corning) at sub-confluent density. The
cells were then maintained in the same conditions until they reached 60%-70%
confluence. Doubling dilutions of the virus supernatant were then added to wells, in
quadruple replicates. The cells were then observed every day and checked for the
formation of syncytia indicating productive infection of the chondrocytes. When
syncytia were readily observed in large numbers, the culture medium was removed from
the wells and the cells fixed in neat methanol. Once fixed, the methanol was removed
and the chondrocytes stained with a solution of GEEMSA (BDH) diluted 1:5 in water, to
identify the wells containing syncytia. Each well was checked for the presence or
absence of syncytia, to determine the concentration of virus at which 50% of wells
showed the appearance of syncytia. This then enabled the calculation of the viral
concentration in the original inoculum.
2.2.2. MVV infection of PBMCs and macrophages in vitro.
Macrophages were infected with MVV by removing the culture medium and
replacing it with 2 ml of supernatant culture medium from 1514 strain infected sheep
chondrocytes for 5 min, then adding 3 ml of warm fresh culture medium for overnight
incubation. PBMCs were infected by incubation with 2 ml of the supernatant culture
medium for 3 hours prior to injection.
2.2.3. Proliferation assay
In order to establish whether the lymphocytes obtained from sheep productively
infected with MVV were responding to the addition of virus under tissue culture
conditions, a proliferation assay was carried out. This involved the collection of blood
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from the same MVV infected sheep whose PBMCs were injected into scid mice. Blood
was collected into universal glass tubes containing glass beads and gently inverted for
10 min. The resulting fibrin clot was then removed, and the blood divided into 50 ml
centrifuge tubes, supplemented with SPBS to a volume of 40 ml. As before, this
solution was underlaid with 10 ml Lymphoprep and centrifuged at 200g for 20 min. The
cells at the resulting interface between the SPBS and the Lymphoprep were removed
and suspended in a solution of RPMI containing 1% FCS up to a volume of 20 ml. This
was then centrifuged at 200g for 10 min. The cell pellets obtained at this stage were
then washed twice in 10 ml of RPMI with 1% FCS, and spun again at 150g for 5
minutes. Following resuspension in culture medium RPMI containing 0.4 mM L-gln
and supplemented with 0.01 mM M/E and 10% FCS, a sample of the cells were
counted. The remaining cells were then recentrifuged and resuspended in the culture
medium at 106 cells/ml.
Cells were then seeded in 96 well plates. Fresh culture medium was used as a
negative control. Differing concentrations of ConA (50 pg/ml, 25 pg/ml, 12.5 pg/ml,
6.25 |4g/ml, 3 pg/ml and 1.5 pg/ml), a known mitogen serving as a positive control, and
virus supernatant (diluted 1:2, 1:4, 1:8, 1:16, 1:32, and 1:64) were then added to the
wells containing cells. These were incubated together for 5 days in a humidified 95%
air, 5% C02 atmosphere at 37°C. Proliferation was measured by pulsing the cells with 1
pCi/well of tritiated thymidine followed by incubation for 5 hours. This molecule is
incorporated into any new DNA formed as a result of proliferative activity. Cells were
harvested onto glass fibre mats, scintillant added and the value of radioactive
disintegrations per minute scored on a Wallac Microbeta counter.
2,3. STEREOTAXIC INJECTIONS
2.3.1. PBMC and macrophage cell preparations.
To obtain cells for injection, PBMCs were washed twice in SPBS, by
centrifugation at lOOg and resuspension, counted on a haemocytometer and resuspended
in the appropriate volume of SPBS. Macrophages were also washed twice in SPBS,
before being scraped off the flask. A sample of cells was diluted 1:1 in 0.01% trypan
blue to assess cell viability, and the unstained, live cells counted, to allow the
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resuspension of the macrophages in the correct volume of SPBS for injection.
Macrophages were obtained at various stages of maturity, namely 24 hours in culture, 2
days in culture, 4 days in culture and 1 week in culture, and were injected at different
densities of 2xl03 cells/pl, 5xl03 cells/pl and 7xl03 cells/pl. Similarly, PBMCs were
injected at differing concentrations of 105 cells/pl, 5xl05 cells/pl, and 106 cells/pl.
2.3.2. MVV and HIV tat peptide injections
Injections were made of 20 pg (9.6 nmol) of the MVV or 20 pg (9 nmol) HIV tat
peptides. All the substances used for intracerebral injection were dissolved in sterile
saline and administered in 1 pi. The MVV tat peptide and the ovalbumin peptide were
synthesised by standard FMOC chemistry, desalted and purified, as previously described
(Hayman et al. 1993). The HIV tat peptide was obtained from the MRC AIDS directed
programme (Fig. 2.1). In the neuroprotection experiments, 20 pg (25 nmol) L-NAME
(Research Biochemicals International, St. Albans, UK) was co-injected with the MVV
tat peptide, as was 10 pg (6 nmol) aMSH (Sigma). MK801 (Research Biochemicals
International) was administered intraperitoneally at a dose of 0.01 mmol/kg one hour
before the injection, as was NBQX (Tocris Cookson, Bristol, UK) at a dose of 30
mg/kg. Control intracerebral injections were also made with 5 pg (56.8 nmol) ibotenic
acid (Sigma), 0.9% sterile saline, 100 pg (61.9 nmol) ovalbumin peptide, 20 pg (25
nmol) L-NAME, and 10 pg (6 nmol) ocMSH.
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Peptide Amino acid code
MVV tat peptide (Ac)-MWKHKGAAVRRNCGCRLC-
(NH2)
HIV tat peptide CFTTKALGISYGRKKRRQRRRPPQG
SQTHQVSLSKQ
HIV(43-72) tat peptide LGISYGRKKRRQRRRPPQGSQTHQV
SLSKQ
HIV(48-72) tat peptide GRKKRRQRRRPPQGSQTHQVSLSKQ
aMSH N-(Ac)-SYSMEHFRWGKPV-(NH2)
Ovalbumin peptide (Ac )-ISQAVHAAHAEINEAG (NH)
Fig. 2.1: Single letter amino acid code of the peptides used.
(Ac): Acetylated, (NH): Amidated.
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2.3.3. Sterotaxic injections in scid mice.
Scid mice were obtained from the University of Edinburgh Medical
Microbiology Transgenic Unit. All injections were performed under sterile conditions
in a laminar flow hood. Male adult mice were anaesthetised by intraperitoneal injection
of Hypnorm/Hypnovel (0.1-0.15 ml per mouse). Although no stereotaxic frame was
available, anaesthetised mice showing no paw withdrawal reflexes were kept immobile
through the use of a clamped tooth bar. The Hamilton syringe used to make the
injections was attached to a micrometer supported by an arm fitting to a solid base.
Injections of 1 pi of the macrophage and PBMC cell solutions to the striatum were made
approximately 1 mm laterally to Bregma. After the surgery, the mice were returned to
their sterile isolators and left to recover for 3, 7 or 21 days. Following a lethal injection
of pentobarbitone (Sagatal, Vet Drug Co., Falkirk, UK, 1 ml/kg), mice were
transcardially perfused with 10 ml of heparinised saline followed by 50 ml of fixative
containing 4% paraformaldehyde and 0.05% gluteraldehyde in 0.1 M Phosphate Buffer
(PB) pH 7.4. Their brains were removed and placed in a 50/50 solution of fixative and
20% sucrose overnight at 4°C.
2.3.4. Stereotaxic injections in rats.
Male Sprague Dawley rats were anaesthetised using halothane and placed in a
stereotaxic frame. The injection site was determined following the coordinates: 0.7 mm
anterior, 2.5 mm lateral to Bregma and -5 mm ventral from the surface of the brain
(Paxinos and Watson, 1986). Once the injection was made, the Hamilton syringe used to
make the injections was left in place for 5 min in order to minimise needle reflux. At the
appropriate time after the injection, the experimental animals were injected with a lethal
dose of pentobarbitone (Sagatal, 1 ml/kg) and transcardially perfused, firstly with 50 ml
of warm saline and then with 300 ml of a fixative solution containing 4%
paraformaldehyde, 0.05% gluteraldehyde in 0.1 M PB pH 7.4. Their brains were
dissected out and placed in a 50/50 mixture of 20% sucrose and fixative solution
overnight at 4°C.
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2.4. IMMUNOCYTOCHEMISTRY
2.4.1. Detection of viral expression in macrophages.
Indirect immunofluorescence against the viral antigen p25 was employed to
determine the presence of MVV in infected macrophages. Cultured infected and
uninfected macrophages were washed twice in SPBS, scraped off the culture flask into 1
ml of SPBS and cytospun onto slides. The resulting deposit of cells on the slides was
then washed twice in HBSS, and fixed with a solution of ice-cold 80% acetone in 0.15
M sodium chloride (NaCl) for 2 min. The cells were allowed to air dry, before being
blocked in PBS containing 0.01% Tween (Sigma) and 10% normal sheep serum (NSS)
for 30 min, to minimise any non-specific binding of the antibody. This solution was
then shaken off, the cells washed once in PBS containing 0.01% Tween and 2% NSS,
and incubated for 1 hour in a humidified environment at room temperature with a
monoclonal antibody against p25 (VPM 70, University of Edinburgh, UK), diluted
1:5000 in the wash solution. Following removal of the antibody, the cells were washed
five times in the same wash solution as previously. The biotinylated secondary antibody
sheep-anti-mouse, diluted 1:400 in the wash solution, was then applied for 1 hour at
room temperature. The cells were then again washed in PBS containing 0.01% Tween.
Avidin conjugated to the fluorescent marker Fluorescein isothiocyanate (FITC, Sigma),
diluted 1:400 in PBS with 0.01% Tween and 2% NSS, was applied for 1 hour at room
temperature to the preparation to visualise any positive cells. These were finally washed
twice in PBS containing 0.01% Tween, mounted in PBS containing 15% glycerol and
examined under ultraviolet microscopy.
2.4.2. Immunocytochemical and histological processing.
Coronal sections of brain 50 pm thick were cut on a freezing microtome. Free-
floating sections were reacted histologically in multiwell plates. On sections obtained
from rats injected with the HIV or MVV tat peptides, immunocytochemistry was
routinely performed for Glial Fibrillary Acidic Protein (GFAP), to reveal astrocyte
activation (McQueen et al. 1990); the neuron specific nuclear protein NeuN (A60), to
assess neuronal damage (Mullen et al. 1992); and the type 3 complement receptor
(0X42), to estimate microglial activation (Robinson et al. 1986). In addition, on
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samples from animals perfused 7 days after injection of the MVV tat peptide,
immunocytochemistry was performed for Parvalbumin (PV), a calcium binding protein
co-localising to gamma amino byturic acid (GABA)-ergic interneurons (Kita et al.
1990), and Choline Acetyl Transferase (ChAT) to reveal acetylcholine-containing
neurones (Bolam et al. 1984). The NADPH-Diaphorase histochemical method was also
performed for the detection of NOS containing neurons (Dawson et al. 1991), by
incubation with a solution containing 2.5 mg of Nitro Blue Tetrazolium (NBT, Sigma)
and 25 mg NADPH (Sigma) in 25 ml PBS-TX pH8, for 45 min at 37°C. NOS reduces
the NADPH resulting in the deposition of a blue formazan dye.
On sections recovered from scid mice, immunocytochemistry was performed for
F4/80, an antibody against activated mouse microglial cells; GFAP, to detect astrocytes;
Myelin Basic Protein (MBP), to estimate any possible myelin loss; neurofilament (NF)
to reveal neurons; MAC3, an antibody against CD14, to detect injected macrophages;
and p25 to detect MVV.
The antibodies to GFAP (Dako, Ely, UK), OX42 (Serotec, Oxford, UK), NeuN
(a gift from W. Staines, University of Ottawa, Canada), PV (a gift from Prof. P. Emson,
University of Cmbridge, UK), F4/80 (Serotec), MBP (a gift from Prof. P. Brophy,
University of Edinburgh, UK) and NF (Genosys, Cambridge, UK) were revealed using
the ABC method (Vectastain ABC and ABC Elite kits, Vector, Peterborough, UK) with
3,3'-diaminobenzidine (Vector) as the chromogen. p25 immunocytochemistry was
carried out in the same manner but in the presence of a 'mouse blocking' kit,
(Histomouse, Vector), due to the use of a monoclonal antibody in mouse tissue. The
antibody to ChAT neurons (Boehringer-Mannheim, Lewes, UK) was revealed using the
PAP method. The MAC3 antibody (a gift from Dr. J. Hopkins, University of
Edinburgh, UK) was biotinylated and therefore revealed by avidin peroxidase without
the need for the addition of a secondary antibody. Sections were mounted on gelatin
coated slides, dried, dehydrated through alcohols, except for the Diaphorase sections,
cleared in xylene and mounted in DPX (BDH). Diaphorase sections were cleared in
xylene and mounted in Permount (Sigma).
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Direct method Indirect method PAP method ABC method
Fig. 2.2: Immunocytochemical detection of tissue antigens.
The primary antibody (IgG class) is raised in species x against the antigen A (x-anti-A).
The secondary antibody is raised in species y against the IgG of species x (y-anti-x). The
PAP complex is raised in species x against horse radish peroxidase (HRP), and attaches
to the spare binding site of y-anti-x. The secondary antibody for the ABC reaction is
biotinylated, and attaches the biotin of the ABC complex. The presence of the
peroxidase enzyme is visualised with the chromogen DAB, resulting in a dark brown
deposit.
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2*wash PBS 2*woshPBS 2*washPBS 2*wush PBS
React with lmg'ni DAK 0.01% II20, in 1120,4*wash EES
Repeat from**
Fig. 2.3: Experimental protocol for immunocytochemistry on free-floating sections
ly: Primary antibody. 2y: Secondary antibody. PBS: 0.05% Phosphate Buffered Saline.
PBS-TX: PBS containing 0.03% Triton-X-100. TBS: Tris Buffered Saline, rt: room
temperature.
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2.5. ELECTRON MICROSCOPY (EM)
EM necessitates the good ultrastructural preservation of tissue. Animals
destined for EM analysis were therefore perfused with a fixative solution of 4%
paraformaldehyde, 1% gluteraldehyde. Sections 70 jam thick were cut on a vibratome.
Sections washed 6 times for 10 min in PB. Some sections were processed for A60
immunocytochemistry. These were freeze-thawed to enhance the penetration of
reagents. Sections were first washed in sodium borohydride to reduce any background
staining, and then in increasing concentrations (5%, 10%, and 20%) of DMSO in PB for
10 min. Most of the liquid was then removed, leaving just a covering layer, and the
sections frozen on dry ice (approx. 40 sec) and thawed at 4°C. This was repeated 3
times. Sections were then washed and processed for A60 following the ABC protocol,
except that the secondary antibody and ABC solutions were applied for longer (8-12
hours). After the DAB stage, sections were washed 6x10 min in PB. Sections were
then laid flat on slides and 1% osmium tetroxide (OsCU) applied for 40 min. Four
washes of 10 min in PB were followed by a rinse in water. Sections were then passed
through alcohols, 50% ethyl alcohol for 5 min, 70% ethyl alcohol containing 1% uranyl
acetate in the dark for 40 min, 95% ethyl alcohol for 15 min and 100% ethyl alcohol for
2x10 min. Propylene oxide was then applied for 2x10 min and the sections then
immersed in resin for 12 hours and mounted. Thin sections of the areas of interest were
cut and observed under EM (Totterdell et al. 1992). Photographs of representative areas
of the lesion were taken and compared with control areas.
2.6. IMAGE ANALYSIS.
2.6.1. Degree of astrocytosis and gliosis is scid mice.
The degree of astocytosis and gliosis in injected brains was measured through
the use of a CCD camera attached to a microscope and an Apple Mac. The NIH Image
1.44 software was used to capture the image of a section. The area of GFAP and F4/80
immunoreactivity was first measured on the injected side, by density slicing the image,
ensuring that all positively stained cells were identified. This was then repeated on the
unlesioned side of the same section, without changing the parameters. The subtraction
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of the unlesioned side area from the lesioned side area then provided the value of the
area of overall GFAP and F4/80 immunoreactivity for that section. This procedure was
applied to all sections showing a visible difference in staining between the injected and
uninjected sides of each brain section. The total volume of GFAP and F4/80
immunoreactivity per brain was then calculated based on the number of sections
showing a difference in staining combined with the numerical value of the total area of
immunoreactivity.
2.6.2. MVV and HIV tat peptide induced lesions.
Sections were examined under the light microscope and camera lucida drawings
were made of the lesioned area stained with NeuN or GFAP. These were then scanned
into the NIH Image 1.57 software package on an Apple Macintosh computer, and
quantified by measuring the area of the drawing. The volume of the lesion was then
calculated by the multiplication of the lesioned area by the number and thickness of
sections containing the lesion.
2.7. RCC TOXICITY ASSAYS.
2.7.1. Application of MVV tat peptide.
After 4 days in culture, the RCC culture medium was removed and either the
MVV tat peptide (235 nM), the ovalbumin peptide (235 nM) or culture medium added
to the cells. After 24 hours the cell cultures were then assayed for cell death, either by
measuring Lactate Dehydrogenase release (LDH, see section 2.7.3), or the MTS assay,
(see section 2.7.4).
2.7.2. Application of the macrophage culture supernatant.
Supernatant from uninfected and MVV infected 1 week old macrophage cell
cultures was removed and applied to the cortical cell cultures before being left for 24
hours in cell culture conditions. Toxicity of the supernatant was measured using the
MTS assay.
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2.7.3. Lactate Dehydrogenase (LDH) assay
LDH is an enzyme released by cells upon lysis and is therefore an indicator of
cell death. Released LDH from cell cultures catalyses the formation of NADH and
pyruvate from NAD+ and lactate. Using a cytotoxicity assay (CytoTox 96™, Promega,
Southampton, UK), the amount of NADH formation can be measured using a reaction
which converts a tetrazolium salt into a red formazan dye. The amount of colour is
proportionnal to the number of lysed cells.
Rat cortical cell cultures were incubated with the MVV tat peptide, ovalbumin or
culture medium for 24 hours. To measure the spontaneous release of LDH (LDH0), 50
pi of the cultured cells in each condition was transferred to 96 well plates. The cells
were then washed once in HBSS, culture medium containing 0.1% Triton-X-100 added
to lyse the cells which were then left for 15 min. The culture plate was then gently
shaken and 50 pi of the lysed cell solution added to the remaining wells of the 96 well
plates. This gives the value of maximum LDH release (LDHi). Control wells were also
set up, containing culture medium alone and culture medium with 0.1% Triton-X-100
but no cells. The substrate solution of the cytotoxicity assay (50 pi) was then added to
each well and the plate left for 30 min wrapped in foil to minimise any light
interference. The stop solution (50 pi) was then added and the absorbance of each well
at 490 nm read, blanking on the control wells. The value of LDH release was then
calculated following the formula:
% LDH release = (LDH0)/(LDH0 + LDH,) xlOO
2.7.4. MTS assay
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt) is a compound that is reduced by
dehydrogenases found in metabolically active cells, into a formazan. The quantity of
formazan can be measured by its absorbance at 490 nm and is directly proportionnal to
the number of living cells in culture. The CellTiter 96™ AQue0us Non-Radioactive Cell
Proliferation Assay (Promega) was used to determine the number of viable cells in
culture, based on the reduction of MTS in the presence of an electron coupling reagent
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(phenazine methosulfate, PMS). After the RCC cultures had been incubated with the
MVV tat peptide or macrophage supernatant, 100 pi of the MTS/PMS (333 pg/ml MTS,
25 pM PMS) solution was added to the culture medium in each well, and left in culture
conditions for 4 hours. A sample of culture (100 pi) medium from each well was then
transferred to wells of a 96 well plate and the absorbance read at 490 nm. The relative
amount of cell death was then calculated based on the subtraction of cell viability
measurement from 100%.
2.8. RT-PCR OF CYTOKINE mRNA FROM CULTURED MACROPHAGES.
2.8.1. Isolation and Reverse Transcription (RT) of mRNA from MVV
infected and uninfected macrophages.
RT involves the making of DNA from an RNA template. RNA is extracted from
cells or tissues of interest, to which is added a reverse transcription enzyme, in this case
obtained from the Moloney Murine Leukemia Virus (MMLV), in the presence of dNTPs
and either random hexamers or specific primers. The use of random hexamers would
result in the transcription of all mRNA molecules present in the tissues or cells of
interest, creating a cDNA library. The use of specific primers for genes of interest, on
the other hand, results only in the transcription of mRNA for these genes. Random
primers were used here to create cDNA from which specific genes were amplified in a
subsequent polymerase chain reaction (PCR).
Macrophages were cultured for 1 week as previously described. mRNA from
uninfected macrophages and macrophages infected with MVV overnight was extracted,
with the aid of an RNeasy kit (QIAGEN, Crawley, UK). All collection tubes and
eppendorfs were autoclaved to ensure that they were "clean", i.e. RNase free. Cells
were first washed in SPBS twice to remove any culture medium. They were then lysed
in the culture vessel with 600 pi of the RNeasy lysis buffer RLT containing 10 pl/ml (3-
mercaptoethanol (Sigma). This buffer contains guanidinium isothiocyanate which
denatures and inactivates any RNases to ensure isolation of intact RNA. The
homogenate was then transferred to a clean eppendorf, to which was added 600 pi of
70% ethanol. The presence of ethanol allows appropriate binding conditions for the
adherence of RNA to the silica gel in the RNeasy spin column. This solution was then
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applied onto an RNeasy spin column and microfuged for 15 sec at 10000 rpm. The
flowthrough was discarded and 700 pi of the wash buffer RW1 applied to the spin
column and centrifuged as before. Once again, the flowthrough was discarded and 500
pi of the wash buffer RPE was applied to the spin column and centrifuged. This was
repeated but centrifuged for 2 min. The wash buffers are high in salt content and
therefore wash away smaller RNA molecules, allowing the remaining RNA to be
relatively richer in larger RNA molecules. At this stage, the mRNA was eluted with 20
pi of Sigma water, spun for 1 min at 10000 rpm. The mRNA obtained (13 pi) was then
added to the RT mix, containing 5 pi of 5xRT buffer (provided with the RT enzyme),
1.5 pi (3 pM) random primers, 2.5 pi (0.05 mM) dNTPs and 1 pi (1 mM) DTT. This
solution was then heated at 80°C for 3 min to melt the secondary structure of the RNA,
and cooled on ice for 3 min to prevent reannealing. The RTase enzyme (Gibco) was
then added (1 pi), along with 1 pi of RNasin (Gibco), an RNase inhibitor, and incubated
at 45°C for 1 hour. The RTase enzyme was then heat inactivated at 95°C for 5 min,
giving the solution of cDNA.
2.8.2. Polymerase Chain Reaction (PCR)
The PCR is an enzyme mediated amplification of DNA. Using primers for
specific genes of interest, it allows the denaturation of DNA, followed by attachment of
primers to binding sites and copying of the DNA. Forward and reverse primers are
specifically designed to bind to certain sequences on opposite strands of the DNA
molecule. A DNA polymerase can then generate a complimentary strand of DNA to
that of the original DNA which results in a copy of the original DNA which can itself be
duplicated. Here, primers for the cytokines TNFa, EL-1(3, IL-6 and TGF[3 were used. In
order to be able to semi-quantitate the amount of DNA subsequently obtained, PCR for
a house keeping gene, the alpha subunit of the (Na/K) ATPase pump, was also
performed as its concentration is kept constant in cells.
The cDNA (1 pi) obtained from the RNA of cultured uninfected and MVV
infected macrophages was added to 48 pi of the primer mix. For the cytokines this
consisted of 1 pi (2 pM) of both the forward and reverse primers (Genosys), 2 pi (2
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mM) of magnesium chloride (MgCh), 5 pi of the lOxPCR buffer (Gibco), 5 pi (0.1
mM) of dNTPs and 34 pi of sterile distilled water (SDW). For the ATPase reaction, the
primer mix consisted of 32.5 pi of SDW, 1 pi (2 pM) of each of the primers, 5 pi (0.1
mM) of dNTPs, 5 pi of the lOxPCR buffer and 3.5 pi (3.5 mM) of MgC^. The solution
was then overlaid with 30 pi of mineral oil, to prevent evaporation. The eppendorf tube
containing the mixture was then heated to 95°C to hot start the PCR reaction, and then
maintained at 80°C while lpl (1 Unit) of the DNA polymerase Taq Pol (Boehringer
Mannheim), obtained from the bacterium Thermits aquaticus, was added to the solution.
The PCR was then started by heating the mixture to 95°C for 1 min to denature the
DNA, cooling to 55°C for 2 min to allow specific binding of the primers to binding
sites on the DNA, followed by heating to 72°C to permit the DNA polymerase to use the
annealed primers to initiate copying of the DNA strand. PCRs for IL-6, IL-1, ATPase
and TNFa were run over 33 cycles, and 31 cycles for TGF(3. cDNA was also sampled
from different cycle points. This was performed to enable the semi-quantification of
cytokine cDNA against the equivalent cycle points of ATPase cDNA. For ATPase, IL-1,
IL-6 and TNFa, samples of cDNA were obtained at 27, 31 and 35 cycles. For TGF(3,
cDNA was obtained at 23, 27, 31 and 35 cycles. At the end of the cycles, the mixture
was maintained at 72°C for 5 minutes to enable the formation of equal length chains of
DNA. All reactions were run with a negative control consisting of the above mixtures
without the addition of cDNA, to detect any cross contamination.
2.8.3. Agarose gel electrophoresis.
To visualise the DNA obtained by PCR, it was run on an agarose gel to which
was applied an electrical current. A 1.6% solution of agarose (Sigma) was prepared in
Tris-acetate buffer (TAE), composed of 0.04 M Tris-acetate and 0.001 M EDTA and
heated to dissolve the agarose. Ethidium bromide (EtBr, 50 pg) was then added to the
100 ml agarose solution, which was then poured into a mould to cool and harden. The
gel was run in TAE, and 10 pi of cDNA mixed with 5 pi of loading dye placed in the
wells of the hardened gel. A voltage of 100 mV was then applied across the gel for at
least 1 hour. The PCR bands fluoresced when viewed under ultraviolet light, due to the
presence of EtBr.
60
Chapter 2: Materials and methods
2.8.4. Southern Blotting
In order to semi-quantify the amount of DNA obtained from RT-PCR, the
agarose gel was probed with radioactive markers. The gel was first soaked in 0.4 N
NaOH for 20 min on a rotary platform to denature the DNA. DNA was then transferred
to a nylon membrane (GeneScreen Plus®, NEN™ Life Science Products, Hounslow,
UK) from the gel via capillary action. The membrane was then rinsed twice in Standard
Saline Citrate (SSC) buffer for 5 min each and dried at 80°C between two pieces of 3
MM paper (Whatman, Maidstone, UK) to fix the DNA onto the membrane. The
membrane was then washed with 2 x Standard Salt Phosphate EDTA (SSPE) buffer and
incubated with 10 ml of the hybridisation mix for 1 hour at 65°C. A further 5 ml of
hybridisation mix containing 50 pi of herring sperm DNA, was added to block any non¬
specific attachment of the DNA probe to the membrane, the 32P labelled probe was then
added and the membrane incubated overnight at 65°C. The membrane was then washed
twice in 2xSSPE for 5 min, and then twice in 2xSSPE containing 1% SDS at 65°C for
30 min each to remove any unbound radiolabelled probe. The membrane was finally
washed in 0.1% SSPE for 3 min before being exposed to X-ray film (X-OMAT™ ARC,
Kodak) to obtain an autoradiograph.
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Fig. 2.4: The Polymerase Chain Reaction.
DNA is first denatured to separate the strands, which allows the primers to anneal to the
specific 5' and 3' ends of the DNA. These then elongate through the action of a DNA
polymerase to form 2 copies of the original strand of DNA. This cycle is repeated as
many times as is necessary to obtain enough DNA to visualise on an agarose gel.
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2.9 STATISTICAL ANALYSIS
Data was analysed using the SPSS statistical package. The comparison of data
from more than two groups was analysed using a one-way ANOVA and post-hoc
Bonferroni's and Duncan test. Statistical analysis of data obtained from two groups only
was carried out using a one-way ANOVA, if experimental numbers were high, or a
Student's t-test, if experimental numbers were low.
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Chapter 3: A model ofMW encephalopathy in scid mice
3.1. INTRODUCTION
MVV infection of sheep shows the invasion of virally infected macrophages into
the CNS, accompanied by neuropathological changes manifest as demyelination,
astrocytosis and liquefactive necrosis. Some investigators attribute the mechanisms of
this neurodegeneration to the action of viral proteins on neuronal cell types, or to the
release of diffusible mediators such as cytokines from infected cells. Other investigators
propose that circulating immune cells may gain access to the CNS in MVV infection
and be responsible for the observed brain damage. Since the progression of disease in
sheep is slow, a small animal model of MVV infection would be useful to the
understanding of the mechanisms involved in lentivirus mediated neurodegeneration. In
pursuit of this aim, scid mice were used to investigate the role of macrophages in the
development of neurodegeneration and to establish a preliminary putative model of
MVV encephalopathy. These mice are immunodeficient in that they lack T and B cells.
They can therefore allow the experimental isolation of immune responses, and permit
the investigation into how a pathology relates to factors other than cell- or antibody-
mediated immune mechanisms. Macrophages and PBMCs were infected with MVV in
vitro and injected into the CNS of scid mice. The effects of free virus injection were
also evaluated. Neuropathological changes were subsequently revealed
immunocytochemically, to detect any changes in the normal organisation of astrocytes,
microglia and neurons. In this thesis, significant increases in GFAP and F4/80 staining
will be referred to as inflammation.
Several pro-inflammatory cytokines, in particular TNFa, EL-1(3, IL-6 as well as
the anti-inflammatory cytokine TGF(3 have been implicated in the pathological
processes of HIV infection, as well as other neurological diseases. In vitro and in vivo,
TNFa, rL-l(3 and IL-6 have been shown to cause astroglial and microglial proliferation,
and can also cause neuronal death (Campbell et ah, 1993; Hertz et al., 1990; Barna et
al., 1990; Gelbard et al., 1993). The actions of TGF{3 appear to be more neurotrophic
(Chao et al., 1995), although the actions of this cytokine may be detrimental at high
concentrations. The profile of TNFa, IL-ip, IL-6 and TGFP mRNA synthesis was
investigated in uninfected ovine macrophages and macrophages infected with MVV in
vitro, through the use of RT-PCR. This was carried out in order to evaluate any
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upregulation of these cytokines caused by MVV infection, as a measure of virus-induced
macrophage activation.
3. 2. EXPERIMENTAL DESIGN.
Scid mice were injected intracerebrally with free virus, live macrophage cell
suspensions, killed macrophage preparations or PBMCs. Macrophages were obtained
from healthy sheep and cultured for 1, 2, 4 or 7 days prior to infection and injection.
Macrophages were infected with MVV supernatant overnight in vitro. Killed
macrophages were similarly prepared, but underwent 3 cycles of freeze-thawing to
rupture their membranes. PBMCs were obtained from healthy sheep and infected in
vitro on the same day of collection and injection, or directly from diseased sheep and
supplemented with virus in vitro. Uninfected and MVV infected cells were
stereotactically injected, at different densities, into the left striatum of scid mice, which
were then left to recover for 3 days, 7 days or 3 weeks. Microglial and astrocyte
activation, as well as the presence of neurons and myelin, were revealed by
immunocytochemistry on free-floating sections. The degree of microglial and astrocyte
activation, and therefore inflammation, in the brains of scid mice was quantified by
image analysis. The effects of free virus on scid mouse brain were similarly detected,
and the presence of MVV within the brains of injected mice was assessed using an
antibody against the viral protein p25.
The stereotaxic injection method used in these experiments was difficult to
perfect due to the small size of the experimental mice which, due to their
immunosuppresion, do not routinely achieve normal wild type proportions, and because
of the need for all procedures to be carried out in a sterile environment. Therefore,
some of the experimental numbers were small and the results subject to variability.
For RT-PCR analysis, mRNA was extracted from cultures of 1 day, 2 day, 4 day
and 1 week old uninfected and MVV infected macrophages in vitro, from which
cytokine cDNA was amplified by RT-PCR. Samples of cDNA were loaded onto an
agarose gel containing EtBr, and a current of lOOmV applied across the gel. Fluorescent
bands corresponding to the appropriate size of cytokine DNA were visualised under
ultraviolet light. The gel obtained from the migration of cDNA obtained from 1 week
old macrophages was transfered onto a nitrocellulose membrane and probed with
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radiolabeled markers, since it showed differences in the levels of pro-inflammatory
cytokines between uninfected and MVV infected macrophages. This Southern bolt was
then semi-quantified against levels of the housekeeping gene ATPase. This was
achieved by density measurements of autoradiographs to determine the level of ATPase
in uninfected and MVV infected macrophages, reflecting differences in the amount of
RNA obtained from each population of macrophages. Levels of cytokine expression
were then normalised against each background level.
3.3. RESULTS.
3.3.1. Viral infection ofmacrophages.
3.3.1.1. p25 expression in vitro
Measurement of the TCID50 for the MVV virus showed that 50% of sheep
chondrocytes in culture developed syncytia when the virus supernatant solution was
diluted 1:4096. Therefore the TCID50 approximated 2.05x10s viral particles per ml.
The number of macrophages in each culture flask varied between 5xl04 and 15xl04
cells, therefore the addition of 2 ml of virus supernatant solution was theoretically able
to infect all the cells present. Productive infection was demonstrated by the
immunocytochemical detection of the p25 protein in macrophages cytospun onto slides
(Fig. 3.1). Infected cell populations displayed positive immunofluorescence for the
protein but uninfected macrophages did not.
3.3.1.2. p25 expression in vivo
In animals injected with free virus, TCID50 measurements revealed there to be
8.388xl0x viral particles per ml. Since lpl was injected, each animal received
approximately 8.4xl05 viral particles. Results of p25 staining of scid mouse brain
sections surrounding the injection site did not conclusively show the presence of viral
particles in scid mouse striatum. This may be due to difficult detection methods of the
viral p25, as the antibody used was a mouse monoclonal used in mouse tissue, or to the
clearance of virus from brain parenchyma. However, since neuronal nuclei were
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detectable using another mouse monoclonal antibody (NeuN), it seems unlikely that the
only reason for not detecting p25 was technical difficulties with the method used.
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Fig. 3.1: p25 immunoreactivity in MVV infected macrophages in vitro.
Macrophages infected with MVV in vitro displayed positive immunofluorescence for
the viral protein p25, but uninfected macrophages did not.
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3.3.2. Degree of inflammation in injected scid mice brains.
3.3.2.1. Effects offree virus
The injection of free MVV into scid mouse striatum caused some inflammation
one week post-operatively as revealed by immunocytochemistry for GFAP and F4/80.
GFAP staining showed that MVV caused greater astrocytosis than control medium,
although this was not statistically significant as revealed by a Student's t-test (p=0.1,
Fig. 3.2). F4/80 immunocytochemistry showed the presence of activated microglial
cells in scid mouse striatum injected with MVV, but the level of these was not
significantly different to that of scid striata injected with control medium only
(Student's t-test, p-0.3, Fig. 3.2). Thus the inflammatory effects of free virus are not
definite. Although some inflammation is suspected by the apparent increase in GFAP
staining, this is not statistically significant.
Furthermore, the lesion volumes incurred by the injection of free virus are low
when compared to lesions caused by the injection of live macrophages (Figs. 3.6-3.9).
This suggests that free virus alone does not have as severe effects on scid brain
parenchyma as the injection of macrophages infected with MVV.
The lack of staining of scid striata with an antibody directed against p25 suggests
that minimal amounts of virus remain in striatum after injection. This may be due to
clearance of the virus from the brain. This result concurs with previous reports
demonstrating the lack of notable effects of free lentivirus on nerve cells and suggests
the need for cellularly released inflammatory mediators in lentiviral neurodegeneration.
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Fig. 3.2: Effect of MVV injection on GFAP and F4/80 staining in scid striatum
Animals were sacrificed one week post-operatively. The injection of MVV alone (n=3)
to scid mouse striatum appeared to cause greater astrocytosis than the injection of
control medium (n=3), although this was not statistically significant (Student's t-test,
p=0.1). The volume of F4/80 immunoreactivity was also not significantly different
between the injection of MVV alone (n=3) and control medium (n=3, Student's t-test,
p-0.3). Results: Mean ± SEM.
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3.3.2.2. Survival of injected macrophages
Immunocytochemistry for MAC3 (CD 14) showed that the macrophages injected
intracerebrally into scid mice were still present in the striatum of these mice one week
post-operatively (Fig. 3.3). Most were confined to the area surrounding the injection
site, but some were occasionally found to have migrated a small distance away from the
location of the syringe. In some animals where the injection strayed into the lateral
ventricle, MAC3 positive cells were found at the border of the injected ventricle and
striatum, but some were also found in the contralateral ventricle and striatum. These
animals were not included in the image analysis for GFAP and F4/80 staining because
macrophages were present on both sides of the brain.
Immunocytochemistry for p25 in the brains of scid mice injected MVV infected
macrophages did not conclusively reveal positive staining. The antibody used has been
shown to work on cells infected with MVV and cytospun onto slides, but problems of
detection may have prevented the detection of p25 in mouse sections. The antibody
used, the only antibody available, was a monoclonal and was used in mouse tissue.
Detection of p25 in scid mice striata in animals injected with MVV infected
macrophages, using a kit specifically designed to detect monoclonal antibodies in mouse
tissue, did not reveal the presence of this marker. Technical difficulties alone cannot
serve to explain the lack of p25 staining, as the above method successfully marked a
monoclonal neuronal antibody (NeuN).
The absence of p25 staining may reflect a disappearance of MVV from scid
mouse brain, but may also reflect other factors such as virus latency in vivo. Previous
experiments have shown that, in other tissues, MVV becomes down-regulated once in
vivo. Indeed, the injection of MVV to the joints of sheep results in the appropriate
pathology. However, MVV becomes undetectable shortly following injection.
Furthermore, if p25 were residing only in the injected macrophages then the antibody
may not have been able to sufficiently penetrate the cells. The localisation, however, of
ovine macrophage markers within the CNS of scid striatum would suggest the continued
presence of injected macrophages.
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3.3.2.3. Acute inflammation caused by live macrophages
Immunocytochemical detection of activated astrocytes and microglia seemed to
reveal a greater degree of astrocytosis and microgliosis in the striata of scid mice
injected with MVV infected macrophages as compared to those receiving uninfected
macrophages, when observed one week post-operatively. This was evident as greater
numbers of cells displaying GFAP and F4/80 immunoreactivity in vivo (Figs. 3.4 and
3.5). Figure 3.4 shows greater levels of GFAP immunoreactivity in scid mouse striatum
caused by the injection of MVV infected macrophages as compared to uninfected
macrophages. Similarly, Figure 3.5 shows greater F4/80 immunoreactivity in scid
mouse striatum receiving MVV infected macrophages, as compared to the striatum
receiving uninfected macrophages. Furthermore, both control and MVV infected
macrophages appeared to cause greater GFAP staining that the injection of free virus
alone. This suggests a greater detrimental action of macrophage products on brain
parenchyma as compared to MVV alone and may point to the need for cellularly
released agents in causing neurodegeneration.
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Fig. 3.3: Detection of injected CD14 positive M0 in scid striatum
The injected macrophages, 5xl03 cells/pl, were visible in the striatum one week post¬
operatively. Most macrophages remained close to the site of injection although some
were found to migrate short distances within the striatum, away from the needle tract.
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Fig. 3.4: GFAP staining
of scid mouse striatum
1 week post-operatively.
A. Injection of 5x10 cells/pl
uninfected mature M0.
B. Injection of 5xl03 cells/pl
MVV infected mature M0.
C. Control contralateral side of
striatum (no injection).
More GFAP immunoreactive cells
are present in brains injected
with MVV infected M0 (B)
than uninfected M0 (A).
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Fig. 3.5: F4/80 staining
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More F4/80 immunoreactive cells
are present in brains injected
with MVV infected M0 (B)
than uninfected M0 (A).
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These observations were confirmed by image analysis determining the area
occupied by activated astrocytes and microglia. Firstly, the inflammation caused by live
1 day old MVV infected macrophages appeared to be dose dependant. Therefore, the
increase in GFAP immunoreactivity rose with the number of cells injected in scid mouse
striata (Fig. 3.6). Cells injected at 2xl03 and 5xl03 cells/pl caused less inflammation
than cells injected at 7xl03 cells/pl (one-way ANOVA, p<0.01, post-hoc Duncan test
p<0.05). This result suggests that diffusible mediators released from macrophages may
be causing neurodegeneration. Since the injection of 5x10 uninfected macrophages/pl
caused the least background level of astrocytosis with the greatest amount of cells, this
number of cells per preparation was used in all future experiments.
Secondly, the maturity of the macrophage cell preparation was determined as
being important in the degree of astrocytosis and microgliosis caused in scid mouse
striatum one week post-operatively. MVV infected macrophages maintained in vitro for
1, 2, or 4 days, and injected into scid mice striata, did not cause significant differences
in GFAP expression, when compared to the administration of their uninfected
counterparts (Fig. 3.7). However, when macrophages were cultured for 1 week and
injected into scid mouse striata, the inflammation measured by GFAP staining was
greater with MVV infected macrophages than with uninfected macrophages (Fig. 3.7).
A single factor ANOVA comparing the mean GFAP lesion area in mice receiving
macrophages at different maturities shows a significant effect of maturity on lesion
volume (p<0.001). Post-hoc analysis indicates that the group receiving MVV infected
mature macrophages was significantly different to all the other groups, including those
receiving uninfected mature macrophages (Duncan test, p<0.05). Similarly, when F4/80
staining is compared after injection of 1 week old macrophages and 1 week
macrophages infected with MVV, the MVV infected cells cause significantly more
staining (Fig. 3.8, Student's t-test, p<0.05). Thus, the maturity of injected macrophages
appears to be important in causing neurodegeneration in this model, and probably
reflects changes in cellular machinery present at different stages of development of the
macrophage. This may reflect the ability of the macrophage to sustain viral replication
and/or the capability to secrete inflammatory mediators or viral products. Although
inflammation was readily observed and confirmed by semi-quantification of the lesioned
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areas, no loss of neuronal or myelin markers was observed acutely after the
administration of MVV infected macrophages to scid mouse striata.
As described in the methods section, macrophages were removed from the
culture flasks by gentle scraping. When these cells were counted using trypan blue
exclusion, most (approximately 90%) of the cells still appeared live. However, in an
effort to ensure the maximal survival of macrophages injected into scid striata,
experiments were also carried out removing macrophages from the culture flask using
warm versene. Results show that similar significant increases in GFAP and F4/80
induction were observed with the injection ofMVV infected macrophages as opposed to
the injection of uninfected macrophages, one week post-operatively (one-way ANOVA,
/?<0.05, Fig. 3.9).
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Fig. 3.6: Effect ofM0 number on GFAP staining of scid striatum
1 day old M0 were injected intracerebrally at different densities: 2x10 cells/jal (n=3
MVV-, n=3 MVV+), 5xl03 cells/pl (n=3 MVV-, n=5 MVV+) and 7xl03 cells/jul (n=3
MVV-, n=3 MVV+). All mice were perfused one week post-operatively. MVV-:
uninfected M0, MVV+: M0 infected with MVV in vitro overnight prior to injection. A
single factor ANOVA shows GFAP immunoreactivity to be greater in animals receiving
uninfected and MVV infected macrophages at 7xl03 cells/pl (p<0.01 and post-hoc
Duncan test */?<0.05), than in animals receiving macrophages in lesser numbers.
Results: Mean ± SEM.
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Fig. 3.7: Effect of M0 maturity on GFAP staining in scid striatum
M0 were injected after 1 day in culture (die, n=3 MVV-, n=5 MVV+), 2 die (n=3
MVV-, n=2, MVV+), 4 die (n=3 MVV-, n=2 MVV+) or 7 die (n=ll MVV- and
MVV+) at densities of 5xl03 cells/jal. All mice were perfused one week post¬
operatively. MVV-: uninfected M0, MVV+: M0 infected with MVV in vitro
overnight prior to injection. None of the injections of immature macrophages caused
any significant differences between uninfected and MVV infected groups, however,
mature, 7 die, M0 infected with MVV caused greater astrocytosis than all the other
groups (one-way ANOVA, /?<0.001, post-hoc Duncan test, **p<0.05). Results: Mean ±
SEM.
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Fig. 3.8: Effect of liveM0 on F4/80 staining in scid striatum.
Mice were perfused 3 days post-operatively. MVV-: uninfectedM0 (n=2), MVV+: M0
infected with MVV in vitro overnight prior to injection (n=3). The volume of F4/80
immunoreactivity was significantly greater in mice injected with MVV infected M0
(Student's t-test, *p<0.05). Results: Mean ± SEM.
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Fig. 3.9: Effects of liveM0 on GFAP and F4/80 induction in scid striatum
Mice were perfused one week post-operatively. Macrophages were grown for 1 week in
vitro, infected with MVV overnight and removed from the tissue culture flask with
warm versene. MVV infected macrophages (MVV MO, n=5) caused significantly more
GFAP and F4/80 induction than uninfected macrophages (MO, n=5, one-way ANOVA,
*p<0.05). Results: Mean ± SEM.
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3.3.2.4. Acute inflammation caused by killed macrophages
Since the administration of live MVV infected macrophages to the striatum of
scid mice caused greater inflammation than the administration of uninfected live
macrophages, experiments were also carried out to evaluate the inflammation caused by
killed macrophages. These were prepared in exactly the same manner, but received
three freeze-thaw cycles immediately prior to injection, thus disrupting membrane
integrity.
Results show that inflammation was greater in the striata of mice receiving
MVV infected killed macrophages as opposed to those receiving uninfected killed
macrophages (Fig. 3.10). The increase in F4/80 immunoreactivity was statistically
significant (Student's t-test, p<0.01), although the apparent parallel increase in GFAP
immunoreactivity did not reach statistical significance (Student's t-test, p-0.2).
However, the GFAP lesion volumes observed with killed MVV infected macrophages
o
are very low (approximately 0.5-lmm ) compared to lesion volumes observed with live
MVV infected macrophages (4-8mm ). These levels of inflammation are minimal
compared to the effects of live macrophages. Therefore, the results obtained with live
macrophages cannot be explained by their death once injected into scid striata.
Since the membrane integrity of the injected macrophages was disturbed, the
effects of the injection of killed macrophages cannot be attributed to released diffusible
mediators. However, the disruption of macrophage membranes would necessarily
involve the leakage of many intracellular molecules into the injection medium. These
may include diverse agents such as proteases, possibly upregulated by MVV infection,
which may cause inflammation in brain parenchyma. The effects on brain tissue of
many intracellular components of macrophages are not documented, therefore it is not
possible to attribute any of the effects of killed macrophages on scid striata to particular
mediators. It is, however, plausible to comment that there may exist a mediator,
upregulated in live macrophages to cause acute inflammation in scid mouse brain, which
may also be present in the injection of killed macrophages, to cause similar
inflammation.
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GFAP F4/80
Lysed MVV- Lysed MVV+ Lysed MYV- Lysed MVV+
Fig. 3.10: Effects of killed M0 on GFAP and F4/80 induction in scid striatum
Animals were sacrificed 1 week post-operatively. The injection of lysed MVV infected
M0 (Lysed MVV-, n=6) caused greater astrocytosis than the injection of control
uninfected lysed M0 (LysedMVV+, n=6), although this was not statistically significant
(Student's t-test, p-0.2). However, the volume of F4/80 immunoreactivity was
significantly greater in the same mice injected with lysed MVV infected M0 (n=6) than
in those injected with control uninfected lysed M0 (n=6, Student's t-test, */?<0.01).
Results: Mean ± SEM.
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3.3.2.5. Chronic inflammation caused by live macrophages
Since the intracerebral injection of live macrophages in scid mice caused greater
acute inflammation when these were infected with MVV, the longer term effects of live
macrophages on scid mice parenchyma were also investigated. Cells suspensions of live
macrophages were prepared and injected in exactly the same manner as previously, but
experimental animals were left to recover for 21 days post-operatively. Scid brain tissue
was immunocytochemically processed as before.
The results show that the inflammation persists over 3 weeks (Fig. 3.11).
Indeed, increases in GFAP immunoreactivity appear greater in mice injected with MVV
infected live macrophages than with uninfected live macrophages, although this failed to
reach statistical significance (Student's t-test, p-0.6). The increase in F4/80
immunoreactivity in these mice, however, was much more striking. The near fourfold
increase of F4/80 staining following injection of live, infected macrophages as
compared to live uninfected macrophages was highly statistically significant (Student's
t-test, pcO.OOl).
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GFAP F4/80
M0 MVV+ M0 M0 MVV+M0
Fig. 3.11: Chronic effects ofM0 on GFAP and F4/80 staining of scid striatum
Mice were injected intracerebrally with M0 cultured for 7 days, uninfected (M0, n=8)
or infected with MVV (MVV+ M0, n=8). Animals were perfused 3 weeks post¬
operatively. Astrocytosis appeared greater in mice injected with MVV infected M0
than in those injected with uninfected M0, although this was not statistically significant
(Student's t-test, p=0.6). The volume of F4/80 immunoreactivity, however, was
significantly greater in the same mice injected with MVV infected macrophages as
compared to those receiving uninfected macrophages (Student's t-test, */?<0.001).
Results: Mean ± SEM.
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3.3.2.6. Intracerebral injection ofPBMCs
In the naturally occuring disease, lymphocytes and T cells, in addition to
macrophages, are found to invade the brains of MVV infected sheep and indeed, many
researchers attribute the neurodegeneration involved in MVV to the detrimental actions
of these cells. In an effort to investigate the role that these cells may play in causing
neuroinflammation, PBMCs were harvested from healthy sheep and supplemented with
virus, or harvested from productively infected sheep and supplemented with virus.
These cells were then injected in the same manner as in previous experiments and the
levels of astrocytosis and microgliosis evaluated in identical fashion.
Results show, surprisingly, that no variations in GFAP expression were observed
between the groups of mice receiving uninfected PBMCs, virus supplemented PBMCs
and PBMCs harvested from productively infected sheep and supplemented with virus
(Fig. 3.12, one-way ANOVA, p-0.2). Cells were injected at differing higher densities
than for the macrophage cell preparation in order to attempt to deliver the same numbers
of monocyte/macrophages as in the previous experiments. Monocyte/macrophages in
PBMC cell preparation routinely account for about 10% of the total cell count, and the
number of cells/pi was adjusted accordingly.
The observation of no significant differences between the PBMC groups is
surprising since these cells have widely been implicated in MVV induced
neurodegeneration. However, in an attempt to resolve this apparent contradiction, a
proliferation assay was carried out, in order to evaluate whether the cells were
responding to the addition of MVV. The subsequent results show that, although capable
of proliferation in response to a known mitogen, ConA, PBMCs did not proliferate in
response to the addition of virus supernatant (Fig.3.13). This may be due to the killing
of PBMCs by the virus or to inadequate amounts of viral antigen. These results,
therefore, cannot discount the possibility of some neuroinflammatory action of PBMCs,
as has previously been reported, and the present experiments would need to be repeated.
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n°cells (10s) 1 1 5
MVV - +
Fig. 3.12: Effects of PBMCs on GFAP staining of scid striatum
PBMCs were injected at different densities: 1x10s cells/p.1 (n=3 MVV-, n=2 MVV+),
5xl08 cells/jLtl (n=7 MVV-, n=4 MVV+, n=3 MVV++) and lxlO9 cells/fxl (n=2 MVV-,
n=3 MVV+). MVV-: uninfected cells, MVV+: virus supplemented cells, MVV++:
cells obtained from productively infected sheep and supplemented with virus. All mice
were perfused one week post-operatively. No significant differences in degrees of
astrocytosis was observed between any of the groups (one-way ANOVA, p-0.2).
Results: Mean ± SEM.
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MediumConA ConA ConA ConA ConA ConA MVV MVV
50 25 12.5 6.25 3 1.5 1:2 1:4
ug/ml ug/ml ug/ml ug/ml ug/ml ug/ml
MVV MVV MVV MVV
1:8 1:16 1:32 1:64
Fig. 3.13: Degree of proliferation of PBMCs from MVV infected sheep.
PBMCs were capable of proliferating as shown by the addition of ConA to their
medium, but only displayed a limited rate of proliferation in response to the addition of
virus supernatant solution to their medium.
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3.3.2.7. Intravenous injection ofmacrophages and PBMCs
In an effort to mimic further the natural MVV disease, macrophages and PBMCs
were injected into the tail vein of scid mice. No increases in GFAP staining, at 7 days
post-transfer, were observed in the brains of scid mice injected intravenously with 7 day
old uninfected or MVV infected macrophages, or in those injected with PBMCs from
productively MVV infected sheep (data not shown). Furthermore, staining for antigens
located on macrophages and PBMCs did not reveal the presence of any of the injected
cells in the CNS of the scid mice. This may be due do the inaccuracy of the injection
method, the relatively small amount of time between injection and sacrifice, or the
sequestration of macrophages in other tissues.
3.3.2.8. Effect ofMK801 on acute inflammation caused by live macrophages
The potential protection by the NMDA receptor antagonist MK801, of
neuroinflammation caused by MVV infected macrophages was also probed. Animals
receiving MK801 were injected intraperitoneally 1 hour prior to the administration of
MVV infected macrophages. The results show that MK801 reduces the volume of both
the GFAP and F4/80 lesion present in treated mice (one way ANOVA, p<0.05, post-hoc
Duncan test, p<0.05, Fig. 3.14).
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GFAP F4/80
MVV- MVV+ MK801 MVV- MVV+ MK801
Fig. 3.14: Effect of MK801 on GFAP and F4/80 induction in scid striatum
Animals received 5xl03 mature macrophages in lfil and were perfused 1 week post¬
operatively. MK801 was injected i.p. 1 hour pre-operatively. MVV-: uninfected
macrophages (n=ll), MVV+: macrophages infected with MVV in vitro (n=ll),
MK801: MK801 treated animals receiving MVV infected macrophages (n=3). A one
way ANOVA showed a significant effect of treatment on lesion volume (p<0.005) and
post-hoc analysis indicated a greater GFAP and F4/80 lesion volume in animals
receiving MVV infected macrophages as compared to those receiving uninfected
macrophages or treatment with MK801 (Duncan test, *p<0.05). Results: Mean ± SEM.
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3.3.3. Cytokine profile of uninfected and MVV infected macrophages.
3.3.3.1. RT-PCR
RT-PCR successfully isolated mRNA from uninfected and MVV infected 1 day,
2 day, 4 day and 1 week old macrophages, and amplified DNA for the cytokines IL-lp,
IL-6, TGF|3, TNFa and the housekeeping gene ATPase from this mRNA. When the
cDNA obtained from the PCR was run on an agarose gel, no appreciable differences
were found in the levels of cDNA for the cytokines TNFa, IL-ip, IL-6 or TGFP
between uninfected and MVV infected macrophages cultured for 1, 2 or 4 days.
However, levels of TGFP and IL-lp appeared higher in samples obtained from 1 week
old macrophages infected with MVV than in uninfected 1 week old macrophages. Since
the difference in cytokine profile between uninfected and MVV infected macrophages
appeared evident on the agarose gel, it was probed in a southern blot.
3.3.3.2. Southern blotting.
In order to semi-quantify the levels of DNA for each cytokine in 1 week old
macrophages, the gel was probed with specific radioactive markers. Viewing of the
autoradiograph obtained from the Southern blot, and densitometry reading of the
appropriate bands seemed to confirm that levels of the cytokines IL-lp and possibly
TGFP were upregulated in MVV infected macrophages as compared to uninfected
macrophages.
Integrated intensity (II) readings of ATPase bands obtained on the Southern blots
showed approximately the same levels of ATPase at 35 cycles in uninfected cells
(252.934) and MVV infected cells (264.94). Levels of cytokine cDNA were semi-
quantified against these levels of overall cDNA, as shown by ATPase cDNA levels.
Accordingly, II values obtained from cytokine cDNA from uninfected cells were divided
by II readings from uninfected ATPase levels (252.934), and II values obtained from
MVV infected cDNA samples were divided by the MVV infected ATPase densitometry
reading (264.934). Thus cytokine cDNA bands from uninfected and infected samples
were normalised against the appropriate amounts of total cDNA levels. The ratios of
cytokine cDNA obtained from MVV infected macrophages against cytokine cDNA
obtained from uninfected macrophages were then calculated for each cytokine.
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TNFa cDNA levels were not upregulated in MVV infected macrophages as
compared to uninfected macrophages. The II ratio of cDNA obtained from MVV
infected cells (IImvv) to cDNA acquired from uninfected macrophages (IIcont) was 1.19
at 27 cycles, 1.17 at 31 cycles and 0.77 at 35 cycles. Similarly, IL-6 cDNA levels were
not consistently different between uninfected and MVV infected macrophages. The
IImvv : IIcont ratios were 2.21 at 27 cycles, 1.04 at 31 cycles and 1.02 at 35 cycles.
However, TGF(3 cDNA levels appeared slightly increased in MVV infected
macrophages. The IImvv : IIcont band reading ratios for TGF(3 were 0.86 at 27 cycles,
1.17 at 31 cycles and 1.78 at 35 cycles. Likewise, IL-1(3 cDNA was definitely increased
in MVV infected macrophages compared to uninfected macrophages: nMvv : Dcont
ratios equalled 3.4 at 27 cycles, 2.5 at 31 cycles and 2.5 at 35 cycles, corresponding to a
near threefold increase in cDNA levels (Fig. 3.15).
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Cytokine cDNA Cycles IImvv J Hcont Mean IImvv
•HCONT
27 1.19
TNFa 31 1.17 1.04
35 0.77
27 3.4
IL-1|3 31 2.5 2.8
35 2.5
27 2.21
IL-6 31 1.04 1.42
35 1.02
27 0.86
TGF(3 31 1.17 1.27
35 1.78
Fig. 3.15: Densitometry analysis of cytokine cDNA obtained from uninfected and
MVV infected macrophages.
Cytokine cDNA integrated intensity values were calculated from bands obtained in
Southern blots and normalised against total levels of ATPase cDNA. TGF(3 and EL-6
cDNA levels are slightly higher in MVV infected macrophages as compared to
uninfected macrophages, but TNFa levels remain unchanged. Levels of IL-ip cDNA
are definitely elevated in MVV infected macrophages when compared to their
uninfected counterparts.
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3.4. DISCUSSION
The current experiments suggest a possible role for macrophages infected with
MVV in causing neurodegeneration. The injection of live MVV infected macrophages
into scid mouse striatum caused greater GFAP and F4/80 induction, when compared to
uninfected macrophages, one week post-operatively. The increase in GFAP staining
appears to be an acute transitory phenomenon, not lasting beyond one week post¬
operatively. The induction of microgliosis, however, persists and is still significant 3
weeks post-operatively. The effects of free virus injection are not clear cut, as, although
some increase in GFAP staining appears to be incurred when compared to the injection
of control medium, this is not statistically significant. F4/80 staining is likewise not
significantly altered. The injection of freeze thawed, killed macrophages previously
infected with MVV up-regulated F4/80 staining, as compared to uninfected
macrophages, but had no significant effect on GFAP induction. Furthermore, the
injection of free virus and killed macrophages caused smaller lesions than the injection
of live macrophages.
The aim of these experiments was to investigate whether MVV infected
macrophages had any effects on brain parenchyma in the absence of other cell-mediated
immune effectors. The results suggest that macrophages infected with MVV may cause
acute GFAP expression, therefore transitory astrocytosis, and more chronic F4/80
induction and therefore microgliosis. These effects seem to depend on the state of
maturation of the injected macrophages as older macrophages, maintained 1 week in
vitro, cause greater neuroinflammation than younger macrophages, maintained for fewer
days in vitro. This may be due to the increased capability of macrophages, as opposed to
monocytes, to support viral infection and gene expression (Gendelman et al., 1986). The
acute gliosis reflected by elevated GFAP expression may be due to the actions of
mediators released by MVV infected macrophages. Astrocytes represent a relatively
malleable population of cells within the CNS and the lack of persistent astrocytosis may
reflect a return to steady state functions of astrocytes following the initial insult.
The persistence of microgliosis within the striata of scid mice injected with
MVV infected macrophages may, however, reflect more severe changes in CNS
functions, an increased recruitment of blood borne macrophages to the CNS, or both.
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The activation of microglia over a period of 3 weeks post-inoculation in scid striatum is
taken to be the most significant event in these experiments. This continuance may
represent the establishment of lesions in the natural disease, and contribute to the
symptoms of neurologic MVV infection. The putative importance of activated microglia
in the pathogenesis of MVV induced CNS lesions has also been recently highlighted
independantly, by the correlation of activated microglia and severity of lesion patterns in
experimentally MVV infected sheep (Bergsteinsdottir et al., 1998). These investigators
attribute a significant degree of importance to the expression of MHC antigens on
activated microglia in the induction of CNS lesions. Although activated microglia were
only detected in the present scid mice experiments by the induction of F4/80, an
investigation into the MHC expression profile of these activated microglia would be
worthwhile. Nevertheless, the present findings reinforce a role for microglia in the
response of the CNS to the challenge of MVV infected cells, and the establishment of
neuropathology in the absence of other cell-mediated immune effectors.
The lack of significant effects of free virus on scid striata, as well as the lack of
demonstrable p25 antigen in scid brains one week post-operatively, would suggest either
that not enough virus was delivered to the striata of scid mice, although the amount of
viral particles delivered was calculated at over 800 000, or that virus was being cleared
from scid mouse CNS. It is also possible that the lack of p25 staining may be due to the
down-regulation of MVV in vivo. Although MVV can infect cells readily in vitro and
replicate, the effects in vivo may be different. This has been observed in other tissues
where the injection of MVV into joints causes pathology characteristic of MVV
infection, but no viral markers can be detected shortly after the injection. Similarly, in a
recent report involving the intracerebral inoculation of sheep with MVV, few viral
antigens were located in the CNS of diseased sheep, but neuropathology characteristic
of visna infection was evident (Bergsteinsdottir et al., 1998). A similar phenomenon
may be at work in scid mice injected with MVV infected macrophages or free virus. The
virus may initiate inflammation, but then become latent, causing the down-regulation of
viral proteins, including p25.
Although no firm conclusions as to the effects of free virus on scid CNS can be
upheld, it would seem plausible to suggest that, because of the actions of live
macrophages, diffusible mediators may be necessary to the induction of GFAP and
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F4/80. The injection of killed macrophages also caused a slight increase in GFAP
staining as well as a significant increase in F4/80 induction, when these were infected
with MVV. However, the injection of killed macrophages caused smaller GFAP and
F4/80 lesion volumes than the injection of live macrophages to scid striatum. This
would suggest that, although killed macrophages may be having some effect on scid
parenchyma, this effect is minimal. Thus, the effects of live macrophages may
incorporate an effect of killed macrophages, since some macrophages may perish during
the injection process. However, live macrophages have a greater effect on scid GFAP
and F4/80 expression, therefore it is unlikely that these effects are due to the artefact of
injecting 'dead' macrophages.
The lysis of uninfected and MVV infected macrophages necessarily involved, by
the freeze thawing method used here, the spillage of cellular contents into the injection
medium. The actions of many of these cellular components are not documented and
therefore no conclusions are possible as to what may be causing F4/80 induction by
killed macrophages. However, if an inflammatory mediator is responsible for the
neurodegeneration caused by live macrophages, then this mediator may also be present
in the injection medium of killed macrophages, and may be exerting similar effects.
The administration of MK801 prior to the injection of macrophages caused the
reduction of GFAP and F4/80 induction caused by MVV infected macrophages. This
suggests that any putative mediator released by MVV infected macrophages to cause
increases in GFAP and F4/80 staining, may be acting through glutamate receptors. The
presence of glutamate receptors on astrocytes is suspected, as excitatory amino acids can
depolarise astrocytes in vitro (Bowman et al., 1984). The effect on microglia may be an
indirect effect, as there is little evidence to suggest the presence of glutamate receptors
on microglia. The inhibition of astrocyte activation by MK801, may secondarily inhibit
the actions of activated astrocytes on surrounding cells and, consequently, microglia.
Thus, microglia may be upregulated by activated astrocytic mediators, for example
cytokines, as well as by macrophage effectors, and that inhibition of the effects of
astrocytes by MK801 may, in turn, cause less microglial activation. However, the
actions of MK801 wan-ant further investigation, as the experimental numbers using
MK801 were low.
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The injections of PBMCs in these experiments did not cause significant
increases in GFAP or F4/80 staining. This does not, however, discount any effects of
immune cells on scid brain. Further experiments using the injection of MVV reactive
lymphocytes would be required to clarify the role of circulating immune cells in causing
inflammation in scid striata. Indeed, neuronal loss or myelin disruption may require the
presence of both macrophages and PBMCs in brain parenchyma. Neither of these events
were observed with the injection ofMVV infected macrophages alone.
Preliminary investigations into the cytokine profile of MVV infected
macrophages as compared to uninfected macrophages revealed an upregulation of IL-ip
mRNA, and a possible increasing effect on the expression of TGFP and IL-6 mRNA.
Levels of TNFa mRNA were unchanged. The probing of the pattern of cytokine
expression was intended primarily as a tool for the measure of activation of
macrophages destined for injection into scid mice, but may also offer clues as to the
identity of a pro-inflammatory mediator contributing to the lesions seen in scid mice.
MVV infection of ovine cells has been shown to alter cytokine mRNA patterns both in
vitro and in vivo. Indeed, mRNA levels for the cytokine interleukin-8 (IL-8) are
increased in alveolar macrophages infected with MVV in vitro (Legastelois et al., 1998).
Accompanying this effect is an increase in levels of EL-lp mRNA. In vivo experiments
from the same laboratory using naturally MVV infected tissue also show elevated levels
of IL-8 mRNA in macrophages. In these cells, virus expression was not always evident,
suggesting that cytokine induction may be a downstream predictor of virus activated
cells, following clearance of MVV from macrophages. Similarly, TGFp expression has
been found to be increased in the alveolar and interstitial macrophages of naturally
MVV infected sheep (Moreno et al., 1998). The immunohistochemical detection of
TGFP correlated with the occurrence of early lesions in the lungs of these sheep, and, as
for EL-8, followed a distinct expression pattern. The current finding of a near three-fold
increased expression of IL-ip mRNA in blood borne macrophages following MVV
infection in vitro is therefore taken as an indicator of cellular activation in response to
MVV infection. This finding may also serve to compensate for the lack of p25
expression in macrophages once injected into scid mouse striatum. It is possible to
speculate that MVV infection of macrophages in vitro initiates a cascade of events,
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including changes in cytokine expression, which may persist after the clearance or
down-regulation of the virus in vivo.
The induction of fL-l(3 mRNA in MVV infected macrophages in vitro may
suggest its release upon transplantation of macrophages into scid mouse brain tissue. It
is appealing to propose that this cytokine may be involved in causing the astrocytosis
and microgliosis observed in scid parenchyma following the injection of MVV infected
macrophages. Indeed, IL-1 (3 has been found to have a variety of effects on brain cells,
including astrocytes, microglia and neurons (Campbell et al., 1993; Hertz et al., 1990;
Bama et al., 1990; Gelbard et al., 1993; Chao et al., 1995), and is generally accepted as
a pro-inflammatory mediator. However, further experiments would be needed to clarify
the presence of ovine TL-1 (3 in scid parenchyma following MVV infected macrophage
transplantation, in order to assign any role to this cytokine in causing neuroinflammation
in the experiments carried out in this thesis. Furthermore, species specificity may
prevent any actions of ovine cytokines on murine cells. In particular, recombinant ovine
TNFa and IL-6 have been shown only to have limited effects on some murine cell lines.
Recombinant ovine TNFa does not cause cytotoxicity to murine L929 cells in vitro
(Green et al., 1993) and recombinant ovine IL-6 does not induce the proliferation of
murine B9 myeloma line cells, in contrast to the effect of murine IL-6 (Ebrahimi et al.,
1995). However, in the same investigations, murine L929 cells do show activity
attributable to TNFa, which is blocked by antibodies to the ovine recombinant protein,
and the IL-6 studies used recombinant ovine pre-protein. Thus, ovine cytokines may be
capable of exerting effects on these murine cell lines, albeit at higher concentrations
than needed for the endogenous cytokines. Moreover, the effects of these recombinant
proteins have not been studied on any other murine cell types, such as astrocytes and
microglia. The investigation of the effects of ovine cytokines on murine cells would
ceitainly prove valuable in the context of the present experiments.
In summary, the experiments carried out here seem to suggest a possible role for
macrophages infected with MVV in causing astrocytosis and microgliosis in the absence
of other cell-mediated immune responses in vivo. Astrocytosis and microgliosis are
characteristics of the natural MVV disease (Georgsson et al., 1977), but these
experiments do not confirm that macrophages are solely responsible for the observed
changes in brain parenchyma. The induction of astrocytic and gliotic responses in scid
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CNS may involve a cellularly released mediator. The identity of such a mediator cannot
conclusively be suggested as a cytokine, although levels of EL-1(3 mRNA are increased
in MVV infected macrophages. The inhibitory action of MK801 suggests that any
putative mediator may act through glutamate receptors. This is at odds with the proposal
of a cytokine as a detrimental effector, and raises the possibility that a viral protein may
be playing a role in the inflammation observed, possibly in concert with any cytokine
action. The actions ofMVV peptides on CNS cells are addressed in the next chapter.
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Chapter 4: In vitro neurotoxicity ofMW infected macrophage products and lentiviral Tat
4.1. INTRODUCTION
In the scid mouse model of MVV encephalopathy described in the previous
chapter, no neuronal loss was observed in the brains of mice injected with MVV
infected macrophages. However, in naturally occurring MVV, areas of necrosis are
regularly found, particularly in the vicinity of invading macrophages. Neuronal loss is
also common in HIV encephalopathy. Many candidates have been proposed as
neurotoxic agents in lentiviral encephalopathies, including cytokines and the lentiviral
proteins Tat and envelope glycoproteins. Since the previous experiments showed that
MVV infected macrophages caused greater CNS inflammation than uninfected
macrophages when injected into scid mice, the supernatant from these cells was applied
to neurons in vitro and neuronal cell death evaluated. Since the lentiviral protein Tat
has also been shown to be released from HIV infected cells, the neurotoxic potential of a
lentiviral tat peptide derived from the basic region ofMVV Tat protein was also probed
in vitro.
4.2. EXPERIMENTAL DESIGN
The neurotoxic potential of macrophage supernatants and MVV tat peptide was
evaluated in vitro. Cultures of E17 rat cortical neurons were established and
maintained in serum free medium for 5 days prior to application of supernatant or
peptides. Supernatant was removed from mature 1 week old uninfected and MVV
infected macrophages and applied to the neurons in vitro. Cell death was measured
using an assessment of cell viability based on the reduction of MTS. MVV tat peptide
(235 nM) and control ovalbumin peptide (235 nM) were applied to neuronal cells of the
same plate, and cell death evaluated using both the MTS assay, and LDH release.
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4.3. RESULTS.
4.3.1. Characterisation of rat cortical cell cultures
Preliminary experiments were carried out to set up rat cortical cultures enriched
in neurons. Initially, cells obtained from E17 rats were plated out and maintained in
serum containing medium (10% Fetal Bovine Serum). Efforts were made to control the
presence of glial cells in these cultures by the application of 10pM cytosine arabinoside,
a proliferation inhibitor, to wells after 24 hours in vitro. However, repeated experiments
using cytosine arabinoside at 10(iM and lower concentrations, resulted in the
disappearance of neurons as well as glial cells. However, without the addition of
cytosine arabinoside, glial cells proliferated in abundance at the expense of neuronal
numbers. This was revealed by immunostaining of cultures with antigens directed
against the neuronal protein NeuN, the microglial marker OX42 and the astrocytic
marker GFAP. Optimisation of neuronal numbers was achieved by initially plating
cortical cells in culture medium containing 5% FBS, and maintaining them in vitro
using chemically defined, serum free medium. Cells cultured in this manner were
predominantly NeuN positive, with a few 0X42 and GFAP positive cells present in
each well.
4.3.2. In vitro neurotoxicity of macrophage supernatants.
Supernatant from 1 week old cultured MVV infected and uninfected
macrophages was removed and applied to rat cortical cultures. The supernatant from
MVV infected macrophages caused significantly greater neurotoxicity to RCC in vitro
after 24 hours, as compared to the supernatant from uninfected macrophages (Student's
t-test, p<0.005, Fig. 4.1). The increase in cell death was approximately 4-fold. This
was measured using the MTS assay which gave an average value of cell death of 43%
for the supernatant from MVV infected macrophages, as compared to an average value
of 10% for the supernatant obtained from uninfected macrophages.
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Fig. 4.1: In vitro effect ofM0 supernatant on neuronal MTS reduction at 24 hours.
Supernatant from uninfected (MVV-, n=6) and MVV infected (MVV+, n=6) mature
M0 was applied to RCC for 24 hours. Cell death was measured using the MTS assay.
Supernatant from infected M0 produced significantly more cell death than supernatant
from uninfected M0 (Student's t-test, *p<0.005). Results: Mean ± SEM.
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4.3.3. In vitro neurotoxicity of MVV tat peptide.
MVV tat peptide (235nM) was applied to RCC in 12 replicates after 5 days in
culture. At the same time, ovalbumin peptide (235nM) was applied to 12 wells of the
same plate, and the remaining wells received a medium change. These were then left
for 24, 48 or 72 hours in culture conditions. Cell death was measured by an estimate of
LDH release, or by the amount of MTS reduction.
Preliminary data analysis revealed that intrinsic levels of cell death in wells
receiving a medium change alone varied between experiments. In some experiments,
cell death was much higher than in others. This may have been due to many causes
including, for example bacterial infections and excessive tissue disruption during the
dissection and trypsinisation procedures. In an effort to preserve the homogeneity of
samples studied, an arbitrary level of background cell death was determined, above
which samples were discarded. Therefore, if the average level of cell death in wells
receiving a medium change was above 25%, the data from that experiment was
discarded.
4.3.3.1. Effects at 24 hours
After 24 hours, the level of LDH release from neurons treated in vitro with MVV
tat peptide appeared greater than those treated with ovalbumin peptide or medium alone
(Fig. 4.2). LDH release from cells treated with MVV tat peptide rose to 25%, and LDH
release from cells treated with ovalbumin peptide increased to 21%. The average
background cell death in wells receiving only a medium change was 17%. A statistical
one-way ANOVA revealed that there was indeed a significant difference between the
three treatment groups (/?<0.001). Subsequent post-hoc data analysis also showed that
LDH release from cells treated with MVV tat peptide was significantly greater than
LDH release from cells treated with control ovalbumin peptide and those receiving only
a medium change (Modified LSD [Bonferroni's] test, /?<0.05). LDH release
corresponds to total amount of cell death, therefore the incubation of neurons with MVV
tat peptide caused greater numbers of cells to die than did the administration of
ovalbumin peptide or a medium change.
In parallel experiments, cell death was evaluated using an MTS assay, based on
the degree of cell viability (Fig.4.3). In these experiments, cell death increased both in
wells treated with MVV tat peptide and in wells treated with control ovalbumin peptide,
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as compared to wells receiving only a medium change. A single factor ANOVA
revealed that the three treatments caused significant differences in MTS reduction in
neurons (p<0.01). However, subsequent post-hoc statistical analysis did not reveal any
differences between treatment with MVV tat peptide and control ovalbumin peptide.
Both treatments, however, did cause lesser MTS reduction, and therefore greater
neuronal cell death, than a medium change alone (Modified LSD [Bonferroni's] test,
p<0.05).
4.3.3.2. Effects at 48 hours
At 48 hours in vitro, MVV tat peptide, ovalbumin peptide and a medium change
caused significant differences in LDH release between treatments (one-way ANOVA,
p<0.01, Fig. 4.4). Indeed, LDH release rose to 26% in neurons treated with MVV tat
peptide and to 21% in cells treated with ovalbumin peptide. The average background
level of cell death in wells receiving only a medium change approximated 19%. Post-
hoc analysis showed that treatment with MVV tat peptide caused greater LDH release,
and thus cell death, than treatment with ovalbumin peptide or a medium change alone
(Modified LSD [Bonferroni's] test, p<0.05).
In similar experiments using the MTS assay as an indicator of cell death, a one¬
way ANOVA revealed a significant effect of treament on MTS reduction (pcO.OOl,
Fig.4.5). Neuronal cell death in wells treated with MVV tat peptide rose by 25%,
whereas cell death in wells treated with ovalbumin peptide increased to 18%, as
compared to control cells receiving a medium change, where the average value of cell
death was 14%. Post-hoc analysis also showed that treatment of cells with MVV tat
peptide caused greater LDH release than both the control ovalbumin peptide and
medium change groups (Modified LSD [Bonferroni's] test, p<0.05). These results
strongly suggest that MVV tat peptide is exerting a neurotoxic effect on neurons after 48
hours incubation in vitro.
4.3.3.3. Effects at 72 hours
After 72 hours incubation, a single factor ANOVA revealed a significant effect
of treatment on neuronal LDH release (/?<0.001, Fig. 4.6). MVV tat peptide treatment
caused an increase in LDH release to 19% as compared to 14% in wells receiving the
control ovalbumin peptide, and 13% in wells receiving only a medium change.
Subsequent post-hoc data analysis showed that LDH release, and therefore cell death,
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was significantly increased in cells receiving MVV tat peptide as compared to those
receiving ovalbumin peptide, or a medium change alone (Modified LSD [Bonferroni's]
test, p<0.05).
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Fig. 4.2: In vitro effect of MVV tat peptide on neuronal LDH release at 24 hours.
Results: Mean ± SEM. Cell death was measured using the LDH assay, 24 hours after
application of MVV tat peptide (n=24), ovalbumin peptide (n=24) or a medium change
(n=24) to RCC. A single factor ANOVA revealed a significant effect of treatment on
LDH release (p<0.001). Post-hoc analysis showed LDH release in the MVV tat peptide
group was significantly greater than in both the ovalbumin and medium groups
(Modified LSD [Bonferroni's] test, *p<0.05).
108
Chapter 4: In vitro neurotoxicity ofMW infected macrophage products and lentiviral Tat
Fig. 4.3: In vitro effect of MVV tat peptide on neuronal MTS reduction at 24 hours.
Cell viability was measured using the MTS assay, 24 hours after application ofMVV tat
peptide (n=24), ovalbumin peptide (n=24) or a medium change (n=24) to RCC. A
single factor ANOVA revealed a significant effect of treatment on MTS reduction
(p<0.01). Post-hoc analysis showed that treatment with MVV tat peptide did not cause
significantly greater cell death than treatment with ovalbumin peptide, but both these
treatments did cause significantly greater cell death then a medium change alone
(Modified LSD [Bonferroni's] test, **p<0.05). Results: Mean ± SEM.
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Fig. 4.4: In vitro effect of MVV tat peptide on neuronal LDH release at 48 hours.
Cell death was measured using the LDH assay, 48 hours after the application of the
MVV tat peptide (n=24), ovalbumin peptide (n=24) or a medium change (n=22) to
RCC. A single factor ANOVA revealed an effect of treatment on LDH release
(p<0.001). Post-hoc analysis showed LDH release in the MVV tat peptide group was
significantly greater than in both the ovalbumin and medium groups (Modified LSD
[Bonferroni's] test, *p<0.05). Results: Mean ± SEM.
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Fig. 4.5: In vitro effect of MVV tat peptide on neuronal MTS reduction at 48 hours.
Cell viability was measured using the MTS assay, 48 hours after the application of
MVV tat peptide (n=24), ovalbumin peptide (n=24) or a medium change (n=24) to
RCC. A single factor ANOVA (p<0.001) revealed a significant effect of treatment on
MTS reduction. Post-hoc analysis showed that MTS reduction in the MVV tat peptide
group was significantly less than in both the ovalbumin and medium groups (Modified
LSD [Bonferroni's] test, *p<0.05). Results: Mean ± SEM.
Ill
Chapter 4: In vitro neurotoxicity ofMVV infected macrophage products and lentiviral Tat
Fig. 4.6: In vitro effect of MVV tat peptide on neuronal LDH release at 72 hours.
Cell death was measured using the LDH assay 72 hours after treatment of cells with
MVV tat peptide (n=12), ovalbumin peptide (n=12) or a medium change (n=12). A
single factor ANOVA revealed a significant effect of treatment on LDH release
(p<0.001). Post-hoc analysis showed that LDH release in the MVV tat peptide group
was significantly greater than in both the ovalbumin and medium groups (Modified LSD
[Bonferroni's] test, *p<0.05). Results: Mean ± SEM.
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4.4. DISCUSSION
The current experiments suggest that supernatant obtained from MVV infected
macrophages is more neurotoxic than supernatant derived from uninfected macrophages
after 24 hours application to neurons in vitro. The experiments carried out here also
suggest that MVV tat peptide is neurotoxic to cultured neurons. This effect begins at 24
hours and is definite by 72 hours.
The aim of these experiments was to test the posible neurotoxicity of
macrophage supernatants and that of an MVV tat peptide. Although macrophages
infected with MVV did not cause any noticeable neuronal cell death in scid mice, as
mentioned previously, the investigation of any neurotoxicity, in a different experimental
setting, was deemed worthwhile. The subsequent finding that MVV infected
macrophages supernatant causes greater toxicity to neurons than uninfected macrophage
supernatant lends support to the neurodegenerative potential of products released from
lentivirally infected macrophages. Lentiviral Tat protein has been shown to be released
from infected cells and may move transcellularly (Frankel et al., 1988). MVV Tat
protein may therefore also be released from infected macrophages. Peptides derived
from MVV Tat protein have previously been shown to be neurotoxic in vitro and in vivo
(Hayman et al, 1993; Strijbos et al., 1995), and the current experiments confirm this.
Furthermore, these experiments suggest an acute neurotoxic action of MVV tat peptide.
This peptide exerts its effects rapidly, as some neurotoxicity is apparent in neurons
incubated with the peptide after 24 hours. At 48 hours incubation, MVV tat peptide
exerts definite neurotoxicity, both by measurement of total cell death and total cell
viability.
However, it should not be inferred from these experiments that MVV Tat is
considered here to be the only mediator possibly present in MVV infected macrophage
supernatant that may be neurotoxic. Other mediators, for example cytokines or other
viral proteins, may also be contributing to neurotoxicity. These experiments do serve to
prove however, the neurotoxicity of a lentiviral peptide, putatively released from MVV
infected macrophages, and can justify the subsequent testing of this peptide in vivo.
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5.1. INTRODUCTION
The neurotoxic capability of lentiviral Tat has previously been documented in
vitro and in vivo. However, no studies have been conducted on the acute neurotoxic
potential of MVV tat peptide. In an effort to investigate any neurodegenerative effects
of the MVV tat peptide in the short term, MVV tat peptide was administered in vivo,
and its effects studied at short time courses. The long term effects of MVV tat peptide
in vivo have been attributed to NO mediated glutamate neurotoxicity. Neuroprotection
studies were therefore also carried out to investigate whether the same neurotoxic
mechanisms operate acutely.
5.2. EXPERIMENTAL DESIGN.
The in vivo neurotoxic ability of HIV and MVV tat peptides was assessed by the
stereotaxic injection of these into rat striatum. Neuronal loss, and activation of
astrocytes and microglial cells were measured by immunocytochemical detection and
morphometric image analysis of the lesion incurred at 30 minutes, 1 hour and 2 hours
after injection. Some animals were also examined at later time points. The mechanisms
of neurotoxic action of MVV tat peptide were then probed through the use of glutamate
receptor antagonists, a NOS inhibitor and a TNFa antagonist.
5.3. RESULTS.
5.3.1. Lesion characteristics
MVV and HIV tat peptides (20 pg in lpl) were injected into rat striata, which
were then recovered and examined at 30 minutes, 1 or 2 hours after the time of
injection. An acute lesion was induced by MVV tat peptide as early as 30 minutes post¬
operatively. Furthermore, the appearance of this lesion was very distinctive and
unusual. The lesion profile was the same at all the acute time intervals, and was similar
for the HIV tat peptide.
NeuN immunocytochemical staining of rat striatum, injected with MVV tat
peptide and recovered 1 hour post-surgery, showed neuronal loss. Normal NeuN
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staining of rat striatum shows positive cells distributed homogeneously throughout the
striatum (Fig. 5.1.A). Injection of control substances showed disruption of the normal
organisation of NeuN staining, but this was confined to the needle tract (Fig. 5.1.B).
Administration of lp.1 MVV tat peptide caused widespread disruption in NeuN staining.
At the centre of the lesion, NeuN positive cells appeared darkened and distorted (Fig.
5.1.C). Surrounding this area a 'halo' effect was observed of tissue devoid of staining
(Fig.5.1.D). At a higher magnification, NeuN staining revealed neuronal loss both at the
centre of the lesion (Fig. 5.2.A) and in the 'halo' area (Fig. 5.2.B).
This same unusual pattern was evident on GFAP stained sections recovered from
animals injected with lpl MVV tat peptide and sacrificed at 1 hour. Injection of control
substances into rat striatum showed few GFAP positive cells at the injection site 1 hour
post-surgery (Fig. 5.3.A). Injection of 1 jLtl MVV tat peptide, however, caused the
appearance of GFAP positive cells at the centre of the injection site, surrounded by
tissue devoid of staining (Fig. 5.3.B). Astrocytes therefore appear activated at the centre
of the lesion, but are not evident in the 'halo' area surrounding the centre of the lesion.
Immunocytochemistry for activated microglia also showed a similar lesion
profile in MVV tat peptide injected animals recovered 1 hour post-operatively, although
this was much less striking than for the NeuN and GFAP stains. Injection of control
substances caused microglial activation one hour post-surgery (Fig. 5.4.B). The
injection of MVV tat peptide also caused microglial activation, but the pattern of
staining revealed the same 'halo' effect as staining for NeuN and GFAP (Fig. 5.4.A).
When compared to sections recovered 3 days post-injection, microglial activation at the
shorter time points appeared minimal.
Histochemistry for diaphorase positive, NOS neurons also revealed a lesion
caused by MVV tat peptide 1 hour post-operatively. Normal diaphorase staining reveals
NOS positive neurons with long processes throughout the striatum (Fig. 5.5.C). In
animals injected with ibotenic acid, some disruption of diaphorase staining was evident
1 hour post-operatively, but this was confined to the needle tract (Fig. 5.5.B). In
animals injected with MVV tat peptide, diaphorase staining was absent over a large
area, although some cell bodies were still recognisable (Fig. 5.5.A). The administration
of L-NAME also caused the disappearance of diaphorase positive neurons, perhaps due
to its inhibition of NOS.
In animals left to recover for 3 days or one week post-injection, NeuN staining
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was absent at the centre of the lesion, but did not reveal the same pattern as the acute
lesions. GFAP staining revealed astrocyte activation, but, as for NeuN, the distinctive
lesion profile observed at short time intervals post-surgery was absent. In these animals
astrocytosis was more diffuse, with no disappearance of GFAP immunoreactivity.
Diaphorase staining was also reduced as was staining for PV and ChAT neurons (Figs.
5.6 and 5.7). The 0X42 response also showed extensive microglial activation at 3 days,
but this was decreased at one week.
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Fig. 5.2: NeuN staining of rat striatum
A: no injection, B: injection of 1 fj.1 L-NAME,
C: centre of lesion caused by 1|li1 MW tat peptide
D: 'halo' area of lesion
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Fig. 5.3: GFAP induction by 1VIW tat peptide
A Injection of lp.1 saline B Injection of lp.1 MVV tat peptide Injection ofMW tat
peptide caused astrocyte activation at the centre of the injection site, but a disappearance
of GFAP positive cells surrounding the lesion site.
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Fig. 5.4: OX42 induction by MW tat peptide
A. Injection of lpl MW tat peptide B Injection of 1 pi ovalbumin peptide. The
injection ofMW tat peptide caused microglial activation as did the injection of ibotenic
acid. However, the pattern of microglial activation caused by MVV tat peptide was
similar to the lesion profile seen with NeuN and GFAP staining.
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Fig. 5.5: Loss of Diaphorase staining
induced by MW tat peptide.
A: Injection of lplMW tat peptide
B: Injection of lpl ibotenic acid
C: No injection. Injection ofMW
tat peptide caused the loss of
NOS-containing neurons.
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Fig. 5.6: Loss of PV immunoreactive neurons induced byMW tat peptide
A Injection of 1 jul MW tat peptide B No injection Some non-specific staining is
observed surrounding the lesion area in the tat peptide injected striatum. Parvalbumin
positive cells are not as readily observed in the MW tat peptide injected striatum as
compared to the uninjected striatum
123
L
Chapter5: In vivo neurotoxicity oflentiviral Tat
Fig. 5.7: Loss of ChAT immunoreactive neurons induced by MW tat peptide
A. No injection B Injection of 1 pi MW tat peptide ChAT immunoreactive neurons
are absent in the MVV tat peptide injected striatum.
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5.3.2. Morphometric analysis.
The administration of control substances, saline, ovalbumin peptide and ibotenic
acid, did not cause any lesions at 30 minutes post-surgery, as measured by the amount of
NeuN staining and compared to the volume of the lesion caused by MVV tat peptide
(Fig. 5.8). A one-way ANOVA revealed a significant effect of treatment on lesion
volume (p<0.05). Post-hoc analysis showed that the MVV tat peptide treated group
caused a significantly greater NeuN lesion than any of the control groups (Duncan test,
p<0.05). Similarly, the GFAP activation caused by the injection of MVV tat peptide
was greater than that caused by the injection of control substances at 30 minutes (One¬
way ANOVA, p<0.005, and post-hoc Duncan test, p<0.05, Fig. 5.9). However, no
visible differences in 0X42 staining were observed with the injection of control
substances 30 minutes after administration. The HIV tat peptide group was omitted from
statistical analysis due to the small number of experimental animals.
At 1 hour post-injection, the administration of a control substance, L-NAME,
caused a significantly smaller NeuN lesion than the administration of MVV tat peptide
(Student's t-test, p<0.05, Fig. 5.10). The injection of L-NAME into rat striatum did not
cause any measurable GFAP lesion, but both the MVV and HIV tat peptide groups
caused a large GFAP lesion (Fig. 5.11). L-NAME did, however cause the disappearance
of diaphorase positive neurons, due to its inhibition of NOS. No significant changes in
OX42 immunoreactivity were observed with any of the control substances.
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Fig. 5.8: Effect of intra-striatal injection of lentiviral tat peptides on NeuN staining
at 30 minutes.
Treatment had a significant effect on lesion volume (one-way ANOVA, /?<0.05), and
the MVV tat peptide lesion (n=3) was significantly greater than the application of saline
(n=2), ibotenic acid (n=2) and ovalbumin peptide (n=2) control substances (post-hoc
Duncan test, *p<0.05).The HIV tat peptide group is illustrated from one animal and was
omitted from statistical analysis. Results: Mean ± SEM.
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Fig. 5.9: Effect of intra-striatal injection of lentiviral tat peptides on GFAP
staining at 30 minutes.
MVV tat peptide (n=3) caused a significantly greater lesion than the saline (n=3),
ibotenic acid (n=2) and ovalbumin peptide (n=2) control groups (one-way ANOVA,
*/?<0.005, post-hoc Duncan test p<0.05). The HIV tat peptide group is illustrated from
one animal and was omitted from statistical analysis. Results: Mean ± SEM.
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Fig. 5.10: Effect of intra-striatal injection of lentiviral tat peptides on NeuN
staining at 1 hour
The L-NAME (n=5) control group was significantly different from the MVV tat peptide
group (n=18) and the HIV tat peptide group (n=3, one-way ANOVA and post-hoc
Duncan test, *p<0.05). Results: Mean ± SEM.
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Fig. 5.11: Effect of intra-striatal injection of lentiviral tat peptides on GFAP
staining at 1 hour.
The control substance, L-NAME (n=5), did not cause any measurable GFAP lesion.
Both the MVV tat peptide (n=18) and the HIV tat peptide (n=3) caused significant
lesions. Results: Mean ± SEM.
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5.3.2.2. Time course
Administration ofMVV tat peptide induced a lesion in the striatum, visible with
NeuN and GFAP staining, as early as 0.5 hours post-operatively. The amount of
neuronal loss, as measured by the NeuN lesion volume, increased over a period of 24
hours (Fig. 5.12). Statistical analysis revealed that the lesions caused by MVV tat
peptide at 1 and 24 hours were significantly greater than that at 30 minutes (one-way
ANOVA and post-hoc Duncan test, p<0.05). The lesion visible at 24 hours,
approximately 15mm , was of the same order of magnitude as that observed at one week
as previously documented. Similarly, the GFAP lesion caused by the injection of MVV
tat peptide increased significantly between 30 minutes and 24 hours (one-way ANOVA
and post-hoc Duncan test, p<0.05, Fig. 5.13).
5.3.2.3. Neuroprotection experiments
The effects of various putative neuroprotectants on the lesion caused by the
MVV tat peptide was assessed by their prior or co-administration with the peptide.
Since the MVV tat peptide lesion approximated maximal proportions at 1 hour,
substances were tested at this time point. The NMDA receptor antagonist MK801, and
the AMPA receptor antagonist NBQX, were injected intraperitoneally 1 hour prior to
the intra-striatal injection ofMVV tat peptide. L-NAME, an NOS inhibitor, and aMSH,
a TNFa inhibitor were co-injected with the peptide. Preliminary investigations did not
reveal any effects of NBQX and aMSH. However, the administration of MK801
reduced the volume of the NeuN lesion caused by the MVV tat peptide (Fig. 5.14). The
administration of L-NAME seemed to slightly increase the volume of the MVV tat
peptide induced NeuN lesion. A one-way ANOVA revealed a significant effect of the
administration of treatment on the MVV tat peptide induced NeuN lesion volume
(p<0.05). Post-hoc analysis showed the injection of MK801 caused a reduction in the
lesion volume caused by the MVV tat peptide (Duncan test, p<0.05). The administration
of L-NAME, however, had no significant effect. Similarly, MK801 reduced the volume
of the GFAP lesion caused by the MVV tat peptide (one-way ANOVA and post-hoc
Duncan test, p<0.05, Fig. 5.15), whilst the administration of L-NAME had no
significant effect.
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Fig. 5.12: Progress over time of the NeuN lesion induced by MVV tat peptide.
The lesion caused by the MVV tat peptide increased consistently over time, being
significantly greater at 1 (n=18) and 24 hours (n=2) than at 30 minutes (n=3; one-way
ANOVA and post-hoc Duncan test, */?<0.05). Results: Mean ± SEM.
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Fig. 5.13: Progress over time of the GFAP lesion caused by MVV tat peptide
The GFAP lesion caused by the MVV tat peptide increased significantly over time
between 30 minutes (n=3), and 24 hours (n=2; one-way ANOVA and post-hoc Duncan
test, p<0.05). Results: Mean ± SEM.
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Fig. 5.14: Effect of neuroprotectants on the MVV tat peptide induced NeuN lesion
at 1 hour.
Statistical analysis using a one-way ANOVA revealed a significant effect of treatment
on lesion volume (p<0.05). Post-hoc analysis showed the administration of MK801
(n=7) to significantly reduce the volume of the lesion caused by the MVV tat peptide
(n=18, Duncan test, *p<0.05), but the administration of L-NAME (n=5) did not.
Results: Mean ± SEM.
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Fig. 5.15: Effect of neuroprotectants on the MVV tat peptide induced GFAP lesion
at 1 hour.
The administration of MK801 (n=7) significantly reduced the volume of the GFAP
lesion caused by the injection of MVV tat peptide (n=12, one-way ANOVA and post-
hoc Duncan test, */?<0.05). The administration of L-NAME (n=5) did not cause any
significant difference to the lesion volume. Results: Mean ± SEM.
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5.3.3. Electron Microscopy
Observation at the ultrastructural level of the lesion induced by the MVV tat
peptide at one hour revealed necrosis, but no apoptotic cells. Apoptosis and necrosis are
readily distinguishable by the morphological characteristics of dying cells. Necrosis
causes an increase in cell volume, swelling of intracellular organelles, and eventual
lysis. In contrast, apoptotic cells gradually become digested. Endogenous proteases are
activated, causing cytoskeletal disruption, cell shrinkage and membrane blebbing.
Mitochondrial function is also lost. Endonucleases are activated to degrade DNA into
oligonucleosomal fragments, and the nuclear chromatin becomes condensed.
Throughout this process, membrane integrity is preserved until the cell is phagocytosed.
Inspection of neurons at the centre of the lesion, revealed no chromatin condensation in
the nucleus or membrane blebbing (Fig. 5.16). In the 'halo' area surrounding the centre
of the lesion, massive tissue disruption was evident and no recognisable cell types could
be identified. Glia at the centre of the MVV tat peptide lesion presented vacuolated and
disrupted cytoplasms (Fig. 5.17).
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Fig. 5.16: Electron microscopy of neurons at the site of the lesion caused by MVV
tat peptide.
A. No lesion B. Injection of lpl MVV tat peptide. The cytoplasm of neurons in the
striatum injected with MVV tat peptide is disrupted, but there is no evidence of
chromatin condensation of the nucleus, or ofmembrane blebbing.
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Fig. 5.17: Electron microscopy of glial cells at the site of the lesion caused by MVV
tat peptide.
A. Normal striatum B. Injection of 1 pi MVV tat peptide. In the injected striatum, glia
present vacuolated cytoplasms (arrows).
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5.4. DISCUSSION.
The present experiments demonstrate the acute in vivo neurotoxicity of a peptide
derived from the basic region of the MVV transactivating protein Tat. Lentiviral Tat
and related peptides have previously found to be neurotoxic in vitro and in vivo
(Gourdou et al., 1990, Sabatier et al., 1991, Hayman et al., 1993, Strijbos et al., 1995,
New et al., 1997), although their effects have not been studied at the short time courses
investigated here. The current experiments therefore provide further evidence for the
neurotoxic potential of this viral protein. Although the doses investigated here may be
deemed high, Tat has been shown to be released in the vicinity of infected cells (Frankel
and Pabo, 1988), and its levels may become elevated in the neighbourhood of the many
infected cells, commonly surrounding glial nodules.
MVV tat peptide exerts, in these experiments, a very rapid disruption of neurons
and astrocytes. It is possible that the lack of staining with NeuN does not in fact reflect
the loss of neurones, although there are experiments which certainly indicate that it is a
sensitive marker for healthy neurons (Wolf et al., 1996). It is possible that some form
of rapid degradation of the nuclear marker has reduced the staining, perhaps by some
loss of access to the epitope recognised by the monoclonal antibody due to some
modification of the antigen or neighbouring proteins in the nucleus. Nevertheless, the
size of the lesions observed with this method and with the markers for gliosis in the
same sections is very similar. Perhaps more strikingly, the volumes of the lesion
detected by different methods in earlier work (Hayman et al., 1993), are very similar to
those detected by the loss of NeuN staining. Together these observations suggest that
the lack of staining leads to, even if it does not immediately represent, the loss of viable
neurones. MVV tat peptide causes a significantly greater acute NeuN lesion than the
control substances saline, ibotenic acid, ovalbumin peptide and L-NAME. Similarly,
MVV tat peptide causes significantly greater astrocytosis in the striata of injected rats
than any of the control substances. These lesions increase consistently over time
between 30 minutes and 24 hours after administration, and approximate the size of
lesions observed one week post-operatively. Overall, the astrocytic lesion remains
smaller than the neuronal lesion, and this may reflect a greater sensitivity of neurons to
the MVV tat peptide, or may indicate a slower initiation of astroglial responses.
The lack of a lesion after injection of the well-known neurotoxin, ibotenic acid,
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points to the dramatically short time course of these experiments. At one week after the
injection of the same dose of ibotenic acid caused a lesion almost double the size of that
seen after the dose of MVV tat peptide used in these experiments (Hayman et al., 1993).
Yet the peptide induced damage is almost as large at 1 hr as it is at one week.
Preliminary tests with injections of endothelin close to the middle cerebral artery, which
cause large lesions after 24 hr (Sharkey and Butcher, 1998), also show the damage after
MVV tat peptide to occur more rapidly than the anoxic damage following arterial
occlusion (Sharkey, Starling, Arbuthnott - unpublished).
The unusual profile of the lesion caused by the MVV tat peptide, with a
surrounding 'halo' lacking neuronal staining, may be due to a number of actions of the
peptide. Oedema surrounding the injection site is one possible explanation. The
actions of the MVV tat peptide may also be amplified at distant sites due to neuronal
glutamate release and increased receptor occupation. This may cause a greater number
of neurons to die at the edges of the injection site. Indeed, lentiviral Tat has been shown
to depolarise neurons (Magnusson et al., 1994), and may exert its neurotoxic effects via
an overstimulation of calcium entry through glutamate receptors, to cause excitotoxicity
(Strjibos et al., 1995, Hayman et al., 1993). The present experiments also support this,
as the administration of MK801, an NMDA glutamate receptor antagonist, reduces the
volume of the lesion caused by the MVV tat peptide at 1 hour. The administration of L-
NAME did not cause any reduction in MVV tat peptide induced lesion volume in these
acute experiments, and the testing of an AMPA receptor antagonist and a TNFa
inhibitor did not reveal any conclusive actions of these molecules on the lesion volume.
Therefore, in the short term at least, the neurotoxic mechanisms of the MVV tat peptide
appear to be mediated by actions at glutamate receptors on neurons. In the longer term,
however, the detrimental actions of this peptide on neurons may involve other mediators
such as NO and cytokines.
In an early description of the disease caused in sheep by MVV infection
Georgsson (1977) describes neuronal damage in areas of liquefactive necrosis as early
as one month after the infection. Although the doses we have used are large, these
doses were effective in producing large lesions in the longer-term studies (Hayman et
al., 1993). The aim of these experiments was less to model the disease than to examine
the dynamics of neuronal damage by this agent. If this peptide has any role in the
generation of the neurotoxicity in the disease then it will only be after the toxin has
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accumulated in the region of glial nodules containing infected cells. Should the peptide
be made in any quantity during the metabolism of Tat released from such accumulations




The present experiments allow some limited conclusions regarding neuropathological
mechanisms in MVV infection to be drawn. The aims of the work carried out here
were i) to investigate whether macrophages infected with MVV caused any neural
changes after injection in vivo, in the absence of other cell mediated immune effectors,
ii) to test the neurotoxic potential ofMVV infected macrophage products in vitro, and
iii) to probe the acute in vivo neurotoxic effects of a peptide derived from lentiviral
Tat protein.
6.1. EFFECTS OF MVV INFECTED MACROPHAGES ON SCID CNS.
The effects of MVV on the CNS of infected sheep have been attributed to the
actions of mediators arising from circulating immune cells. To investigate any
possible role of MVV infected macrophages on neural cells, immunodeficient (scid)
mice were used, thus eliminating the contribution of cell-mediated immune responses.
The injection of live macrophages into scid mouse paranchyma caused
significant short term astrocytosis and microgliosis, as well as significant longer term
microgliosis. This was measured by estimating the extent of GFAP and F4/80
induction, and was replicated in experiments where macrophages were removed from
their culture vessel by two different methods. GFAP induction was measurable one
week after the delivery of MVV infected macrophages to scid mouse striatum.
However, 3 weeks post-operatively the amount of GFAP staining induced by MVV
infected macrophages was not significantly different from that incurred by uninfected
macrophages. F4/80 induction at this time point, however, remained significantly
more elevated when MVV infected macrophages, as opposed to uninfected
macrophages, were injected. These results strongly suggest that MVV infected
macrophages cause short term astrocytosis and long term microgliosis. These two
events can be considered markers for inflammation within the CNS, and are
characteristic of natural MVV infection of sheep (Georgsson et al., 1977). Of the two
events, the prolonged microgliosis is suggested here as the more important
phenomenon. Although the experimental scid mouse model described in this thesis is
removed from the natural disease, it allows the plausible speculation that the invasion
of macrophages in the CNS of MVV diseased sheep may account, either in whole or
in part, for the establishment of microgliosis in CNS lesions. Indeed, it has also been
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recently independantly reported that MHC antigen expression on microglia correlates
with the severity of lesions in experimentally MVV infected sheep (Bergsteinsdottir et
al., 1998).
Certain technical considerations regarding the transplantation of macrophages
into scid mouse CNS were deemed problematic. Firstly, the possibility that
macrophages had become lysed during removal from their culture flask and before
injection into scid mice was taken into consideration. Experiments were carried out
using deliberately lysed macrophage injections into scid mouse CNS, to investigate
whether these had the same effects as live macrophages. These experiments showed
that lysed macrophages were, in fact, able to cause F4/80 up-regulation, but not GFAP
up-regulation. However, lesion volumes obtained with killed macrophages were
smaller than those caused by live macrophages. This suggests that killed macrophages
may have a slight effect on the induction of microgliosis, but, overall, have a lesser
effect on scid parenchyma than live macrophages.
Up-regulation of F4/80 staining by lysed macrophages may be due to the
spillage of cellular contents into the injection medium. The effects of many
macrophage cellular components on brain parenchyma are not documented and
therefore any conclusions as to the method of action of lysed macrophages on F4/80
induction are impossible. If one infers, however, that some lysed macrophages were
contained within the cell preparations of macrophages scraped off the tissue culture
flasks, then the effect of the live macrophages may be combined with the effect of
lysed macrophages in causing F4/80 induction.
However, experiments using macrophages which were removed from their
culture flask using warm versene, a less disruptive procedure, showed similar results
to experiments where macrophages were gently scraped off their culture vessel.
Versene-removed macrophages caused significantly more GFAP and F4/80 staining
when they were MVV infected as compared to when they were uninfected. The extent
of GFAP and F4/80 activation was comparable between macrophages removed from
culture flasks with versene, and those removed by gentle scraping. This result




Astrocytosis and microgliosis are characteristics of the natural MVV disease in
sheep (Georgsson et al., 1977), and macrophages infiltrate the CNS in experimental
infection (Georgsson et al., 1979). The short lived increase in GFAP expression
observed here probably corresponds to changes in astrocyte morphology and number,
in response to changes in the local brain microenvironment. These changes have been
found to occur in response to several different types of injury within the CNS (Landis
1994). The return of GFAP expression to background levels 3 weeks after the
injection of MVV infected macrophages, may reflect the dynamics of astrocytes
returning to steady-state functions. Changes in F4/80 expression reflect the activation
of microglia. As with astrocytes, activation of these cells results in an altered
physiological state, resulting in the upregulated expression of several inflammatory
mediators. Increases in F4/80 induction may also reflect increased recruitment of
monocytes from the circulation. In other models of injury to the CNS, monocytes are
recruited, after a delay, to the site of injury (Marty et al., 1991). This recruitment is the
result of a chemokine signal attracting fresh monocytes to the area. This chemokine
agent may be released by activated microglia or by the injected macrophages.
Therefore, MVV infected macrophages may play a role in the establishment of the
astrocytosis and microgliosis obserevd in MVV infection. However, this is not to
assume that they are the sole effectors causing this pathology in MVV infection,
although these experiments support this possible role.
The lack of significant effects of free virus on GFAP and F4/80 expression
would seem to suggest the presence of a mediator released by MVV infected
macrophages to cause astrocytosis and microgliosis, as opposed to a direct effect of
the virus. p25 immunostaining did not localise MVV either when this was injected
alone, or in MVV infected macrophages. The lack of p25 staining would suggest that
the virus was no longer present within the striata of scid mice. Antibodies directed
against ovine CD 14, however, did reveal the presence of injected macrophages within
the striatum of scid mice. Several suggestions are possible to explain the lack of p25
staining. For the injections of free virus alone, MVV may have been cleared from scid
striatum, perhaps through extracellular fluid drainage. Another possibility is that
MVV has become latent in scid tissue. Productive MVV replication is readily
observed in cells in vitro, but in vivo environments have been observed to down
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regulate the activity of MVV replication. For example, MVV injected into sheep
joints, in models of the arthritic aspects of the disease, can be detected at short
intervals post-injection, but the detection rate decreases with time, although pathology
still becomes manifest. Similarly here, replication of MVV in in vivo environments
may become latent. This would account for the lack of p25 staining in both the free
virus injected animals and the MVV infected macrophage injected animals.
Furthermore, in several accounts of the naturally occuring MVV disease,
neuropathology is observed without the detection of specific viral antigens (Georgsson
et al, 1977; Georgsson et cil., 1982; Bergsteinsdottir et al., 1998).
A more reliable predictor of cellular activation following MVV infection
resides in the cytokine profile of infected cells. Infection of alveolar macrophages
results in increased levels of IL-8 and EL-1 (3 mRNA in vitro (Legastelois et al., 1998),
and elevated levels of IL-8 mRNA and TGF(3 expression in vivo (Moreno et al.,
1998). Other investigators report augmented levels of TNFa mRNA in MVV infected
microglia and macrophages (B. Ebrahimi, personal communication; Zhang et al., in
preparation). RT-PCR performed on the blood borne macrophages destined for
injection into scid mice, found a threefold increase in EL-1(5 mRNA levels when these
were infected with MVV in vitro. This is taken to signify that these cells were in a
state of activation after infection with MVV and at the time of transplantation into
scid mice. This activation may also serve to explain the dichotomy between the effects
of macrophages in scid parenchyma and the lack of staining for viral antigens.
The increased synthesis of EL-lp mRNA in MVV infected macrophages may
also represent a pro-inflammatory mediator released from MVV infected macrophages
to cause astrocytosis and microgliosis in scid mouse brain. The pro-inflammatory
effects of EL-1(3 both in the CNS and in the periphery are well documented. Although
this is an attractive hypothesis, further experiments would be needed to detect any
ovine EL-1(3 in scid parenchyma following injection of MVV infected macrophages.
Furthermore, the putative species specificity of ovine and murine cytokines would
need to be addressed.
Many other mediators have been proposed as neurodegenerative effectors in
lentiviral infections. These incluse viral proteins. Of these, the lentiviral protein Tat
has been shown to be released from HIV infected cells (Frankel and Pabo, 1988), and
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has been shown to cause seizures in vivo in mice, accompanied by astrocytosis and
neuronal loss (Philippon et al., 1994). Recently also, HIV Tat has been proposed as a
chemokine (Conant et al., 1998). Speculation might allow the proposal that Tat may
be released from MVV infected macrophages, to cause astrocytosis and microgliosis,
as well as act as a chemoattractant for monocytes circulating in the periphery. It is also
possible that MVV Tat may attract other monocyte/macrophage cells to the CNS of
scid mice, and that the presence of these is required for any neuroinflammation.
However, the effects of macrophages in the absence of other cell mediated immune
responses on astrocytes and microglia, suggest a contributory role for these cells and
their released products in the neuropathology ofMVV infection.
6.2. EFFECTS OF MACROPHAGE PRODUCTS AND MVV TAT PEPTIDE
ON NEURONS IN VITRO.
Injection ofMVV infected macrophages did not cause any obvious neuronal or
myelin loss in scid mice. The aim of testing macrophage supernatant on neuronal
cultures was to investigate whether macrophage products could exert any neurotoxic
action in a different experimental setting. The results showed that, indeed, supernatant
obtained from MVV infected macrophages was significantly more neurotoxic than
supernatant obtained from uninfected macrophage cultures.
Many molecules may be responsible for exerting this neurotoxic action. As
previously mentioned, the cytokine release profile ofMVV infected macrophages may
be altered in MVV infection. MVV infection has been shown to increase TNFa
mRNA expression in alveolar macrophages and microglia (B. Ebrahimi, personal
communication; Zhang et al., in preparation), as well as IL-8 mRNA and TGFP
expression in vivo (Legastelois et al., 1998; Moreno et al., 1998). MVV infected
macrophage supernatant may also contain many other mediators responsible for the
observed neurotoxicity. Among these are viral proteins such as envelope
glycoproteins and Tat protein.
Lentiviral Tat has been shown to be released from infected cells (Frankel and
Pabo, 1988), and bears some sequence homology to snake venom neurotoxins (Garry
and Koch, 1992). Peptides derived from the MVV Tat protein have previously been
found to be neurotoxic in vitro (Strijbos et al., 1995). In an effort to evaluate the time
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course of MVV tat peptide neurotoxicity in vitro, MVV tat peptides were synthesized
and applied to rat cortical neurons. Neurotoxicity was evaluated based on both total
cell viability and total cell death. The results revealed that MVV tat peptide begins to
exert neurotoxic actions after 24 hours incubation with neurons. This was suggested
by the increase in LDH release, but was not similarly reflected by decreased MTS
reduction in neuronal cultures. It must therefore be emphasised that a neurotoxic
action ofMVV tat peptide is only suspected at this time point. However, by 48 and 72
hours, a definite neurotoxic effect of MVV tat peptide is evident, as the peptide causes
both significantly increased LDH release and decreased MTS reduction, when
compared to a control proteinaceous compound and a medium change alone. These
represent new observations, in particular the observed neurotoxicity at 48 hours, as
previous experiments only document MVV tat peptide toxicity at 72 hours (Strijbos et
al., 1995). However, whilst these experiments point to a neurotoxic action of
MVV tat peptide, they cannot confirm the existence of this peptide in the supernatant
of MVV infected macrophages. It is possible that MVV Tat protein is present in the
supernatant of MVV infected macrophages, but a detailed chemical analysis of this
supernatant would be necessary in order to ascertain its composition.
Previous experiments have attributed the neurotoxicity of MVV tat peptide in
vitro to an action occuring through NMDA receptors and involving excessive calcium
influx at 72 hours (Strijbos et al., 1995). Fentomolar concentrations of HIV Tat have
also recently been reported as causing depolarisations to neurons in culture, possibly
via an action on AMPA receptors (Cheng et al., 1998). These experiments suggest a
rapid action of MVV tat peptide in causing neurotoxicity. In an effort to further
investigate this action, and underlying mechanisms, toxicity studies were carried out
in vivo.
6.3 EFFECTS OF LENTIVIRAL TAT PEPTIDES IN VIVO.
MVV tat peptide has previously been found to be neurotoxic to rat striatum in
vivo as have HIV tat peptides (Gourdou et al., 1990; Hayman et al., 1993; Philippon et
al., 1994). Most of these reports document a neurotoxicity occuring one week after the
administration of peptides in vivo. The previous experiments carried out here point to
a neurotoxic action of MVV tat peptide occuring rapidly in vitro. The effects of MVV
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tat peptide application in vivo have not been investigated at short time courses.
Although the relevance of MVV tat peptide neurotoxicity to the naturally occuring
disease has previously been thought of as limited, lentiviral Tat has been implicated as
a contributory agent to neuronal demise in other lentiviral infections, notably HIV
(Lipton 1992a). If Tat were to have a role in the establishment of lentiviral
neuropathologies, then the dynamics of this agent are of interest. The aim of these
experiments was therefore to investigate the time course of the neurotoxicity ofMVV
tat peptide in vivo as well as its possible mechanisms of neurotoxicity. The results
suggest that MVV tat peptide may play a role in the neuropathology of the naturally
occuring disease.
The application of MVV tat peptide to rat striatum caused neurotoxicity
rapidly, within 30 minutes of application. This was assessed by decreased NeuN
staining. NeuN is a relatively unconventional neuronal marker but has been reliably
proven to stain neurons (Wolf et al., 1996). GFAP induction was also caused by MVV
tat peptide 30 minutes post-operatively. These results were replicated 1 hour after
administration, and caused significantly larger effects that the application of control
substances. After 24 hours recovery, animals injected with MVV tat peptide
developed a neuronal lesion of the same order of magnitude as that observed one
week post-operatively (Hayman et al., 1993). All neuronal subtypes were affected by
the administration of MVV tat peptide, including cholinergic interneurons,
parvalbumin positive neurons, and diaphorase positive neurons.
The appearance of the NeuN lesion was distinctive with intense neuronal
disruption at the centre of the injection site, surrounded by an area lacking staining.
This may reflect oedema surrounding the injection site, or an increased vulnerability
of neurons at sites more distant from the injection site. IfMVV tat peptide is exerting
its actions through a specific receptor on neurons, the mechanisms of this vulnerability
may reflect receptor occupancy effects. It is possible that at the centre of the lesion,
receptor sites may become saturated, whilst at the edges of the lesion the action of
MVV tat peptide may be amplified by neuronal glutamate release. Similar lesions
were observed with GFAP staining, and may reflect similar dynamics. The GFAP
induction was smaller in size than the NeuN lesion and may reflect a greater
vulnerability of neurons to this neurotoxic agent, or a slower activation of GFAP. The
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doses ofMVV tat peptide used in these experiments were high. The minimum amount
of MVV tat peptide shown to cause neurotoxicity in vivo has previously been shown
to be 0.5nmol (Hayman et al., 1993). However, the doses used here represent effective
amounts to cause neurotoxicity, as previously determined. Moreover, comparable
amounts of ibotenic acid, a known neurotoxin, do not cause neurotoxicity in vivo at
the short time courses studied here. It is also plausible to comment that large amounts
of MVV Tat protein may be released in the vicinity of MVV infected cells within the
CNS of diseased sheep. The release of this agent and its accumulation may cause
eventual neurotoxicity.
The neurotoxic mechanisms of MVV tat peptide have been ascribed to NO-
mediated glutamate actions, one week post-operatively in vivo (Hayman et al., 1993).
Cytokines, in particular TNFa, have also been implicated as mediators contributing to
MVV tat peptide mediated neurotoxicity (Philippon et al., 1994). In an effort to
ascertain whether any of these mechanisms may be operating at the time points
studied here, neuroprotection experiments were carried out using MK801, an NMDA
receptor antagonist, NBQX, an AMPA receptor antagonist, L-NAME, a NOS
inhibitor, and aMSH, a TNFa inhibitor. Since the NeuN lesion observed at 1 hour
post-injection to the striatum was comparable in magnitude to that seen at 24 hours
and 1 week, this time point was chosen for the neuroprotection studies. Preliminary
experiments using NBQX and aMSH did not reveal any significant effects of these
agents on the MVV tat peptide induced neuronal lesion, although NBQX did seem to
reduce the volume slightly. MK801 did, however, signficantly reduce both the amount
of neuronal loss and GFAP induction. This points to an action ofMVV tat peptide on
NMDA receptors to cause neurotoxicity. However, the role of cytokines, AMPA
receptors and NO in aiding this neurotoxicity was not confirmed. This is not to say
that these agents do not contribute to any observed neurotoxicity at later time points.
Limited experiments were carried out with ITIV tat peptide. This agent caused
the same lesion profile as MVV tat peptide, notably the disappearance of NeuN
staining surrounding the injection site. Experimental animal numbers were small, due




6.4. CONCLUSIONS AND FUTURE DIRECTIONS
The present experiments permit certain conclusions. Firstly, macrophages may
contribute to the establishment of neuropathology in MVV infection. This may be
suggested by the actions ofMVV infected macrophages on astrocytes and microglia in
scid mice. Secondly, MVV tat peptide is rapidly neurotoxic to neurons in vitro and in
vivo, and its actions can be inhibited by the glutamate receptor antagonist MK801.
Although these experiments cannot suggest a link between the actions of macrophages
on scid tissue and the neurotoxicity of MVV tat peptide, it may be plausible to suggest
that MVV Tat is released from MVV infected macrophages to contribute to
neurodegeneration. This molecule may also act as a chemokine to attract other cells to
the CNS. However, this was not examined in the present experiments.
Future experiments would be needed to clarify the presence of MVV within
scid CNS at differing time points. Although no virions were detected by the
monoclonal antibody to p25 within the CNS of scid mice one week after the
administration of MVV infected macrophages, they may be present at earlier time
points. Also, although no neuronal loss was evident in scid mice in these experiments,
the possibility of this occurrence may be explored at later time points, using more
quantitative methods. A more detailed chemical analysis of macrophage supernatants
would be essential for the determination of the presence of putative inflammatory
mediators and neurodegenerative molecules such as Tat protein, gpl35, NTox, PAF,
NO and numerous others. Further experiments would also be carried out involving the
MVV tat peptide. Neuronal excitatory proterties should be investigated, possibly by
using patch-clamping techniques, and the ability of other, more specific, agents to
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43.3
ACTIVATION OF THE KYNURENINE PATHWAY IN
THE BRAIN IN AIDS - A NEUROTOXIC MECHANISM?
A.M.Sardar. CJ.Eegett and G P.Reynolds. Department of
Biomedical Science. The University of Sheffield. Sheffield
S10 2TN U.K.
HIV-associated dementia is a frequent consequence of of HIV
infection and is associated with neuronal deficits. HIV
invasion of the brain is considered to be primarily via
macrophages/microglia, that when activated produce soluble
neurotoxic factors. Macrophage activation can lead to the
induction of indoleamine-23-dioxygenase (IDO) that regulates
tryptophan/kynurenine metabolism, and thus to the
overproduction of two neurotoxins, 3-hydroxykynurenine
(3HK) and quinolinic acid We find that 3HK. like quinolinic
add, is able to induce neuronal cell damage in a chick embryo
retina preparation. This effect is blocked by AP5, implicating
NMDA receptors in the mechanism of 3HK toxidty. We have
determined 3HK concentration and the activity of both IDO
and the 3HK catabolic enzyme. 3HKase. in brain tissue taken
post-mortem from the frontal cortex of HIV-positive
individuals and matched control subjects. 3HK was increased
in the AIDS group, an effect which is greatest in patients with
dementia. 3HKase activity was similarly increased in the brain
in AIDS. IDO was found to be increased in AIDS patients,
but only reached significance in the group of patients with
dementia. Thus we conclude that an activation of the
kynurenine pathway in the brain in AIDS, as a consequence of
the increase in IDO activity, is responsible for increased
formation of 3HK and, presumably, quinolinic add. These
neurotoxins may well be responsible for the neuronal losses
underlying HIV-assodated dementia.
43.5
IMMEDIATE EARLY GENE EXPRESSION AND CELL DEATH
IN THE IMMATURE RAT STRIATUM FOLLOWING AN
EXCITOTOXIC LESION.
Carolyn A. Walker and Stephen W. Davio.
Department ofAnatomy and Developmental Biology, University College London. Gwer Street,
Loodon. WC1E6BT.
Wc have investigated the molecular mechanisms underlying
exritotoxin-induced striatal ceil death to determine any differences that
might exist between the adult and the developing rat striatum- An
injection of the excitotoxin kninic acid into the striatum of postnatal day
10 rats results in a contrasting pattern of cell death to that seen in the
adulL There is a sparing of the NADPH-diaphorase striatal cell type
coupled with a 75% loss of the cholinergic neuron; the opposite to that
seen in the adulL
Using this model of excitotoxin-induced cell death we have
examined by immunocytochemistry and in situ hybridisation the spatial
and temporal expression of immediate early genes belonging to the AP-1
transcription factor complex, jiamely c-fos, c-jun, fos-B, jun-B and jun-D.
to establish whether cell death is accompanied by an up-regulation of
these genes. In the adult there is a rapid and transient expression of c-fos
and jun-B within the 'peripheral shell* of the striatum which is followed
by a delayed expression of fos-B, c-jun, and jun-D within the central
lesioned 'core' of the striatum. However, in the developing striatum the
immediate early gene expression contrasts that seen in the adulL
Immediate early gene primary transcripts are minimally up-regulated and
protein induction cannot be detected during development
Furthermore, we have sought to define the means by which cells
are dying in this model, whether necrotic ot apoptotic. Using the
technique of in situ nick end labelling it is possible to establish whether
nuclear condensation is occurring and using agarose gel electrophoresis it
is possible to observe DNA laddering, both characteristic features of
apoptotic cell death. It is important to note that the effect of excitotoxin-
induced cell death differs markedly during development and this may
provide some insight into the mechanisms of cell death in
neurodegenerative diseases.
43.4
ACUTE NEUROTOXICITY OF A PEPTIDE FROM MAEDI VISNA
TAT.
I. Starling. S. Hunt AK. Wngbt. I. Nome. G.W Artnnhnon. G. Harkiss'
MRC Ejaernal Scientific Staff. University of Edinburgh Centre for
Seuroscience. Preclinical Vet. Sciences. Depanmem of Veterinary
Pathology. Summerkail Edinburgh, EH9 IQH.
A short peptide sequence which forms part of the tat protein synthesised by
the sheep virus Maedi Visna. has been shown to be neurotoxic. Most of our
measurements of its action so far have relied upon what we believed to he
the glial response to the neuronal damage caused by the peptide. Indeed
this is a common method for the assessment of neuronal damage by many
agents, including excitatory amino acids for instance.
Our conclusion that the peptides were indeed neurotoxic was supported by
the demonstration that a neurone specific antigen NeuN was absent in the
region into which the peptide had been injected in rat brain, and by
evidence of frank neuronal loss in the hippocampus after injection into
mice.
To decide between a neuronal site of action and a glial one we have studied
the effect of tat peptide injections shortly after their application. Within 30
mtn of the injection of the pepude into the striatum a significant action of
the peptide is seen in the striatum. There is a halo' round the injection site
which is free of staining. Within the circle formed by this "halo" is an area
where the morphology of the cells looks changed. The ceil profiles seem
shrunken and the staining a little darker. Over the following two hours this
staining in the centre of the mjccuon site fades and by three hours there is
an area of no staining which is some 50% of the final volume of damage
which we recorded by measuring the microglial response ooe week after the
injection.
Although we do not at present have a clear idea of the mechanism of action
of the peptide it is clear thai the acuon occurs immediately and is, at least in
the early stages neurotoxic. There are changes in glial staining in the short
term animals but the glial proliferation which marks the full blown lesion
takes three days to develop.
43.6
ABNORMAL NEURONALNITRIC OXIDE SYNTHASE EXPRESSION
IN NEURONES OF THE MUTANT MOUSE WOBBLER
G.J.Clowry' and S.McHanwell2, Department of Child Health1. Sir James
Spence Institute, and Division of Neurobiology2. Medical School,
Framlington Place. Newcastle upon Tyne, NE2 4HH, United Kingdom.
Somatic motor neurones do not normally express nitric oxide synthase
(NOS). However, axocal injury when it leads to cell death can induce
expression of NOS in dying motor neurones'The wobbler mouse is an
autosomal recessive mutant characterized by vacuolar degeneration and
loss of motor neurones in the spinal cord and brainstem3. We have
investigated the expression of neuronal NOS in the brainstem, spinal cord
and cerebellum by NADPH diaphorase histochemistry in frozen sections
of paraformaldehyde perfused tissues. Studies were made on younger
wobbler mice aged from 5 to 8 weeks, when motor neurone death is
actively occurring and in older mice from 10 months to 1 year when
motor neurone death is largely completed. Unaffected littermates were
used as controls. In the spinal cords of younger wobbler mice, but not
unaffected litermates, large NOS positive swollen neurones with eccentric
nuclei were found in the motor columns of the cervical and lumbar spinal
cords. Abnormal neuronal profiles could also be seen in the vestibular
nuclei of the younger wobblers. Such profiles were not found in the
brainstem motor nuclei at any age or in the spinal cords of older animals.
However, in the ventral horn of older animals unusually large numbers of
NOS positive beaded axons were present often meeting in tangled foci in
both white and grey matter. NOS staining m the cerebellum was abnormal
at both ages examined being overexpressed in the granule cell layer of
younger animals but underexpressed in older animals. This study
demonstrates the complex pattern of neurodegeneration in a mutant often
regarded simply as a model for motor neurone disease.
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MAED! V1SNA VIRUS INDUCED NEUROINFLAMMATION: A SCID MOUSE MODEL
I. Starling (1), G. Harkiss (2) and G. Arbuthnott (1)
1) Dept. of Preclinical Vet. Sci. Royal (Dick) School of Vet. Studies. Univ. of Edinburgh. U.K.
2) Dept. of Veterinary Pathology. Royal (Dick) School of Vet. Studies. Univ. of Edinburgh. U.K
In late stages on infection, Maedi Visna virus (MW) causes ataxia and paralysis in sheep.
The accompanying neuropathology shows demyelination, axonal lesions and reactive
astrocyctosis in both grey and white matter structures. Also characteristic is the invasion of
monocytes along the ventricular system, followed by T cell infiltration. At present, it is not clear
whether the neuroinflammation in MW is caused by a direct action of the virus on neuronal cell
types, possibly via the action of cytokines, or by an immune type response occuring within the
CNS. - "
In order to investigate the potential causes of neuroinflammation occuring in MW, severe
combined immunodeficient (scid) mice were used. These lack T and B cells and are unable to
mount any immune response, thus allowing investigation into a direct action of virus infected
cells on neuronal cell types.
In the first set of experiments, sad mice were injected int-astriatally with mature
macrophages infected with MW. Immunocytochemistry for GFAP and F4/80 was then carried
out on fixed brain tissue and the degree of astrocytosis was measured by image analysis.
Results show that at one week postoperatively, the degree of astrocytosis is significantly
greater in those mice injected with virus infected macrophages as opposed to those injected with
uninfected macrophages, suggesting that the virus infected macrophages are having a direct'
effect on the CNS.
In a second set of experiments, mononuclear cell preparations containing infected and
uninfected monocytes have been injected into sad mice in the same manner as above, and the
results are currently being collated in order to evaluate the role of the immune response in
causing brain damage.
The current results seem to suggest the feasability of a model of MW encephalopathy
in scid mice.
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Abstract
Lentiviruses such as Maedi Visna virus (MVV) in sheep, and human immunodeficiency virus (HIV) in man often cause a variety of
neurological syndromes in later stages of infection. Neuropathological investigations reveal damage to myelin and astrocytosis in both
white and grey matter. MVV infection induces axonal damage with some areas of necrosis while neuronal loss, and synaptic damage have
been reported in HTV-1 infection. It is not clear, at present, how this neurodegeneration is mediated but, as these viruses do not directly
infect neurons, an indirect neurotoxic action of the viruses is indicated. Previous experiments have shown that the intra-striatal injection in
rats of a synthetic peptide derived from the basic region of the MVV transactivating protein Tat causes considerable neurotoxicity 1 week
post operatively. By in vivo stereotaxic injections of the same synthetic peptide, and subsequent immunocytochemical detection of
neurons, astrocytes and microglia, we show that this neurotoxicity displays a distinctive and unusual lesion profile and is evident as
rapidly as 0.5 h post-operatively. Furthermore, neuroprotection studies suggest that the early effects of the MVV tat peptide may involve
glutamate neurotoxicity via the A'-methyl-D-aspartate (NMDA) receptors since the application of dizolcipine (MK801) reduces the volume
of the lesion seen at 1 h after the injection of neurotoxic peptide, while l-NAME is ineffective. The mechanism of this early neurotoxicity
is thus different from the longer term actions already described. © 1999 Elsevier Science B.V. All rights reserved.
Keywords: Neurotoxicity; Lentivirus; Maedi Visna virus; Human immunodeficiency vims; Tat peptides; Rat
1. Introduction
Lentiviral infection of the central nervous system (CNS)
causes damage of astrocytes, microglia and neurons. In
Maedi Visna virus (MVV), post-mortem examination of
the brains of affected sheep also reveals areas of liquefac-
tive necrosis involving both neurones and glia in foci of
infection [12], In human immunodeficiency virus (HIV)-l
infection, neuronal loss is commonly observed in several
areas including cortical regions and the basal ganglia [7,8].
Astrocytosis and some myelin damage are also characteris¬
tic features of both infections [2,11], although multinucle¬
ated giant cells are a hallmark of HIV infection [6]. Neither
MVV nor HIV infect neurons, but HIV and MVV viral
antigens have been co-localised with microglia, astrocytes
and, occasionally oligodendrocytes [16,28,31]. Lentiviral
*
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invasion of the CNS is believed to occur through the
migration of infected macrophages across the blood brain
barrier [23], although HIV may also penetrate the CNS via
cell-free entry. Little cell free virus is usually present in
lentiviral CNS infection. The neurotoxic capabilities of
lentiviruses have therefore been attributed to indirect
mechanisms.
Several lentiviral proteins have been proposed as neuro¬
toxic candidates. The HIV envelope glycoprotein gpl20
has been shown to be neurotoxic both in vivo and in vitro.
In vitro, the neurotoxic mechanism of gpl20 has been
attributed to glutamate toxicity occurring at the V-methyl-
D-aspartate (NMDA) receptor [18], aberrant calcium influx
[17] or apoptotic mechanisms [1], In vivo, gpl20 causes
neuronal damage [15], and transgenic mice overexpressing
gpl20 develop severe neurologic abnormalities [30],
The transactivating protein Tat of HIV and MVV is
necessary for efficient lentiviral replication, although it
only functions as a weak transactivator of MVV [3].
Lentiviral Tat contains amino acid sequences related to
0006-8993/99/$ - see front matter © 1999 Elsevier Science B.V. All rights reserved.
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some snake venom neurotoxins [10] and has been shown to
depolarise neurons [4,19], Moreover, it is released from
HIV infected cells and may move transcellularly [9]. HIV
Tat protein and a peptide derived from the basic region of
the protein have been found to be neurotoxic. Several
investigators have documented this neurotoxicity in vitro
and report HIV Tat to cause excitotoxic [26] or apoptotic
[22] neuronal demise. Similarly, a peptide derived from the
basic region of MVV Tat protein has been shown to be
neurotoxic in vivo and in vitro. Its effects, in vitro, have
been attributed to excessive calcium influx in neurons [29].
In vivo, the neurotoxic actions of MVV tat peptide, seen at
1 week after the injection, seemed to depend on nitric
oxide mediated glutamate neurotoxicity [14], with the con¬
comitant release of proinflammatory cytokines [24]. Here
we report the rapidly developing neurotoxicity of the
MVV tat peptide when administered in vivo to rat stria¬
tum, and conclude that although it is sensitive to NMDA
antagonists at this early stage, nitric oxide synthesis inhibi¬
tion does not protect striatal neurones during the first hour
after the peptide injection.
2. Materials and methods
2.1. Stereotaxic injections
Fifty-two male Sprague-Dawley rats were anaes¬
thetised with halothane and placed in a stereotaxic frame.
The injection site was determined following the coordi¬
nates: 0.7 mm anterior to Bregma, 2.5 mm lateral and — 5
mm ventral from the surface of the brain. Rats were either
injected with 20 p-g (9.6 nmol) MVV (22 rats) or 20 p,g (9
nmol) HIV (4 rats) tat peptide dissolved in 1 (jlI sterile
saline. The MVV tat peptide and a control ovalbumin
peptide were synthesised by standard FMOC chemistry,
desalted and purified, as previously described [14]. The
HIV tat peptide was obtained from the MRC AIDS di¬
rected programme (Table 1).
In the neuroprotection experiments, 20 p,g (25 nmol)
l-NAME (Research Biochemicals International) was co-in-
jected with the MVV tat peptide (6 rats). MK801 (Re¬
search Biochemicals International) was administered intra-
peritoneally at a dose of 0.01 mmol/kg 1 h before the
injection of MVV tat peptide (9 rats).
Control injections were also made with 5 p.g (56.8
nmol) ibotenic acid (Sigma) (2 rats), 0.9% sterile saline (2
rats), 100 p.g (61.9 nmol) ovalbumin peptide (2 rats) and
20 pg (25 nmol) L-NAME (5 rats).
Table 1
Single letter amino acid code of the peptides used





(NH): Amidated position on the peptides synthesised in house.
HIV tat was obtained from the MRC AIDS directed programme.
Once the injection was made, the Hamilton syrinj
used was left in place for 5 min in order to minimi;
needle reflux. At the appropriate time, after surgery, ra
were injected intraperitoneally with a lethal dose of penti
barbitone (1 ml/kg, Sagatal) and transcardially perfuse
with 50 ml of warm saline containing 1000 units i
heparin sulphate, followed by 300 ml of 4% paraforma
dehyde, 0.05% gluteraldehyde in 0.1 M Phosphate buff
pH 7.4. Their brains were dissected out and placed in
50:50 solution of 20% sucrose and fixative overnigl
Sections, 50 pm thick, were subsequently cut on a free
ing microtome.
2.2. Immunocytochemistry
Free-floating sections were reacted histologically
multiwell plates. Immunocytochemistry was performed f
Glial Fibrillary Acidic Protein (GFAP) to reveal astrocy
activation [20], the neuron specific nuclear protein Neu
to reveal possible neuronal damage [21,32], and the type
complement receptor (OX42) to estimate microglial activ
tion [25], The NADPH-Diaphorase method was also pe
formed for the detection of NOS containing neurons [.'
The antibodies to GFAP (1:2000, Dako), 0X42 (1:50C
Serotec) and NeuN (1:500, a gift from Dr. R. Mullen) we
revealed using the ABC method (Vectastain ABC ai
ABC Elite kits, respectively) with 3,3'-diaminobenzidi
(Vector) as the chromogen.
2.3. Image analysis
Mounted sections were examined under the light micr
scope and camera lucida drawings were made of the enti
lesioned area, including the pale area surrounding t
injection site, in sections stained with NeuN. The volur
of the lesioned area was measured by scanning the set
serial drawings of the lesioned area, and measuri
the total area in the 'NIH Image' software packa-
(http://rsb.info.nih.gov/nih-image). The total lesion vi
ume was then calculated using the number of sectio
Fig. 1. Immunocytochemical detection of the lesion caused by the MVV Tat peptide at 1 h. (A,C,E) injection of 1 p.! MVV tat peptide, (B,D,F) injectior
1 pi control substances saline, ibotenic acid and ovalbumin, respectively. (A,B) NeuN immunocytochemistry shows a lack of staining in MVV tat pept
injected striatum (A) compared to control striatum (B). (C,D) Detection of GFAP in activated astrocytes shows an increase in GFAP activation at
centre of the injection site with a halo devoid of staining surrounding the injection area (C). Some GFAP upregulation is visible with the injection
ibotenic acid (D). (E,F) Diaphorase histochemistry reveals a loss of NOS positive neurons and neuropile in MVV tat peptide injected striatum (E),
minimal loss in control injected striatum (F), the insets in E and F show 10 x enlargements of the area within the boxes in the main pictures, to illustj
the cell morphology. Scale bar represents 100 pm in A, B, C, D, while in E and F the scale bars are 500 pm in the main picture, and 50 pm in the ins
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showing a lesion (n), the thickness of each section (50
p.m), the number of immunocytochemical stains (5) per¬
formed in the experiment (GFAP, NeuN, 0X42 and Di-
aphorase) and the sum of the areas (x) of the drawings of
lesion, according to the formula:
lesion volume (mm3) = Ex X n X 0.05 X S
2.4. Stastical analysis
Areas of the lesions were compared with a one-way
analysis of variance followed by Duncan's range test to
indicate the source of any significant differences detected.
We have used a significance level of p < 0.05 throughout.
3. Results
3.1. Lesion characteristics
The appearance of the lesion induced by the MVV tat
peptide was distinctive and unusual. At the centre of the
lesion, towards the location of the tip of the Hamilton
syringe, cells appear darkened and distorted on sections
processed for NeuN (Fig. 1A), GFAP (Fig. 1C) and OX42.
On these same sections, the central area of the lesion was
surrounded by a 'halo' of unstained cells. This profile was















Saline Ibotenate Ovalbumin MWTat
Treatment
Fig. 2. Lesion volumes induced by the MVV tat peptide (n = 3), saline
(n = 2), ibotenic acid (n = 2) and ovalbumin (n = 2) intra-striatal injec¬
tions at 0.5 h. Values are mean + S.E.M. Control lesions were signifi¬
cantly smaller than the MVV tat peptide induced lesion (one-way
ANOVA, p < 0.05; post hoc Duncan test, *p < 0.05).
Time (hours)
Fig. 3. Progress over time of the lesion caused by the MVV tat peptit
The lesion was measured according to disappearance of neuronal staini
as revealed by immunocytochemistry for the NeuN antibody. The lesi
occurs as rapidly as 0.5 h post-operatively (n — 2), is larger at 1
(n = 18), and increases over a period of 24 h (n = 2). The lesion at 24
which is of the same order of magnitude as that measured 1 we
post-operatively, is significantly greater than that at 0.5 h (one-w
ANOVA, p < 0.05; post hoc Duncan test, *p < 0.05).
h), although no 'halo' surrounded the older lesions studk
previously [14]. The intracerebral injection of saline, ovt
bumin, ibotenic acid and l-NAME did not cause a lesii
as revealed by immunocytochemistry for neurons and ?
trocytes (Fig. IB and D), but injection of HIV tat pepti
had very similar effects to MVV tat peptide in the ft
animals on which we were able to test it (one rat perfus
0.5 h after the injection 3 at 1 h). On sections process
for Diaphorase histochemistry, the MVV tat peptide caus
loss of staining of Diaphorase positive, NOS containi
neurons at the injection site (Fig. IE). It is interesting
note that the terminals of these cells were most affecte
some cell bodies still being recognisable, even at the cent
of the lesion. The injection of l-NAME is known to resi
in the disappearance of Diaphorase positive neurons [.
None of the other control substances caused any alterati
in Diaphorase staining. The state of microglial activatic
as revealed by 0X42 staining, was minimal when coi
pared to its optimal response, observed at 3 days post-c
eratively.
At 0.5 h, a one-way ANOVA revealed a signific;
effect of treatment on lesion volume. Post hoc analy
showed that the lesion volume caused by the MVV
peptide was significantly different to that caused by t
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three other control injections (Duncan test, p < 0.05, Fig.
2), HIV tat peptide produced a lesion of similar volume
(20.0 ± 8.9 mm3 at 1 h compared with 11.9 ± 2.6 mm3 for
MVV tat at the same time point). At 1 h, the injection of
l-NAME alone caused a reduction in Diaphorase staining
that was significantly smaller than that following the injec¬
tion of the MVV tat peptide (Duncan test, p < 0.05).
3.2. Time course
Administration of the MVV tat peptide induced a lesion
in the striatum, visible with all the staining techniques
used, as early as 0.5 h post-operatively (Fig. 3). The
volume of the lesion induced by the MVV tat peptide
increased over time between 0.5 and 24 h and was signifi¬
cantly greater at 1 and 24 h than at 0.5 h (one-way
ANOVA and post hoc Duncan test, p < 0.05). The lesion
visible at 24 h was of the same order of magnitude as that
observed at 1 week.
3.3. Neuroprotection experiments
Since the lesion was nearly maximal 1 h after injection
of the peptide, neuroprotective actions of two different
treatments were tested at this timepoint. Administration of
MK801 1 h before the peptide injection and co-injection of
l-NAME with the peptide were tested. Statistical analysis
revealed a reducing effect of MK801 on the volume of the
lesion caused by the MVV tat peptide (one-way ANOVA
MW Tat Tat+MK801Tat+L-NAME L-NAME
Treatment
Fig. 4. Effect of MK801 and l-NAME on the MVV tat peptide induced
lesion at 1 h. Values are mean + S.E.M. The volume of the lesion caused
by the injection of the MVV tat peptide (n = 18) was reduced by the
administration of MK801 (n = 9), but not by l-NAME (n = 6), (one-way
ANOVA, p < 0.05; post hoc Duncan test, *p < 0.05).
and post hoc Duncan test p < 0.05, Fig. 4), but the
co-injection of l-NAME did not cause any significant
difference in the volume of the lesion caused by the MVV
tat peptide.
4. Discussion
We demonstrate here the acute in vivo neurotoxicity of
a peptide derived from the basic region of the MVV
transactivating protein Tat. Lentiviral Tat and related pep¬
tides have been previously found to be neurotoxic in vitro
and in vivo [13,26,14,29,22], although their effects have
not been studied at the short time courses investigated
here. The current experiments therefore provide further
evidence for the neurotoxic potential of this viral protein.
Although the doses investigated here may be deemed high,
Tat has been shown to be released in the vicinity of
infected cells [9], and its levels may become elevated in
the neighbourhood of many infected cells. Moreover, in¬
jections of similar doses of ibotenic acid, and a control
peptide derived from ovalbumin, do not reveal any signifi¬
cant disruption to the brain parenchyma in vivo at this
short time after the injection.
The lack of a lesion after injection of the well-known
neurotoxin, ibotenic acid, points to the dramatically short
time course of these experiments. At 1 week after the
injection, the same dose of ibotenic acid caused a lesion
almost double the size of that seen after the dose of MVV
tat peptide used in these experiments [14], Yet the peptide
induced damage is almost as large at 1 h as it is at 1 week.
Preliminary tests with injections of endothelin close to the
middle cerebral artery, which cause large lesions after
24-72 h [27], also show the damage after tat peptide to
occur more rapidly than the anoxic damage following
arterial occlusion (Sharkey, Starling, Arbuthnott, unpub¬
lished).
The unusual profile of the lesion caused by the MVV
tat peptide, with a surrounding 'halo' lacking neuronal
staining, may be due to a number of actions of the peptide.
Oedema surrounding the injection site is one possible
explanation. The actions of the MVV tat peptide may also
be amplified at distant sites due to neuronal glutamate
release and increased receptor occupation. This may cause
a greater number of neurons to die at the edges of the
injection site. Indeed, lentiviral Tat has been shown to
depolarise neurons [4,19] and may exert its neurotoxic
effects via an overstimulation of calcium entry through
glutamate receptors, to cause excitotoxicity [14,29]. Our
present experiments also support this, as the administration
of MK801, an NMDA glutamate receptor antagonist, re¬
duces the volume of the lesion caused by the MVV tat
peptide at 1 h.
It is possible that the lack of staining with NeuN does
not in fact reflect the loss of neurones, although there are
experiments which certainly indicate that it is a sensitive
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marker for healthy neurons [32], It is possible that some
form of rapid degradation of the nuclear marker has re¬
duced the staining, perhaps by some loss of access to the
epitope recognised by the monoclonal antibody due to
some modification of the antigen or neighbouring proteins
in the nucleus. On the other hand, the size of the lesions
observed with this method and with the markers for gliosis
in the same sections is very similar. Perhaps more strik¬
ingly, the volumes of the lesion detected by different
methods in the earlier work [14], are very similar to those
detected by the loss of NeuN staining. Together these
observations suggest that the lack of staining leads to, even
if it does not immediately represent, the loss of viable
neurones.
In an early description of the disease caused in sheep by
MVV infection, Georgsson et al. [12] describes neuronal
damage in areas of liquefactive necrosis as early as one
month after the infection. Although the doses we have
used are large, they were doses which were effective in
producing large lesions in the longer-term studies [14], Our
aim was less to model the disease than to examine the
dynamics of neuronal damage by this agent. We would
expect that, if this peptide has any role in the generation of
the neurotoxicity in the disease, then it will only be after
the toxin has accumulated in the region of glial nodules
containing infected cells. Should the peptide be made in
any quantity, during the metabolism of tat released from
such accumulations of infected cells, then rapid and per¬
manent neuronal damage seems inevitable.
In conclusion, the MVV tat peptide exerts rapid neuro¬
toxicity in vivo, which can be reduced by the administra¬
tion of an NMDA receptor antagonist. This acute neurotox¬
icity, as well as the previously documented longer-term
effects of lentiviral Tat, may offer insights into neuronal
deficits in naturally occurring lentiviral diseases.
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